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Platelets are small highly reactive anucleate cells that circulate in the blood and regulate 
haemostasis and thrombosis. Understanding the mechanisms regulating platelet function has 
implications for health and disease. Immunoreceptor tyrosine-based inhibition motif (ITIM)-
receptors regulate megakaryocyte and platelet function. The aim of this thesis was to determine 
the role of ITIM-receptors LAIR-1 and TLT-1 in platelet production and function. LAIR-1 
ablation in megakaryocytes results in enhanced SFK activity which is transferred to platelets, 
rendering them hyper-reactive. LAIR-1 deficient mice exhibit enhanced ferric chloride, but not 
laser-induced thrombosis in vivo, correlating with GPVI hyper-reactivity observed in vitro. 
LAIR-1/PECAM-1 double deficient (DKO) mice were mildly thrombocythemic, with platelets 
hyper-responsive to GPVI activation in vitro. Interestingly, DKO mice lacked the enhanced 
SFK activity and in vivo thrombosis phenotype of single KO mice. TLT-1 deficient mice exhibit 
mild thrombocytopenia, with normal aggregation responses to ITAM-receptor and GPCR 
activation in vitro, and haemostatic response in vivo. Reduced thrombus stability was observed 
following laser, but not ferric chloride-injury in deficient mice, due to marked reduction in α-
granule secretion. In addition, TLT-1 was described as a highly sensitive platelet activation 
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1.1.  Platelets 
Platelets are small highly reactive anucleic cells that circulate in the blood and are critically 
important in maintaining vascular integrity and preventing blood loss. Although their primary 
role is maintaining haemostasis, platelets also contribute to pathophysiological processes 
including atherogenesis, cancer metastasis and inflammation, as well as playing a central role 
in wound healing (Li et al., 2010, Engelmann and Massberg, 2013, Franco et al., 2015, Menter 
et al., 2017). These processes are dependent on the transition of platelets to an activated state.  
Surface proteins on circulating resting platelets bind their respective ligands, inducing 
intracellular signalling pathways producing rapid platelet activation. Understanding the 
modulation of platelet activity by inhibitory signals is therefore critical in order to target the 
pathophysiological functions of platelets. 
 
1.1.1. Thrombosis and haemostasis 
Platelets have been known to play a role in haemostasis and thrombosis for over 130 years. In 
1882, Bizzozero observed disk shaped platelets circulating in guinea pig mesenteric venules 
that formed aggregates at sites of vascular damage and also observed leukocyte recruitment to 
the platelet aggregates. (Bizzozero, 1882). Thrombus formation is the best characterised 
function of platelets, essential to prevent blood loss at sites of vascular damage (Clemetson, 
2012). Inappropriate activation of platelets through the same mechanisms at sites of vascular 
inflammation, such as atherosclerotic plaques, however can obstruct blood flow (Franco et al., 
2015, Lindemann et al., 2007, Lievens and von Hundelshausen, 2011). Directly, by forming an 
occlusive thrombus, or indirectly by occluding smaller vessels downstream following clot 
embolization. The subsequent ischemia caused can result in myocardial infarction or stroke, 
which account for 26% of UK deaths in 2015 (BHF 2017). 




1.1.2. Non-canonical roles 
Primarily known for their role in haemostasis and thrombosis, growing evidence suggests this 
is only one of many important roles platelets play in both health and disease (Franco et al., 
2015, Morrell et al., 2014). Increasing evidence has shown an important role of platelets in 
inflammation, angiogenesis and wound healing (Kubes, 2016, Walsh et al., 2015, Nurden et al., 
2008).   
Platelets act as immune sensing cells, able to detect, bind and retain pathogens such as bacteria 
and viruses on their plasma membrane or internally (Flaujac et al., 2010, Assinger, 2014, 
Yeaman, 2010b, Yeaman, 2010a, Kapur and Semple, 2016, Jenne and Kubes, 2015). Activated 
platelets also release antimicrobial mediators eliminating pathogens directly (Jenne and Kubes, 
2015). Through binding or release of chemoattractants and soluble mediators such as CD40L 
platelets are able to recruit and activate leukocytes at sites of inflammation and infection(Andre 
et al., 2002). Platelet binding to adherent neutrophils also induces NET release, which capture 
and kill pathogens (Kim and Jenne, 2016). Various pro- and anti-inflammatory cytokines and 
chemokines are released by platelets which also affect wound repair (Mazzucco et al., 2010). 
In addition, studies have shown an important role of platelets in maintaining mature blood 
vessels (Ho-Tin-Noe et al., 2011), as well as a role facilitating cancer metastasis, shielding 
cancerous cells from the immune response and assisting their adhesion to endothelium (Leblanc 
and Peyruchaud, 2016, Franco et al., 2015). All these functions are dependent on platelet 
activation; therefore the ability to effect platelet activation has various implications in health 
and disease. 
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1.2. Platelet physiology 
1.2.1. Structure 
Typically 2-5 µm in diameter and 6-10 fl in volume, platelets are the smallest cells in the blood 
(mouse platelets: mean diameter 0.5µm and mean volume 3-4 fl) (White, 2013, Schmitt et al., 
2001). Resting platelets are discoid in shape, which becomes irregular upon activation 
(Packham, 1994, Schmitt et al., 2001). Platelets are terminally differentiated anucleic cell 
fragments of megakaryocytes. All other organelles (mitochondria, endoplasmic reticulum, 
golgi apparatus and lysosomes) are present (White, 2013). The platelet plasma membrane is 
relatively smooth with small randomly dispersed openings to the surface connected open 
canalicular system (OCS), the chief source of membrane for surface area expansion during 
activation and spreading (White, 2013). 
Platelets contain extensive cytoskeletal networks made up of actin, tubulin and their associated 
binding proteins (Sorrentino et al., 2015). In flowing blood the discoid shape and size of resting 
platelets means they are pushed to the vessel edge, allowing them to detect vascular damage to 
endothelium surface rapidly (Hartwig, 2013). Responsible for this shape is the marginal coil, a 
long microtubule encircling the platelet perimeter (8-12 times) just below the plasma membrane 
(Sorrentino et al., 2015, Hartwig, 2013). The most abundant protein in platelets, actin, forms 
filaments (F-actin) which are cross linked by the actin binding proteins filamin and α-actinin 
into a framework supporting the platelet. Via spectrin tetramers and several binding proteins, 
actin is able to interact with the plasma membrane and integrins (Sorrentino et al., 2015). Upon 
activation, platelets rapidly lose the discoid shape. This morphological transformation results 
from disassembly of the marginal microtubule coil, and greater assembly of F-actin creating 
filopodia and lamellipodia (Sorrentino et al., 2015, Aslan et al., 2012).  
 





Platelets also contain granules, of which α-granules are the largest (0.2-0.5 nm diameter) and 
most abundant. Containing both membrane bound and soluble proteins, α-granules following 
activation fuse with the platelet membrane and facilitate platelet adhesion by releasing their 
soluble cargo (fibrinogen, fibronectin, thrombospondin, vitronectin and Von Willebrand factor 
[vWF]) and exposing their membrane bound receptors on the platelet surface (Flaumenhaft, 
2013, Handagama et al., 1990). Most of the membrane bound α-granule proteins (αIIbβ3 and 
GPIb-IX-V) are already present on the platelet surface. P-selectin however is absent, and only 
expressed on the surface following α-granule secretion (Harrison and Cramer, 1993, 
Whiteheart, 2011). 
Dense  
Dense granules, characterised by an electron dense matrix, are fewer and smaller (0.15 nm 
diameter) than α-granules. Containing high concentrations of the secondary mediators ADP and 
ATP as well as serotonin, dense granule secretion supports thrombus growth through local 
activation of platelets (Flaumenhaft, 2013, White, 1969, Whiteheart, 2011). 
Lysosomes 
Also present in platelets are lysosomes, containing acid hydrolases involved in the degradation 
of proteins, carbohydrates and lipids (Flaumenhaft, 2013). Although the function of platelet 
lysosomes are not well studied, secretion of their contents upon strong activation has been 
shown, and may play important extracellular roles such as receptor cleavage, fibrinolysis and 
ECM degradation (Heijnen and van der Sluijs, 2015). 
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1.3.  Platelet production and clearance 
1.3.1. Megakaryocyte development 
In adults, megakaryocytes are derived from haematopoietic stem cells (HSCs), residing 
primarily in the bone marrow, which undergo long-term self-renewal (Machlus and Italiano, 
2013). Classically HSCs gradually develop into multipotent progenitors (MPP) before 
becoming lineage committed able to give rise to either myeloid or lymphoid cells. Following 
commitment to the myeloid lineage, common myeloid progenitors (CMPs) develop into 
bipotent megakaryocyte-erythrocyte (MEP) and granulocyte-macrophage progenitors (GMP) 
and then unipotent progenitors which develop into mature progeny (Laurenti and Gottgens, 
2018, Hunt, 1995, Debili et al., 1996). 
Recently however, this classical model has been challenged by the identification of new 
progenitor populations. Lymphoid-primed multipotent progenitors (LMPPs) were identified as 
a population retaining high proliferative and lympho-myeloid differentiation potential, but 
unable to take on erythroid of megakaryocyte lineage fates (Adolfsson et al., 2001). A 
megakaryocyte -biased HSC population expressing vWF has also been discovered, as well as a 
subpopulation of HSCs, stem-like megakaryocyte-committed progenitors (SL-MkPs) which are 
activated upon inflammatory stress, but remain quiescent during homeostasis, although primed 
to megakaryocyte-commitment (Haas et al., 2015, Sanjuan-Pla et al., 2013). 
Studies utilizing clonal tracking have also distinguished restricted megakaryocyte potential in 
HSCs or their direct progeny, resulting in a new model of megakaryocyte development, with 
heterogeneous HSCs that bypass classical intermediate progenitors and give rise to MK 
progenitors directly (Shin et al., 2014, Grinenko et al., 2014). Yet classical megakaryocyte-
committed pathways can also occur in parallel (Woolthuis and Park, 2016). 
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1.3.2. Megakaryocyte Maturation and Differentiation 
Megakaryocytes become polyploid through endomitosis – repeated cycles (2-6) of DNA 
replication without cellular division – resulting in cells of up to 64N in humans (and 128N in 
rodents) (Vitrat et al., 1998, Nagata et al., 1997). Polyploidization increases protein synthesis 
in parallel with enlargement of the cell (Raslova et al., 2003, Ravid et al., 2002). Following 
endomitosis is a maturation stage where the cytoplasm is filled with platelet specific proteins 
and organelles ready for packaging and subdivision into platelets. It is during this stage that 
granules are formed along with the invaginated membrane system (IMS) and dense tubular 
system (Kahr et al., 2013). 
The IMS is formed progressively through maturation from the plasma membrane which enfolds 
forming tubular invaginations which permeate the cytoplasm but are still in contact with the 
external milieu. The primary function of the IMS is as a membrane reservoir for proplatelet 
formation (Eckly et al., 2014, Eckly et al., 2012, Radley and Haller, 1982, Schulze et al., 2006). 
The primary driver of megakaryocyte differentiation is the cytokine thrombopoietin (TPO). 
Discovered along with its receptor c-Mpl in the early 1990s (Zeigler et al., 1994, de Sauvage et 
al., 1994), TPO facilitated the development of cell culture systems that reconstitute 
megakaryocyte differentiation and proplatelet formation in vitro, enabling these mechanisms to 
be studied (Machlus et al., 2014, Cramer et al., 1997, Lecine et al., 1998). Binding of TPO to 
c-Mpl results in receptor dimerization and downstream signalling (Kaushansky, 2005). c-Mpl 
expression is restricted to megakaryocytes and platelets, with elimination of either leading to 
sever thrombocytopenia, due to reduced progenitor and mature megakaryocyte numbers, and 
decreased megakaryocyte maturation (Machlus et al., 2014, Gurney et al., 1994). Produced by 
the liver, the circulating plasma concentration of TPO varies inversely to platelet number 
(Machlus et al., 2014). This is due to platelet c-Mpl receptors binding and removing TPO from 
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the plasma, thus increasing platelet number increases removal of circulating TPO. Accordingly 
during thrombocytopenia, elevated TPO levels drive platelet production (Machlus et al., 2014, 
Hitchcock and Kaushansky, 2014). 
Dimerization of c-Mpl upon TPO binding enables associated janus activated kinase-2 (JAK2) 
trans-autophosphorylation, and leads to signalling of phosphoinositide 3-kinase (PI3K) and the 
mitogen activated protein kinases (MAPKs) extracellular signal-regulated kinases 1 and 2 
(ERK1/2) and p38 downstream (Kaushansky, 2005). Interaction of these with transcription 
factors alters gene expression to increase HSC proliferation and megakaryocyte maturation 
(Kaushansky, 2005). 
 
1.3.3. Proplatelet formation and platelet release 
Once mature, megakaryocytes extend long thin branching cytoplasmic processes, termed 
proplatelets, into the sinusoidal blood vessels of the bone marrow, where they fragment 
releasing platelets into the circulation (Tavassoli and Aoki, 1989, Dutting et al., 2017). The 
process of proplatelet formation originates with pseudopod formation which then elongates 
from the plasma membrane. This elongation is dependent on and powered by the microtubule 
cytoskeleton, which undergoes dramatic reorganization, lining the entire length of proplatelet 
extensions and looping at the distal end to form tear shaped platelet size structures (Bender et 
al., 2015). The motor protein dynein is also critical to this process, driving elongation through 
microtubule sliding (Machlus et al., 2014, Patel et al., 2005, Tanenbaum et al., 2013). 
Actin also plays a role, forcing the proplatelet shafts to bend, kink and bifurcate amplifying the 
number of extensions and therefore number of sites platelets can be formed (Italiano et al., 
1999). Although the proplatelet shaft has multiple platelet sized swellings, fragmentation and 
release only occurs from the tips of proplatelets as the swellings along the shaft lack 
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microtubule coils (Italiano et al., 1999, Radley and Hartshorn, 1987). The anucleic fragments 
released from the ends of proplatelets are typically larger than platelets, these barbell shaped 
preplatelets undergo fission in the circulation, dividing into platelets (Figure 1. 1) (Thon et al., 
2012, Thon et al., 2010). Multiphoton microscopy has enabled visualisation of this process in 
the intact bone marrow of mice, with proplatelets seen to provide and release fragments which 
typically exceed platelet dimensions into the marrow vasculature (Junt et al., 2007). This also 
demonstrated the importance of the hydrodynamic shear stress from flowing blood on release 
of intravascular extensions into peripheral blood.  
During proplatelet formation the megakaryocytes entire intracellular contents, is trafficked 
along the microtubules and concentrated within the platelet swellings along the proplatelet shaft 
(Richardson et al., 2005). The exception to this is the multi-lobed nucleus which is retained 
within the cell body before being extruded from the cell and degraded (McArthur et al., 2018). 
Recently it has been proposed that the lung is the primary site of thrombopoiesis. Using 
multiphoton intravital microscopy Lefrancais et al observed large circulating megakaryocytes 
pass through the microcirculation of the lung and produce proplatelet extensions in a flow 
dependent manner (Lefrancais et al., 2017). Following a single lung transplant model they 
found the platelet releasing megakaryocytes in the lung circulation originated extrapulmonarily, 
mostly from bone marrow (Lefrancais et al., 2017). This model is however controversial with 
multiple previous reports using intravital microscopy failing to observe large megakaryocytes 
migrating out of the bone marrow and entering the blood stream (Zhang et al., 2012, Stegner et 
al., 2017). 
The trigger for proplatelet formation is currently not known, with the signals leading to this 
event still a significant gap in our understanding. Megakaryocytes reside in the bone marrow, 
an environment rich in ECM proteins including collagens, laminins and fibronectin. Collagen 
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type-I has been shown to inhibit megakaryocyte proplatelet formation preventing premature 
platelet release (Semeniak et al., 2016, Sabri et al., 2004, Sabri et al., 2006, Zou et al., 2009). 
Whereas collagen type-IV and laminins support proplatelet formation at the sinusoids (Balduini 
et al., 2008). GPVI and α2β1 the major activating collagen receptors on platelets are also 
expressed early in megakaryocyte differentiation. Recent work by the Schulze group has shown 
in megakaryocytes collagen type-I mediates inhibition by GPVI, however this inhibition is 
diminished at the vascular niche where collagen type-IV displaces type-I, thus promoting 
proplatelet formation (Semeniak et al., 2016). No positive enhancement of proplatelet 
formation was observed by bone marrow laminins or fibrinectin (Semeniak et al., 2016). Rather 
results suggest active inhibition of proplatelet formation is required instead of stimulatory 
signals (Semeniak et al., 2016).  
  




Figure 1. 1. Megakaryocyte maturation and platelet release. Megakaryocytes develop from 
haematopoietic stem cells (HSCs) residing in the bone marrow. Megakaryocytes become 
polyploid through process of endomitosis – repeated cycles of DNA replication without cellular 
division. Once mature, megakaryocytes extend long protrusions, termed proplatelets, into the 
sinusoidal blood vessels in a process powered by the microtubule cytoskeleton. Blood vessel 
shear stress then fragments the ends of these proplatelets, releasing preplatelets into the 
circulation. Preplatelet fragments are typically larger than platelets and undergo further division 
within the circulation producing mature platelets. 
  
 Chapter 1 – General Introduction   
12 
 
1.3.4. Platelet clearance and turnover 
Platelet production and clearance are balanced in order to strictly control the number of 
circulating platelets. In humans, platelet counts range form 150 – 450 x 106/ml (600 – 1200 x 
106/ml in mice), and approximately 100 billion new platelets are produced each day with an 
average lifespan of 7-10 days (3-5 days in mice). However, only a small proportion of platelets, 
during steady state conditions, are consumed through haemostasis. Old, defective and pre-
activated platelets are rapidly removed from the circulation by macrophages resident in the 
spleen and liver (Josefsson et al., 2013). Platelet clearance is mediated by multiple mechanisms 
(Hoffmeister and Falet, 2016). Platelet desiaylation leads to increased β-gal exposure which the 
Ashwell Morell receptor on surface of hepatocytes and liver macrophages recognises inducing 
platelet clearance (Quach et al., 2018, Grozovsky et al., 2015). Antibody mediated clearance 
where opsonisation by autoantibodies, usually against αIIbβ3 and GPIB-IX, stimulate Fc-
dependent clearance of platelets via macrophages (Quach et al., 2018).  
 
1.4. Platelets in haemostasis and thrombosis 
1.4.1. Primary role platelets 
In order for platelets to perform their primary role and prevent blood loss, they must be able to 
sense and block sites of vascular damage rapidly. Also they must be able achieve this at a range 
of physiological shear rates, and without obstructing or occluding vessel blood flow. Enabling 
platelets to succeed in this are the expression of multiple surface proteins which all contribute 
to the formation of a stable thrombus. The process of thrombus formation is described below 
and illustrated in Figure 1.2. 
Rolling and initiation. Initiation of platelet plug formation begins with the tethering, rolling 
and arrest of moving platelets (Brass, 2003, Offermanns, 2006). vWF present in the plasma 
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binds to extracellular matrix (ECM) collagens (type I and III) exposed at sites of vascular injury 
(Reininger, 2008, Kanaji et al., 2012). A1 domain binding sites then become exposed as the 
vWF is stretched by shear stress, allowing the GPIbα receptor on the platelet surface to bind, 
causing the tethering and slowing of the platelet to arrest (Clemetson, 2012).  
Activation and firm adhesion. GPO (glycine-proline-hydroxyproline) repeats on the exposed 
collagens interact with the GPVI-Fc receptor (FcR) γ-chain complex on platelets producing 
strong activation signals (Clemetson, 2012). This triggers inside-out signalling, switching the 
conformation of integrins αIIbβ3 and α2β1 from low to high affinity state, enabling them to 
bind fibrinogen/fibrin and collagen respectively, resulting in stable platelet adhesion (Watson 
et al., 2005, Nieswandt et al., 2009).  
Spreading. The binding of integrin αIIbβ3 to fibrinogen produces outside-in signalling and 
subsequent cytoskeletal rearrangement and spreading of the platelet (Calaminus et al., 2008, 
Durrant et al., 2017). First by extension of pseudopodia/filopodia and then by extension of 
lamellipodia, flattening and increasing the platelets surface area (Durrant et al., 2017). More 
platelets are then able to attach to the surface of activated platelets and through formation of 
tight junctions prevent blood loss (Clemetson, 2012). 
Secretion and aggregation. Recruitment of circulating platelets to propagate the thrombus 
once all the exposed collagen is covered is through the local accumulation of soluble secondary 
mediators. ADP present in platelet granules is secreted, along with fibrinogen and vWF from 
activated platelets, which also release thromboxane A2 (TxA2) by diffusion (Golebiewska and 
Poole, 2015). ADP produces powerful platelet activation through the G-protein coupled 
receptors (GPCRs) P2Y1 and P2Y12, which along with thromboxane receptor activation by 
TxA2 enables circulating platelets to cross-linking to the platelet aggregate via vWF and 
fibrinogen binding through integrin αIIbβ3 (Brass, 2003, Golebiewska and Poole, 2015). 
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Thrombin generation. Procoagulant enzyme complex assembly is promoted on the surface of 
activated platelets by exposure of phosphatidylserine (PS), and leads to localized generation of 
thrombin through the proteolytic cleavage of prothrombin, by factor Xa and Va of the 
coagulation cascade (Ruggeri and Jackson, 2013). Thrombin is a major platelet activator, acting 
through protease activated receptor (PAR)-1 and -4 GPCRs in human (PAR-3 and 4 in mice), 
as well as converting fibrinogen to fibrin (Chen et al., 1994, Coughlin, 2005, Coughlin et al., 
1992, Ishihara et al., 1997). 
Clot stabilisation and contraction. Thrombin catalyses cleavage of fibrinogen to fibrin, which 
polymerises at growing thombus core. Fibrin binds integrin αIIbβ3 and further activates GPVI 
stabilizing the clot, preventing embolism (Mammadova-Bach et al., 2015). Contraction forces 
generated by non-muscle myosin II on actin cytoskeleton pulls platelets towards each other, 
retracting the thrombus reducing its size and preventing vessel occlusion (Lam et al., 2011, Kim 








Figure 1. 2. Main stages of thrombus formation. Stages of primary of thrombus formation at 
sites of vascular injury. 1. Initial adhesion to the extracellular matrix (ECM); 2. Firm adhesion; 
3. Integrin-mediated spreading; 4. Secretion of α- and dense granules; 5. Recruitment of 
platelets; 6. Thrombin generation and 7. Thrombus stabilisation by fibrin network generation. 
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1.5. Platelet activation 
Platelet reactivity is determined by the interaction of their receptors with the range of agonists 
and adhesive proteins in their external environment. The major platelet surface receptors 
involved in haemostasis can be categorized as protein tyrosine kinase (PTK) linked receptors 
or GPCRs, with receptors involved at multiple stages of platelet function (Clemetson and 
Clemetson, 2013). 
 
1.5.1. Adhesive PTK linked receptors 
PTK linked receptors initiate primary platelet activation and mediate platelet adhesion. 
 
1.5.1.1. GPIb-IX-V 
Pivotal in initiating and propagating haemostasis and thrombosis, the vWF receptor complex 
GPIb-IX-V consists of GPIbα, GPIbβ, GPIX and GPV subunits. The largest of which, GPIbα, 
is involved in ligand binding, with vWF, P-selectin, thrombin and factor XII of the coagulation 
cascade among others all shown to interact (Andrews and Berndt, 2013, Berndt et al., 2001). 
Ligand binding produces intracellular signalling, with the cytoplasmic tail of GPIbα, filamin-1 
and 14-3-ζ adaptor protein interacting with actin. The GPIbβ subunit also contributes to the 
signalling of the complex through 14-3-ζ binding and phosphorylation of a serine residue that 
regulates actin polymerisation (Dai et al., 2005). 
 
1.5.1.2. Integrins αIIbβ3 and α2β1 
Following vWF mediated tethering and arrest of platelets, integrins bind and stabilize platelet 
adhesion to ECM proteins. Uniquely expressed on platelets, αIIbβ3 is the major platelet 
adhesive integrin which binds fibrinogen, fibronectin and vWF through recognition of a 
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common RGD (Arg-Gly-Asp) sequence (Nieswandt et al., 2009, Bennett et al., 2009). The 
collagen receptor integrin α2β1, is also important, and along with supplemental binding of 
integrins α5β1 (fibronectin), α6β1 (laminin) and αVβ3 (vitronectin) results in firm platelet 
adhesion. Central to their function, integrins undergo activation by inside-out signalling, 
switching them from a low to a high affinity state (Clemetson and Clemetson, 2013, Bledzka et 
al., 2013). Initiation of this mechanism is triggered through engagement of various adhesion 
receptors and GPCRs.  
Ligand binding to αIIbβ3 initiates outside-in signalling through SFKs or interaction with 
cytoskeletal proteins (Durrant et al., 2017). Activated integrin αIIbβ3 binding of divalent 
fibrinogen or multivalent vWF is also necessary for aggregate formation, cross-linking platelets 
together (Clemetson and Clemetson, 2013, Bledzka et al., 2013). Unlike αIIbβ3, α2β1 primary 
function is adhesion, and it mediates only weak activation signals. 
 
1.5.2. ITAM signalling 
More powerful activation signals are required than elicited through the vWF receptor complex 
GPIbα-IX-V and integrins for full platelet activation (Barrow and Trowsdale, 2006). 
Characterised by a conserved YxxL/Ix6-12YxxL/I motif in the cytoplasmic tail, ITAMs, first 
identified in antigen receptors of T-cells and B-cells, are found across all haematopoietic 
lineages (Reth, 1989). Expressed in human platelets are the ITAM-containing receptor 
complexes GPVI-FcRγ-chain and FcγRIIA, and the hemi-ITAM-containing C-type lectin-2 
(CLEC-2) receptor (Gibbins et al., 1997). Although lacking any integral catalytic activity, 
ITAM-containing receptors mediate powerful activation of platelets through recruitment of 
PTKs following receptor cross-linking (Barrow and Trowsdale, 2006). 
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1.5.2.1. GPVI-FcR γ-chain 
Exclusively expressed on megakaryocytes and platelets, GPVI is a type 1 transmembrane 
protein with two extracellular Ig domains, a transmembrane region and a short cytoplasmic tail. 
GPVI is found complexed through a salt-bridge in the transmembrane domain to the FcRγ-
chain (Nieswandt et al., 2000). This association is essential for the surface expression and 
signalling of GPVI, which does not possess the ability to signal on its own (Pollitt et al., 2013, 
Nieswandt and Watson, 2003). The FcRγ-chain itself, is a covalently linked homodimer 
containing an ITAM in each cytoplasmic tail (Gibbins et al., 1997). 
Classically thought of as a collagen receptor, GPVI has also been shown to bind laminins (but 
at much lower affinity), and more recently fibrin (Pollitt et al., 2013, Onselaer et al., 2017, 
Mammadova-Bach et al., 2015). Binding of the glycine-proline-hydroxyproline (GPO) repeats 
conserved within collagen fibres initiates signalling of the GPVI complex (Asselin et al., 1999). 
The two tyrosine residues conserved within the ITAMs of the FcRγ-chain are rapidly 
phosphorylated by the SFK Lyn, which is constitutively associated to the intracellular tail of 
GPVI via a proline rich region (PRR) (Suzuki-Inoue et al., 2002). Phosphorylation can also be 
performed by another SFK Fyn, however it is not constitutively associated with GPVI, and 
rather involved in prolonged activation of the receptor (Watson et al., 2010). The tyrosine 
kinase Syk, via its SH2 domains, is recruited to the phosphorylated ITAM and undergoes 
activation by autophosphorylation on tyrosines 525 and 526 (519 and 520 in mice). Activated 
Syk then phosphorylates numerous tyrosines on the adaptor protein linker for activation of T-
cells (LAT), which recruits Grb2 and Gads plus its associated protein Slp76. Assembly of this 
signalosome activates PLCγ2 and PI3K. Activation of PI3K aids recruitment of PLCg2 to the 
membrane and supports its activation by Tec family kinases (Tec and Btk) which phosphorylate 
residues of the SH2-SH3 linker region of PLCγ2 (Humphries et al., 2004, Nieswandt and 
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Watson, 2003). Cleavage of phosphatidylinositol 4, 5-bisphosphate (PIP2) by PLCγ2 releases 
diacylglycerol (DAG) and inositol 1, 4, 5-trisphosphate (IP3), which subsequently initiate 
release of intracellular Ca2+ and activation of protein kinase C (PKC). This results in platelet 
integrin activation and granule secretion. 
 
1.5.2.2. FcγRIIA 
Consisting of two extracellular Ig-like domains, a transmembrane domain and an ITAM-
containing intracellular tail, FcγRIIA is a low affinity receptor for the IgG Fc domain and is 
expressed on human, but not mouse platelets (Kasirer-Friede et al., 2007). Activation of the 
receptor through clustering induced by IgG binding, results in phosphorylation of the conserved 
tyrosine residues in its ITAM and signalling via the same pathway as the GPVI FcR γ-chain 
complex (Clemetson and Clemetson, 2013). 
 
1.5.2.3. CLEC-2 
CLEC-2 is a type-II transmembrane protein highly expressed in platelets. Consisting of an 
extracellular C-type lectin carbohydrate-like binding domain, a single transmembrane domain 
and an intracellular tail, CLEC-2 is expressed on the surface of platelets as a non-disulfide-
linked homodimer (Hughes et al., 2010, Watson et al., 2009). The intracellular tail of CLEC-2 
contains a conserved YxxL hemi-ITAM. 
Rhodocytin, purified from the venom of the Malayan pit viper, was the first exogenous ligand 
identified for CLEC-2, with an endogenous ligand podoplanin since identified (Suzuki-Inoue 
et al., 2006, Suzuki-Inoue et al., 2007). Podoplanin is an extensively glycosylated cell surface 
protein with an extracellular domain of unknown structure. It is expressed at high levels in lung 
type 1 alveolar cells, kidney podocytes and lymphatic endothelial cells, as well as also being 
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upregulated on inflammatory macrophages and a variety of tumours and implicated in 
metastasis (Kato et al., 2003, Kerrigan et al., 2012). Interaction of platelet CLEC-2 with 
podoplanin is essential for separation of blood and lymphatic vascular systems (Osada et al., 
2012, Lowe et al., 2015). However vascular endothelial cells and platelets do not express 
podoplanin, which suggests it is unlikely to play a general role in haemostasis (Watson et al., 
2010). Instead CLEC-2 has significant roles in many non-classical functions of platelets, 
particularly vascular integrity and thrombosis during inflammation where podoplanin is 
upregulated and accessible to platelets (Suzuki-Inoue, 2017). 
Dimerization of CLEC-2 is essential for commencement of receptor signalling, as binding of 
the two SH2-domains of Syk is key for its activation, and CLEC-2 only possesses a single 
tyrosine residue (Hughes et al., 2015). Crosslinking and further clustering of CLEC-2 induces 
more powerful stimulation (Hughes et al., 2010). Signalling events downstream of CLEC-2 are 
very similar to those of GPVI-FcR γ-chain complex, although there are some differences. In 
CLEC-2 signalling, SFK and Syk kinases appear to act more cooperatively, with Syk 
significantly contributing to hemi-ITAM phosphorylation, whereas during in GPVI signalling 
these kinases have a  clearly defined hierarchy (Spalton et al., 2009, Severin et al., 2011). Also 
unlike GPVI, actin polymerisation and positive feedback by the secondary mediators ADP and 
TxA2 are critical to phosphorylation of CLEC-2 following ligand engagement (Suzuki-Inoue et 
al., 2006). 
 
1.5.3. G protein coupled receptors 
Following activation platelets secrete secondary mediators which induce activation and 
recruitment of circulating platelets to the thrombus, as well as positively feeding back onto the 
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already activated platelets. TxA2 and ADP are the chief mediators of this, activating platelets 
through GPCRs (Brass et al., 2013).  
ADP is released from dense granules following platelet activation, and by damaged endothelial 
cells, it activates platelet P2Y1 and P2Y12 receptors (Clemetson and Clemetson, 2013, Brass 
et al., 2013). P2Y1 receptors are Gq coupled, leading to PLC activation and an increase in 
intracellular Ca2+ (Brass et al., 2013). The Gi-coupled P2Y12 receptors, inhibit cAMP 
formation by adenyl cyclase, reducing PKA activity allowing platelet activation, and also leads 
to phosphorylation of PKB/Akt downstream of PI3K (Cattaneo, 2013). The GTPase Rap1 is 
also activated downstream of PI3K, with Rap1 shown to contribute to integrin activation 
(Cattaneo, 2013). 
Produced from arachidonic acid by cyclooxygenase and thromboxane synthase, TxA2 is also 
released from platelets upon activation. TxA2 activates the thromboxane receptor (TP), a Gq-
coupled receptor with the same mechanism of platelet activation as P2Y1 (Clemetson and 
Clemetson, 2013). 
Thrombin mediates powerful platelet activation via the protease-activated receptors (PARs) 1 
and 4 (PAR4 only in mice)(Coughlin, 2005). These GPCRs require cleavage of their N-
terminus by thrombin to expose a tethered ligand that produces activation signals via Gq and 
G13 (Clemetson, 2012, Brass et al., 2013, Chen et al., 1994). Downstream PLC and Rho 
activation then lead to intracellular Ca2+ increase and actin cytoskeletal rearrangement and 
shape change (Brass et al., 2013). 
Cleavage of fibrinogen by thrombin stimulates fibrin polymerization which stabilizes the 
thrombus as well as activating GPVI (Mammadova-Bach et al., 2015, Onselaer et al., 2017). In 
humans, rapid cleavage of PAR1 by low thrombin concentrations provides early activation 
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before it is downregulated protecting platelet sensitivity. PAR4 responds more slowly, requiring 
higher concentration of thrombin for activation (Covic et al., 2000). 
 
1.6. Inhibition of platelets 
1.6.1. Cyclic nucleotides  
Healthy undamaged endothelial cells release inhibitory mediators, prostacyclin (PGI2) and 
nitric oxide (NO) to maintain circulating platelets in a quiescent state (Bye et al., 2016, Nagy 
and Smolenski, 2018). PGI2 secreted by endothelial cells binds the prostaglandin receptor (IP 
receptor), a GPCR present on the platelet surface, activating the Gα subunit (Figure 1.3). This 
stimulates the production of cAMP through activation of membrane bound adenyl cyclases. 
The cAMP then uncouples the catalytic subunits of the serine/threonine kinase PKA which 
phosphorylates its target substrates, resulting in inhibition of platelet activation (Bye et al., 
2016). NO inhibits platelet activation in a similar manner, through the serine/threonine kinase 
PKG, which phosphorylates many of the same target substrates as PKA (Figure 1.3). Generated 
by endothelial nitric oxide synthase in endothelial cells, NO diffuses across the cell membrane 
and into platelets where it activates soluble guanyl cyclase production of cGMP. cGMP 
uncouples the regulatory domain PKG, enabling phosphorylation of its substrates and inhibition 
of platelet activation (Nagy and Smolenski, 2018). The short half-lives of both PGI2 and NO 
means inhibition is transient and only occurs close to the vessel wall. This enables platelets to 
respond rapidly to any endothelium damage. 
  




Figure 1. 3. Cyclic nucleotide-mediated inhibition of platelet activation. Prostacyclin (PGI2) 
and nitric oxide (NO) stimulate adenyl and guanyl cyclase, respectively. Production of cyclic 
adenosine monophosphate (cAMP) and cyclic guanine monophosphate (cGMP) then activate 
protein kinase A (PKA) and protein kinase G (PKG), respectively. PKA and PKG 
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1.6.2. ITIM-containing receptors 
First identified in immune cells, immunoreceptor tyrosine base inhibition motif (ITIM)-
containing receptors mediate intracellular inhibition of ITAM-containing receptor signalling 
(Daeron et al., 2008, Muta et al., 1994, Daeron et al., 1995). Defined as the consensus sequence 
(I/V/L/S)-x-Y-x-x-(L/V), ITIMs are present in the cytoplasmic tail of receptors, usually in pairs 
separated by approximately 20 amino acids. Platelet inhibition mediated by ITIM-containing 
receptors, unlike cyclic nucleotides which maintain platelets in a quiescent state, occurs 
following initiation of platelet activation, restraining activation signalling and preventing 
excessive thrombus growth (Bye et al., 2016, Coxon et al., 2017).  
Phosphorylation of the conserved tyrosine residues within ITIMs provide docking sites for lipid 
and protein tyrosine phosphatases. These negative regulators of platelet activation, due to the 
receptors clustering with ITAM-containing receptors, are then able to dephosphorylation and 
inactivate key activation signalling pathway components (Bye et al., 2016, Du, 2014). Several 
ITIM-containing receptors have so far been identified in platelets and megakaryocytes (Coxon 
et al., 2017). 
 
1.6.3. ITSM-containing receptors 
Immunoreceptor tyrosine-based switch motifs (ITSMs) can also be found in tandem with ITIMs 
(Newman and Newman, 2013). Although the consensus sequence of ITSMs (T-x-Y-x-x-V-I) 
is similar to ITIMs, they are, depending on which proteins they recruit, able to produce either 
activation or inhibition signals (Ostrakhovitch and Li, 2006)(Cannons et al., 2011). 
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1.6.4. Canonical ITIM signalling 
Once phosphorylated, usually by SFKs, the conserved tyrosine residues in ITIMs provide 
docking sites for Src homology 2 (SH2) domain containing inositol phosphatase-1 (SHIP-1) 
and the structurally similar SH2 domain containing tyrosine phosphatases Shp1 and Shp2. Due 
to the close proximity these phosphatases are then able to dephosphorylate and inactivate key 
signalling components of ITAM-containing receptor activation pathways (Figure 1. 4) (Bye 
2016, Du 2014). C-terminal Src kinase (Csk) has also been shown to interact with some ITIM-
containing receptors. Csk inhibits SFK activity through phosphorylation of their C-terminal 
tyrosine residue. This subsequently induces a conformational change through interaction with 
the SH2 domain, and obstructs the active site of the kinase (Senis et al., 2009). 
 
1.6.4.1. PECAM-1 
The first to be identified and most investigated platelet ITIM-containing receptor is PECAM-
1. Also known as CD31, PECAM-1 is a 130 kDa glycoprotein consisting of 6 highly 
glycosylated extracellular Ig constant 2 (IgC2)-like domains, a transmembrane domain and a 
large intracellular tail containing an ITIM, ITSM, PRR and a transmembrane proximal 
palmitoylation site (Figure 1. 5) (Newman et al., 1990). PECAM-1 is expressed in 
haematopoietic and non-hematopoietic cells, and highly abundant in platelets and endothelial 
cells. Dependent on the two N-terminal IgC2-like ectodomains PECAM-1 primarily undergoes 
trans-homophilic interactions, although these domains have the capacity for cis-homophilic 
binding as well. PECAM-1 is also able to undergo heterophilic interactions with platelet αVβ3 
and CD177 and CD38 on neutrophils (Buckley et al., 1996, Jones et al., 2012, Sachs et al., 
2007, Deaglio et al., 1998).  
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Phosphorylation of the ITIM and ITSM conserved tyrosine residues mediated by SFKs, 
predominantly Lyn, is central to PECAM-1 signal transduction (Ming et al., 2011). The 
sequential phosphorylation of the ITSM by Lyn, enables Csk binding and phosphorylation of 
the ITIM (Tourdot et al., 2013). These phospho-tyrosines provide docking sites for Shp1 and 
Shp2 via their tandem SH2 domains, though it appears Shp2 is preferentially bound, localizing 
them to the plasma membrane and relieving their intramolecular inhibition, enhancing their 
catalytic activity (Edmead et al., 1999, Jackson et al., 1997, Hu et al., 2016). Interaction with 
other proteins (SHIP and SFKs) via their SH2 or SH3 domains have also been identified, but 
functional relevance in platelets is yet to be determined.




Figure 1. 4. Classical ITIM-mediated inhibition of ITAM signalling. Recruitment of Shp1, Shp2 and SHIP to ITIM-containing receptor 
inhibits cellular activation mediated by ITAM-containing receptors. 
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In resting cells, accessibility to the ITSM is controlled by interactions between cytoplasmic tail 
of PECAM-1 and the plasma membrane, which prevents phosphorylation and inhibitory 
signalling. Upon activation, phosphorylation of the lipid interacting segment C-terminal serine 
disrupts this membrane interaction. Subsequent exposure and phosphorylation of the C-terminal 
ITSM by the SFK Lyn completes plasma membrane dissociation, and enables phosphorylation 
of the N-terminal ITIM. Phosphorylation of both ITIMs is required for recruitment of Shp1 or 
Shp2 and inhibitory signalling (Paddock et al., 2011, Newman and Newman, 2013). 
The role of PECAM-1 in platelets and megakaryocytes has been extensively characterised 
through use of a KO mouse model. PECAM-1 deficient platelets display enhanced aggregation 
and secretion responses to collagen and CRP, and subthreshold rhodocytin stimulation, but not 
thrombin or ADP (Patil et al., 2001, Wee and Jackson, 2005, Dhanjal et al., 2007b). Indicating 
PECAM-1 primarily inhibits ITAM (GPVI) and hemi-ITAM (CLEC-2) coupled receptor 
signalling; however at higher agonist concentrations enhancement is lost suggesting only a 
modulatory role. 
Although normal platelet counts are observed in PECAM-1 KO mice (Mahooti et al., 2000), 
recovery following antibody-mediated depletion is delayed due to defective platelet production. 
Deficient megakaryocytes exhibit increased adhesion, and impaired SDF-1α migration which 
also contributes to the delayed recovery (Dhanjal et al., 2007a). The migration defect was found 
to be due to absence of CXCR4 (SDF-1α receptor) polarisation to the megakaryocytes leading 
edge and underlies the abnormal bone marrow distribution of megakaryocytes observed in KO 
mice (Dhanjal et al., 2007b, Wu et al., 2007). 
In vivo thrombosis is also enhanced in absence of PECAM-1, with larger laser-induced thrombi 
and a modest increase in ferric chloride-induced thrombosis observed in deficient mice (Falati 
et al., 2006). Thrombosis to photochemical injury was however normal, with differences 
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probably owing to the different injury mechanisms (Vollmar et al., 2001). Further interrogation 
of the enhanced thrombosis using chimeric mice demonstrates the enhancement results from 
lack of platelet and leukocyte PECAM-1 rather than from endothelial cells. Tail bleeding time 
was also increased in PECAM-1 KO mice, and attributed somewhat paradoxically to absence 
of endothelial PECAM-1 (Falati et al., 2006, Mahooti et al., 2000). 
PECAM-1 has also been suggested to play a role in platelet integrin responses, with delayed 
clot retraction, impaired cytoskeleton rearrangement and focal adhesion kinase (FAK) tyrosine 
phosphorylation reported in deficient platelets by some studies (Wee and Jackson, 2005). Yet 
normal clot retraction and mild increase in fibrinogen spreading reported by subsequent studies, 
with differences credited to the experimental methods used and genetic drift in the PECAM-1 
KO mouse model (Dhanjal et al., 2007b). 
 
1.6.4.2. G6b 
G6b-B is specifically expressed on megakaryocytes and platelets and is the second most highly 
expressed ITIM-containing receptor (Zeiler et al., 2014, Burkhart et al., 2012, Senis et al., 2007, 
Newland et al., 2007). G6b-B consists of a single variable Ig-like (IgV) extracellular domain, a 
transmembrane region and an intracellular tail containing a PRR, an ITIM and ITSM (Figure 
1. 5). Although other G6b isoforms have been identified by transcriptomics, G6b-B is the only 
one conclusively shown to be expressed (Senis et al., 2007, Moebius et al., 2005). 
The conserved tyrosine residues in the ITIM and ITSM of G6b-B are constitutively 
phosphorylated and associated with Shp1 and Shp2 (Senis et al., 2007, Mazharian et al., 2012). 
Phosphorylation is mediated by SFKs, with PTP binding primarily mediated by the ITIM. Shp2 
binds G6b-B with higher affinity than Shp1, and is able to interact when only one motif is 
phosphorylated, whereas Shp1 interaction has an absolute requirement for both (Coxon et al., 
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2012). There is no evidence for lipid phosphatase SHIP-1 binding, but although not confirmed 
in platelets, in vitro evidence suggests it can bind Fyn, Src, Syk which may facilitate Shp1/2 
phosphorylation (Coxon et al., 2012). There is also no evidence for SH3 binding to the PRR of 
G6b-B. 
Initial studies into the function of G6b-B revealed crosslinking of the receptor inhibited CRP 
and ADP-mediated platelet aggregations (Newland et al., 2007). This inhibitory role was 
verified in cell lines where co-expression of G6b-B with the (hemi)ITAM receptors GPVI-FcRγ 
chain and CLEC-2 inhibited activation in an NFAT-luciferase assay (Mori et al., 2008). The 
importance of this receptor was not however realised until the generation of a deficient mouse 
model. 
Mice deficient in G6b present a severe phenotype unique among the platelet and megakaryocyte 
ITIM-containing receptors, with platelet count dramatically reduced by 80%, platelet volume 
increased 35% and altered reactivity (Mazharian et al., 2012). Reduced platelet production in 
combination with more rapid clearance of circulating platelets, due to their preactivated state, 
underlies the observed macrothrombocytopenia. G6b-deficient megakaryocytes undergo 
normal development and proliferation ex vivo, but fail to spread efficiently on fibrinogen, 
fibronectin and collagen, and have reduced capacity to form proplatelets (Mazharian et al., 
2012). These findings establish G6b-B as important novel regulator of terminal stages platelet 
production. 
G6b deficient platelets have impaired collagen reactivity, as GPVI-FcRγ chain expression is 
downregulated to temper tonic GPVI signalling (Mazharian et al., 2012). Altogether, this results 
in reduced thrombus formation and enhanced bleeding in G6b KO mice. Highlighting the 
critical role ITIM-containing receptor regulation has in platelets and megakaryocytes. 
Additional studies in mice expressing a mutant form of G6b-B, where tyrosine residues of the 
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ITIM/ITSM have been mutated to phenylalanine, preventing Shp1/2 docking and downstream 
signalling, report strikingly similar results (Geer et al., 2018). G6b diY/F were 
macrothrombocytopenic due to reduced platelet production and myelofibrosis was observed in 
bone marrow and spleens. Platelets from these mice also exhibited altered reactivity with 
collagen and thrombin responses reduced, but CLEC-2 responses potentiated. Recapitulation 
of the KO phenotype in these mice demonstrates the inhibitory effect of G6b is mediated via 
Shp1 and Shp2 binding to the ITIM/ITSM. 
 
1.6.4.3. LAIR-1 
LAIR-1 is a type 1 transmembrane glycoprotein consisting of a single IgC2 ectodomain, a 
transmembrane region and a cytoplasmic tail containing an ITIM and an ITSM (Figure 1. 5) 
(Brondijk 2010). Widely expressed on haematopoietic cells, including T cells, B cells and 
progenitor cells and immature MKs, LAIR-1 is however not expressed on platelets (Meyaard 
et al., 1997). 
LAIR-1 is a collagen receptor, binding both transmembrane and extracellular collagens with 
high affinity (Lebbink et al., 2006, Lebbink et al., 2007). Like GPVI the interaction is dependent 
on the GPO repeats conserved in all collagen trimers, however LAIR-1 binds these repeats with 
much higher affinity, and has been shown to inhibit collagen induced GPVI signalling when 
they are expressed on the same cell (Brondijk et al., 2010, Lebbink et al., 2006). 
Inhibition mediated by LAIR-1 was initially demonstrated through antibody mediated 
crosslinking of the receptor in immune cells. Crosslinking was able to potently inhibit NK cell 
from mediating lysis of target cells (Meyaard et al., 1997, Meyaard, 2008, Ouyang et al., 2003, 
Poggi et al., 1997), while in effector T cells it was able to diminish cytotoxic activity (Meyaard, 
2008, Meyaard et al., 1997, Meyaard et al., 1999, Maasho et al., 2005, Poggi et al., 1997). 
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Density of surface expression was shown to correlate with inhibitory capacity of LAIR-1 in T 
cells (Saverino et al., 2002). Crosslinking on B cells, was also shown to decreased B cell 
receptor induced Ca2+ mobilization and cytokine production (Merlo et al., 2005). 
LAIR-1 has also been implicated in negative regulation of megakaryopoiesis, with primary 
human CD34+ cell megakaryocyte production upon TPO stimulation decreased with antibody 
mediated LAIR-1 crosslinking (Xue et al., 2011). LAIR-1 has also been shown to play an 
essential role in the development of acute myeloid leukaemia (Kang et al., 2015). 
Upon activation the conserved tyrosine residues in the ITIM and ITSM of LAIR-1’s 
intracellular tail are phosphorylated by SFKs, with both required for full activation (Meyaard, 
2008, Meyaard et al., 1997, Verbrugge et al., 2003, Xu et al., 2000). These phospho-tyrosines 
have been shown to facilitate interaction with the phosphatases Shp1 and Shp2 in humans, but 
not SHIP. In mice, LAIR-1 however does not interact with Shp1, interacting only with Shp2 
(Lebbink et al., 2004). Csk has also been shown to interact with both mouse and human LAIR-
1 (Meyaard, 2008, Verbrugge et al., 2006). 
Co-expression of LAIR-1 with GPVI in transiently transfected DT40 chicken B cells results in 
powerful inhibition of collagen mediated activation of an NFAT reporter assay (Tomlinson et 
al., 2007). Both receptors have been shown to be expressed on a subset of megakaryoblasts 
during human megakaryocyte development, suggesting LAIR-1 may inhibit migration and 
proplatelet formation in immature megakaryocytes before expression is downregulated and lost 
upon mature megakaryocytes (Steevels et al., 2010). 
LAIR-1 KO mice have been generated, the phenotype of which will be discussed in chapter 3. 
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1.6.4.4. CEACAM1/2 and PIR-B 
Despite proteomic and transcriptomic studies questioning their expression in platelets, 
transgenic mouse studies have demonstrated functional roles for the ITIM-containing receptors 
CEACAM-1, CEACAM-2 and PIR-B in platelets (Figure 1. 5).  
While CECAM-1 is expressed in endothelial and hematopoitic cells, CECAM-2 is only present 
in mice kidney, testis, brain and select epithelial cells, with no human ortholog identified 
(Zebhauser et al., 2005). Constitutive KO models of the CEACAM-1 and CEACAM-2 
receptors presented with similar phenotype; increased aggregation to subthreshold agonist 
concentrations, increased thrombus formation in vivo, and both receptors are implicated in 
positive regulation of αIIβ3 integrin function (Alshahrani et al., 2016, Alshahrani et al., 2014, 
Wong et al., 2009, Yip et al., 2016). 
Containing an ITIM and 3 non-consensus ITIM-like motifs, PIR-B, the murine homolog of 
human LILRB2, is expressed in hematopoietic stem cells, myeloid B cells and platelets (Fan et 
al., 2014, Kubagawa et al., 1999, Zheng et al., 2012). Studies using a transgenic mouse model 
lacking the intracellular tail of PIR-B, suggest a role for PIR-B in megakaryocyte development 
as mice exhibited mild thrombocythemia and higher number of megakaryocytes. Platelets from 
this model were also hyper-responsive to low concentration CRP stimulation (Fan et al., 2014). 
Inability to detect these receptors by proteomics and genomics methods is likely due to low 
abundance and technique limitations, but does question the observed phenotypes. 
 
 


















Figure 1. 5. ITIM-containing receptors expressed in mouse megakaryocytes and platelets. LAIR-1 is only 
expressed in immature megakaryocytes. 
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1.6.5. Non-canonical ITIM signalling 
1.6.5.1. TLT-1 
TLT-1 is the most highly abundant ITIM-containing receptor in both human and mouse 
platelets. Identified as the inhibitory analogue of TREM-1 immune receptor family, its 
expression is restricted to megakaryocytes and platelets. TLT-1 consists of a single extracellular 
V-set Ig domain, a transmembrane region and an intracellular tail containing an ITIM and 
ITSM. 3 splice variant isoforms of TLT-1 have been identified in platelets differing only in 
their intracellular tails. Full length TLT-1 has a 127aa intracellular tail containing 2 conserved 
Tyr residues and a proline rich region (Figure 1. 5). The Tyr residues are present in a C-terminal 
classical ITIM and a membrane-proximal non-classical ITSM (Gattis et al., 2006). Whereas the 
shorter splice variant lacks these, instead its 18aa tail encodes a dileucine receptor sorting motif 
akin to variant chain MHC class II molecules (Gattis et al., 2006). The 3rd isoform lacks both 
the intracellular and transmembrane regions, only consisting of the extracellular domain 
(Washington et al., 2009). In addition, cleavage of TLT-1 from the surface by 
metalloproteinases is reported to produce a soluble form, consisting of the extracellular domain. 
The existence of a splice variant lacking the intracellular tail and soluble TLT-1 (sTLT-1) 
suggest some functional involvement of the extracellular domain independent of ITIM-
signalling (Klesney-Tait et al., 2006). In resting megakaryocytes and platelets all these TLT-1 
isoforms are localised in α-granules and upregulated to the surface following activation. 
Details of the downstream signalling of TLT-1 are still not clear, with most of what is known 
to date coming from work in transfected cell lines. Following initial characterization as an 
ITIM-containing receptor, TLT-1 was assessed for interactions with the SH2-domain 
containing protein tyrosine phosphatases. Pervanadate treatment of transfected HEK293T cells 
demonstrated Shp1 interaction with the phosphorylated-ITIMs of TLT-1 (Washington et al., 
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2002). Subsequent work in RBL-2H3 cell lines transfected with wtTLT-1 and mutant tyrosine 
to phenylalanine (Y>F) ITIMs demonstrated effective recruitment of Shp2 upon 
phosphorylation to the classical C-terminal ITIM, but not the non-classical membrane-proximal 
ITIM (Barrow et al., 2004). However, despite abundant expression interaction with Shp-1 or 
SHIP could not be detected.  
Classical models of ITIM-mediated signalling would suggest TLT-1 might inhibit ITAM-
containing receptor signalling. Interestingly, crosslinking of FcɛRI with TLT-1 in these cells 
resulted unexpectedly in increased rather than inhibited intracellular calcium levels (Barrow et 
al., 2004). This indicates stimulation of TLT-1 actually enhances rather than inhibits activation, 
which was dependent on the C-terminal classical ITIM. Shp-2 has been implicated in both 
activation and inhibition signalling depending on conditions (Klesney-Tait et al., 2006). 
Binding assays using Glutothione-S-transferase (GST) fusions of the cytoplasmic tail of TLT-
1 found strong interaction with moesin and their other highly homologous ERM family 
members (ezrin and radixin), with moesin interactions subsequently confirmed in human 
platelets (Washington et al., 2009). ERM family proteins are known to link membrane bound 
proteins to the actin cytoskeleton and implicated in formation filopodia and lamellipodia in 
platelets suggesting TLT-1 may play a role in these processes (Washington et al., 2009).  
Generation of a TLT-1 deficient mouse model has been utilized to interrogate the functional 
role of TLT-1 in platelet aggregation. Deficient mice are viable and fertile, with a decrease in 
platelet count of 20%. Aggregation responses to thrombin, collagen, ADP and U46619 were 
reduced in platelet rich plasma at all concentrations tested, with fibrinogen binding of deficient 
platelets showing a tendency to be decreased compared to wild type following suboptimal 
stimulation with ADP (Washington et al., 2009). In vivo tail bleeding time also showed null 
mice bled more than controls (Washington et al., 2009). 
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As TLT-1 is also a member of the TREM family of proteins, that play important roles in both 
adaptive and innate immunity, the role of TLT-1 has also been evaluated in various models of 
inflammation (Giomarelli et al., 2007). In mice, lipopolysaccharide (LPS)-induced sepsis led 
to detectable levels of plasma sTLT-1 within 2 hours, which continued to increase over 24 
hours. This increase in sTLT-1 inversely mirrored the pattern of thrombocytopenia in these 
mice, suggesting sTLT-1 is released or shed as platelets leave the circulation during 
endotoxemia (Washington et al., 2009). TLT-1 deficient mice succumbed to LPS challenge 
faster than controls, and were also predisposed to haemorrhage associated with inflammatory 
lesions (Washington et al., 2009). Together findings advocate a protective role for TLT-1 during 
inflammation, dampening the inflammatory response and enhancing platelet aggregation at 
sites of vascular injury (Washington et al., 2009) 
 
1.7. Phosphatases 
One of the main ways activation signals are transmitted in platelets is through phosphorylation 
of signalling proteins on key tyrosine residues by PTKs. Regulation of these activation signals 
is achieved through protein tyrosine phosphatases (PTPs), which oppose the actions of PTKs 
by dephosphorylating these residues (Senis, 2013). 
 
1.7.1. Protein tyrosine phosphatases 
PTPs are a family of enzymes that modulate signal transduction within cells through the 
dephosphorylation of tyrosine residues (Senis, 2013). Depending on subcellular localisation 
and downstream targets, this can activate or inhibit cellular responses (Senis, 2013). There are 
two groups of PTPs, non-transmembrane, and receptor-like whose ectodomains vary in shape 
and size (Senis, 2013).  
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Platelets express only a few PTPs, with the receptor-like CD148 first to be identified (Senis et 
al., 2007). CD148 is master positive regulator of SFKs in platelets. In resting platelets CD148 
is critical in maintaining a pool of active SFKs by dephosphorylating their C-terminal inhibitory 
tyrosine residues (Senis, 2013, Mori et al., 2012). However it also attenuates SFK activity by 
dephosphorylating their activation loop. CD148 is therefore a molecular switch modulating the 
optimal level of SFK activity in resting and activated states (Senis, 2013). The non-
transmembrane PTP-1B is also highly expressed in platelets, and plays a specialized role in 
αIIbβ3 outside-in signalling through dephosphorylation of Src C-terminal inhibitory tyrosines 
(Senis, 2013). 
 
1.7.2. Shp1 and Shp2 
Consisting of tandem SH2 domains, a single PTP domain and a short C-terminal tail, the 
structurally related non-transmembrane PTPs Shp1 and Shp2 are crucial for ITIM-containing 
receptor signalling (Senis, 2013). The SH2 domains, via intra- and intermolecular interactions, 
regulate the activity and compartmentalisation of Shp1 and Shp2. The backside loop opposite 
the phosphotyrosine binding pocket of the N-terminal SH2 domain has been shown to obstruct 
the catalytic site of the PTP domain and disrupt the phosphotyrosine binding site of the N-
terminal SH2 domain in the process (Barford and Neel, 1998, Hof et al., 1998). In this inactive 
conformation, the C-terminal SH2 domain is still free to interact with phosphotyrosines (Senis, 
2013). Interactions of the tandem SH2 domains with the phosphor-tyrosines of tandem ITIMs, 
localizes Shp1/2 to the plasma membrane and strongly activates them. 
Despite sharing structural similarity their physiological functions differ. Shp1 is mainly a 
negative regulator of intracellular signalling whereas Shp2 in contrast is a positive regulator of 
growth factor and cytokine signalling (Di Paola, 2013, Senis, 2013). 
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Megakaryocyte and platelet specific KO mouse models of Shp1 and Shp2 highlight the 
differences in their functions (Mazharian et al., 2013). Platelets deficient in Shp1 have reduced 
reactivity to CRP, as a result of downregulated GPVI surface expression and reduced SFK-Syk-
PLCγ2 axis signalling, the reverse to what was predicted of an ITAM signalling negative 
regulator (Senis, 2013, Mazharian et al., 2013). Shp1 deficient platelets also exhibited reduced 
fibrinogen spreading and normal responses to anti-CLEC2 antibody.  On the other hand, Shp2 
deficient platelets responded normally to CRP, and were hyper responsive to fibrinogen and 
anti-CLEC2 antibody (Mazharian et al., 2013). Megakaryocytes of both KO mice showed 
impaired development, but only the Shp2 deficient megakaryocytes had reduced proplatelet 
formation and TPO and integrin signalling, resulting in Shp2 KO mice being 
macrothrombocytopenic (Senis, 2013, Mazharian et al., 2013).  
 
1.8. Key questions 
Although the abundance, structure and functional significance (for which transgenic mouse 
models have been pivotal) of several ITIM-containing receptors have been identified in 
megakaryocytes and platelets, many key questions still remain unanswered.  Such as how 
despite all ITIM-containing receptors interacting with Shp1 and Shp2, dramatically different 
phenotypes are observed in mouse models. As well as how the phosphorylation of ITAM and 
ITIM-containing receptors is balanced upon SFK activation. In addition, it is not known 
whether the roles of ITIM-containing receptors are distinct or if there is redundancy between 
receptors. The mechanisms by which ITIM-containing receptors can modulate integrin 
signalling and GPCR-mediated responses are also yet to be defined (Coxon et al., 2017). 
Considerable work is therefore still required in order to fully understand how ITIM-containing 
receptor signalling is integrated within other platelet receptor signalling networks in order to 
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prevent life threatening thrombosis. Such physiological inhibitory mechanisms could be 
exploited as means to prevent or treat thrombosis. 
 
1.9. Hypothesis and aims 
The predominant hypotheses running throughout this thesis is that ITIM-containing receptors 
are critical regulators of megakaryocyte development and platelet production and function.  
 
These hypotheses were explored through aiming to determine: 
1. The role of LAIR-1 in platelet production and function 
2. Whether the inhibitory function of LAIR-1 is discrete or if there is functional 
redundancy with inhibition mediated by PECAM-1 
3. The role of TLT-1 in platelet production and function  
 
 







Materials and Methods 




Antibodies, agonists and inhibitors used are listed in Tables 2.1, 2.2 and 2.3 respectively. All 
other reagents are from Sigma (Poole, UK) unless otherwise stated. 
 
2.1.1. Mice 
LAIR-1 KO mice were produced by Taconic (Cologne, Germany). Targeting strategy can be 
found in chapter 3 (Figure 3.1) (Smith et al., 2017). PECAM-1 KO mice were a generous gift 
from Dr Tak Mak (Amgen Institute, Toronto, Ontario, Canada), with targeting strategy as 
previously published (Duncan et al., 1999). LAIR-1/PECAM-1 double deficient mice were 
generated by crossing individual LAIR-1 KO and PECAM-1 KO mice strains. TLT-1 KO mice 
were provided by Dr Daniel McVicar (National Institute of Health, USA) / Dr Valance 
Washington (Universidad de Puerto Rico, Puerto Rico). Targeting strategy of TLT-1 can be 
found in Washington et al, (2009). All mice were on a C57BL/6 background and bred using 
heterozygous or homozygous breeding pairs. Control mice were either litter matched, or age 
matched WT mice from breeding pairs within the same colony. All procedures were carried out 
with United Kingdom Home Office approval in accordance with Animals (Scientific 
Procedures) Act 1986. 
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Table 2. 1. Antibodies 





α2 (mouse)  Rat, FITC-conjugated 
(Sam.C1, M071-1)  
Emfret Analytics  FC: 1/100  
αIIb (mouse)  Rat, PE-conjugated  
(MWReg30, 558040)  
BD Biosciences  FC: 1/100  
αIIbβ3, high 
affinity (mouse)  
Rat, PE-conjugated  
(-, M023-2)  
Emfret Analytics  MC: 1/20  
CD11b+ Rat (M1/70, 13-0112) eBioscience MK: 3 µl/mouse 
CD148 Syrian hamster (8A-1) Custom antibody produced by 
Art Weiss (University of 
California San Francisco, USA) 
WB: 1/1,000 
CD16/32 Rat (2.4G2, 553142) BD Bioscience MK: 3 µl/mouse 
CD45R/B220+ Rat (RA3-6B2, 553086) BD Bioscience MK: 3 µl/mouse 
ChK (CtK) Rabbit (C-20, sc470)  Santa Cruz PS: 1/80 
CLEC-2 (mouse)  Rat  
(17D9, MCA5700)  
Bio-Rad Laboratories  AG: 10 µg/ml  
CLEC-2 (mouse)  Rat, FITC-conjugated  
(17D9, MCA5700F)  
Bio-Rad Laboratories  FC: 1/100  
Csk Rabbit (C-20, sc286) Santa Cruz WB: 1/1,000  
PS: 1/10 
ERK 1/2 Rabbit (K-23, sc-153) Santa Cruz WB: 1/1,000 
ERK 1/2 -p Mouse (E4, sc-7383) Santa Cruz WB: 1/200 
Fyn Rabbit ( FYN3, sc-16) Santa Cruz WB: 1/1,000  
Fyn p-Tyr-530 Rabbit (53690) Abcam WB: 1/1,000  
G6b (mouse)  Rat (68-3, -)  Custom antibody produced by 
Biogenes  
FC: 5 µg/ml  
GAPDH Rabbit (14C10, #2118) Cell Signaling Technology PS:1:10 
GPIbβ (X488) Rat, Dylight488-
conjugated (-, X488) 
Emfret Analytics  IV: 0.2 µg/g 
body weight 
GPVI Rat, FITC-conjugated 
(JAQ1, M011-1) 
Emfret Analytics FC: 5 µl per test 
LAIR-1 Armenian hamster, PE-
conjugated (113, 12-
3051) 
eBioscience FC:10 µg/ml 
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Ly6G/Gr1+ Rat (RB6-8C5, 14-
5931) 
eBioscience MK: 3 µl/mouse 
Lyn Rabbit (sc-15) Santa Cruz WB: 1/1,000 
Lyn p-Tyr-507 Rabbit (2731) Cell Signaling Technology WB: 1/1,000 
PLCγ2 Rabbit (DN84) Custom antibody produced by 
Joseph Bolan (DNAX Research 




Rabbit (3871) Cell Signaling Technology  WB: 1/500 
PECAM-1 Rat, FITC-conjugated 
(MEC 13.3, 553372) 

















Rat, FITC-conjugated  
(Wug.E9, M130-1)  






BD IF: 1/500 
IV: 0.2 µg/g 
body weight 
PTP1B Rabbit (ABS40) Millipoore WB: 1/1,000 
p-Tyr  Mouse  
(4G10, 5-321)  
Sigma  WB: 1/1,000  
Shp1  Rabbit  
(C14H6, 3759)  
Cell Signaling Technology  WB: 1/1,000  
Shp2  Rabbit  
(D50F2, 3397)  
Cell Signaling Technology  WB: 1/1,000  
Src Rabbit (44656) Invitrogen WB: 1/1,000  
PS: 1/50 
Src p-Tyr-418  Rabbit  
(44660G)  
Invitrogen  WB: 1/1,000 
PS: 1/10  
Src p-Tyr-529 Rabbit (44662) Invitrogen WB: 1/1,000  
Syk  Rabbit  
(D1I5Q, 12358)  
Cell Signaling  Technology WB: 1/1,000  
PS: 1/10 
Syk p-Tyr525/26  Rabbit  
(-, 2711)  
Cell Signaling Technology  WB: 1/500  
PS: 1/50 
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FC, flow cytometry; IF, immunofluorescence; WB, Western blotting; PS, ProteinSimple; IV, 
in vivo; MK, megakaryocyte culture; AG, aggregations 
  
TLT-1 (human)  Rat, AF488-conjugated 
(268420, FAB 2394G) 
Novus Biologicals FC: 1 µg per test 
IF: 1/250 
TLT-1 (Mouse) Rat, AF488-conjugated 
(268529, NBP-248481) 
R&D systems FC: 1 µg per test 
IF: 1/500 
IV: 0.2 µg/g 
body weight 
TLT-1 (Mouse) Rat, AF647-conjugated 
(268529, NBP-248481) 
R&D systems IV: 0.2 µg/g 
body weight 
Tubulin  Mouse  
(DM1A, T6199)  
Sigma  WB: 1/1,000  
IgG isotypes    
IgG  Rat, FITC-conjugated  
(-, P190-1)  
Emfret Analytics  FC: 1/100  
IgG Armenian hamster, PE-
conjugated 
(eBio299Am, 12-4888) 
eBioscience FC:10 µg/ml 
IgG1 Rat, FITC-conjugated 
(A85-1, 553443) 
BD FC:10 µg/ml 
IgG2A  Rat, AF488-conjugated 
(54447, MAB006)  
R&D systems FC: 5 µg/ml 
IgG2B  Rat, FITC-conjugated  
(-, MCA6006F)  
Bio-Rad Laboratories  FC: 1/100  
Secondary antibodies   
Donkey anti-
rabbit IgG  
Donkey, HRP-
conjugated  
(-, NA934V)  






(-, A-10680)  




conjugated (-, ab6783) 
Abcam WB:1/1,000 
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Table 2. 2. Agonists 
Agonist Receptor target Source 
ADP  P2Y12, P2Y1  Sigma (A2754)  




Provided by Prof. Richard Farndale, 
cross-linked in house  
Convulxin  GPVI, GPIb-IX-V  
Enzo Life Sciences  
(#ALX-350-100)  
CLEC-2 antibody  CLEC-2  
Bio-Rad Laboratories  
(MCA5700)  
Fibrinogen  Integrin αIIbβ3  
Enzyme Research  
(FIB 3)  
PAR4 peptide  PAR4  Alta Biosciences (custom order)  
Thrombin  PAR1, PAR4  Sigma (T4648)  
U46619  TP  Sigma (D8174)  
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Table 2. 3. Inhibitors 
Inhibitor Target Concentration Source 
AEBSF  Serine proteases  1 mM  Calbiochem (101500)  
Aprotinin  Serine proteases  10 µg/ml  Sigma (A1153)  
Apyrase  ATP  2 U/ml  Sigma (A6535)  
EDTA  Divalent cation chelator  5 mM, 20 mM  Acros Organics  
(237205000)  
Fragmin  Potentiates antithrombin III 
activity  
50 U/ml  Pfizer (-)  
GPRP  Fibrin polymerisation  10 µM  Sigma (G5779)  
Heparin  Potentiates antithrombin III 
activity 
FA: 5 U/ml  
PPF: 100 U/ml 
Iduron  
(HEP001)  
Indomethacin  Cycloxygenase  10 µM  Sigma (I7378)  
Leupeptin  Cysteine, serine and 
threonine proteases  
10 µg/ml  Enzo Life Sciences (260-
009-M100)  
Pepstatin  Aspartyl proteases  1 µg/ml  Sigma (P5318)  




Tyrosine phosphatases  5 mM  Sigma (450243)  
FA, flow adhesion; PPF, proplatelet formation 
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2.2. Molecular Biology 
Polymerase chain reaction (PCR) was used to determine genotypes of genetically modified 
mice. Targeting primers are indicated in Table 2.4 (Sigma, Poole, UK). 
 
2.2.1. DNA isolation 
DNA for genotyping was obtained from ear clips collected from preweaned 3-week old pups. 
Tissue was digested in lysis buffer (0.2% SDS, 100 nM Tris.HCl, 5 mM EDTA, 200 nM NaCl, 
pH 8.5) with proteinase K (650 µg/ml) overnight at 55oC. Cell debris was pelleted by 
centrifugation (13,000 × g, 10 minutes, 4oC) and ice cold 100% isopropanol used to precipitate 
DNA. DNA was then pelleted by centrifugation (13,000 × g, 20 minutes, 4oC), dried and 
resuspended in sterile deionised water. 
 
2.2.2. PCR 
PCRs were performed using 10 µl ReadyMix REDTaq PCR reaction mix, 20 µM of primer and 
1 µl purified DNA. Reactions were performed in a Tetrad 2 Peltier thermal Cycler (Bio-Rad 
Laboratories, Watford, UK), denaturing, annealing and extending cycles are shown in Table 
2.5. PCR products were resolved on agarose gels containing 0.0001% ethidium bromide to 
detect DNA. Gels were run in TAE (40 mM tris, 20 mM acetic acid and 1 mM EDTA) at 120 
V for 20-40 minutes, then imaged using a Gene Genius Gel Imaging System (Syngene, 
Cambridge, UK). 
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Table 2. 4. PCR Primers 
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Table 2. 5. PCR Protocols 
Gene target PCR program Product (bp) Agarose gel 








× 35 cycles 




 72 oC 10 s    







1 min 30 secs 




 72 oC 10 min    
TLT-1 95 oC  
95 oC  
56 oC  









 72 oC 10 min    
bp, base pairs; min, minutes; s, seconds 
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2.3. Platelet isolation 
2.3.1. Mouse washed platelet isolation 
Blood was collected from the vena cava of CO2 asphyxiated mice using a 25 gauge needle into 
200 µl acid-citrate-dextrose (ACD) solution in a 1 ml syringe. Blood was then immediately 
diluted in 200 µl Tyrodes-HEPES buffer. Whole blood was centrifuged (2,000 rpm, 5 minutes, 
room temperature [RT]; Microcentaur, Sanyo) and platelet rich plasma (PRP) and third of 
erythrocytes collected. PRP was separated from erythrocytes by centrifugation (200 × g, 6 
minutes, RT) in a swinging bucket centrifuge and collected. To maximise platelet yield an 
additional 200 µl Tyrodes-HEPES buffer was added to erythrocytes, mixed by inversion then 
centrifuged again (200 × g, 6 minutes, RT) and the PRP collected pooled. Collected PRP was 
made up to 1 ml by addition of Tyrodes-HEPES buffer and centrifuged (1,000 × g, 6 minutes, 
RT) in presence 10 µg/ml PGI2 to pellet platelets. Platelets were resuspended in Tyrodes-
HEPES buffer, counted (Coulter Z2 Particle Count and Size Analyzer, Beckman Coulter Ltd, 
High Wycombe, UK) and diluted to 2 × 107 for spreading assay, 2 × 108 for lumi-aggregometry 
and 5 × 108 for biochemistry. Washed platelets were allowed to rest for 30 minutes following 
isolation before beginning experiments. 
 
2.3.2. Human washed platelet isolation 
Blood was collected from drug free, healthy volunteers into sodium citrate (1:10, v:v). 
following collection acid citrate dextrose (97 mM sodium citrate, 111 mM glucose, 71 mM 
citric acid) was added to blood (1:9 , v:v). Anticoagulated blood was then centrifuged (200 × g, 
20 minutes, RT) and PRP separated from red blood cells. Collected PRP was then centrifuged 
(1,000 × g, 10 minutes, RT) in presence 10 µg/ml PGI2 to pellet platelets. Platelets were 
resuspended in modified Tyrodes-HEPES buffer with ACD (1:8, v:v) and centrifuged again 
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(1,000 × g, 10 minutes, RT). Platelet pellet was resuspended in Tyrodes-HEPES buffer, counted 
and diluted to 2 × 107 for spreading assay, 2 × 108 for lumi-aggregometry and 5 × 108 for 
biochemistry. Washed platelets were allowed to rest for 30 minutes following isolation before 
beginning experiments. 
 
2.4. Platelet function assays 
2.4.1. Lumi-aggregometry 
Washed platelets (2 × 108/ml) were incubated (37oC, 1 minute non-stirring, 1 minute stirring 
conditions, 1,200 revolutions per minute [rpm] in a Chrono-Log Lumi-aggregometer 
[Havertown, PA, USA]). Following incubation, agonists (1:100) were added and measurement 
started. Area under the curve (AUC) was calculated for 6 minutes following agonist addition 
by AGGRO/LINK8 software (Chrono-Log, Havertown, PA, USA). 
ATP released from dense granules was measured using Chrono-lume (1:30 [v:v], Chrono-Log, 
Havertown, PA, USA).  A calibration was performed with 2 nmol ATP standard (Chrono-Log, 
Havertown, PA, USA) for each channel at the start of experiments enabling AGGRO/LIK8 
software to subsequently calculate ATP release and AUC. 
 
2.4.2. Platelet spreading 
Glass coverslips (13 mm diameter) were coated with fibrinogen (100 µg/ml, Enzyme Research, 
Swansea, UK) or collagen (10 µg/ml, Takeda, Tokyo, Japan) overnight, 4oC. Coverslips were 
then blocked with denatured fatty acid free BSA (5 mg/ml) for 1 hour, RT. Washed platelets (2 
× 108/ml) were then plated for 45 minutes, 37oC. Adhered platelets were then fixed with 4% 
PFA for 10 minutes, RT. For differential interference contrast (DIC) microscopy, fixed 
coverslips were mounted directly onto microscope slides using Hydromount (National 
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Diagnostics, Hull, UK). For fluorescence microscopy, platelets were permeabilised and stained 
(as below) for actin cytoskeleton (6.6nM phalloidin-AF488, 1 hour, RT) before being mounted 
and imaged. 
 
2.4.3. Flow adhesion 
Glass coverslips (24 × 60 mm) were coated with collagen type I microscpots (100 µg/ml, 
Nycomed Pharma, Munich, Germany). Coated coverslips were blocked with Tyrodes-HEPES 
buffer containing 1% BSA and mounted into parallel plate flow chambers. Blood was collected 
from vena cava CO2 asphyxiated mice into 40 µM PPack, 5 U/ml heparin and 50 U/ml fragmin 
(final concentrations) and perfused over coated coverslips for 3.5 minutes at 1,000 s-1 shear 
rate. Three brightfield and fluorescence images (P-selectin-FITC, JON/A-PE and Annexin A5-
AF647) were captured per microspot. Images were blinded and analysed in Fiji Software 
(Laboratories for Optical and Computational Instrumentation, University of Wisconsin-
Madison, USA), using semi-automated scripts to measure percentage surface area coverage 
(%SAC) of adhered platelets from brightfield images and fluorescence of each antibody. 
 
2.4.4. Integrin activation and granule release 
Whole blood was activated by indicated agonists in Tyrodes-HEPES buffer in presence of 
FITC-conjugated anti-P-selectin antibody or AF488-conjugated fibrinogen (Thermo Scientific, 
Loughborough, UK). GPRP (10 µM) was added to prevent clotting of thrombin stimulated 
samples. Following stimulation samples were fixed with ice-cold 1% PFA and analysed on 
Accuri C6 flow cytometer (BD Biosciences, Oxford, UK). Platelets were gated using forward- 
and side-scatter and median fluorescence intensity analysed from 10,000 events. 
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2.5. Megakaryocyte culture and function assays 
2.5.1. Primary mouse bone marrow megakaryocyte culture 
Bone marrow (BM)-cells were obtained from mice by flushing femurs and tibias with 
Dulbecco’s Modified Eagle Medium (DMEM) containing 10% FBS, glutamine and 
penicillin/streptomycin. BM-cells were centrifuged (1,200 rpm, 5 minutes, 4oC) and the pellet 
resuspended in ammonium chloride potassium lysing buffer (ACK, 150 nM NH4Cl, 1 mM 
KHCO3, 0.1 mM Na2 EDTA) to lyse red blood cells and then filtered (70 µm nylon mesh filter). 
Filtered cells were centrifuged (1,200 rpm, 5 minutes, 4oC) and resuspended in DMEM. Cells 
expressing non-megakaryocytic lineage markers (CD16/32, Gr1+, B220+ and CD11b+) were 
then depleted using immunogenic beads (sheep anti-rat IgG Dynabeads, Invitrogen, Carlsbad, 
USA). The remaining population was then cultured in Stempro medium (Invitrogen, Carlsbad, 
USA) supplemented with 2.6% serum, 2 mM L-glutamine and penicillin/streptomycin. For the 
first 2 days cells were cultured with 20 ng/ml murine stem cell factor (SCF, Peprotech, Rocky 
Hill, USA) and then in presence of SCF and 50 ng/ml TPO (Peprotech, Rocky Hill, USA) for 
a further 4 days. Mature megakaryocyte population was enriched using a 1.5%/3% BSA 
gradient under gravity (1 × g, 1 hour, RT). 
 
2.5.2. Megakaryocyte ploidy 
Cultured megakaryocytes were analysed using a FACSCalibur flow cytometer (BD 
Biosciences, Oxford, UK). Following enrichment, megakaryocytes were co-stained with ant-
αIIb antibody and propidium iodide (PI). PI staining of αIIb-positive cells was then analysed in 
50,000 events. 
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2.5.3. Megakaryocyte spreading and proplatelet formation 
Coverslips were prepared as for platelet spreading. Enriched megakaryocytes were resuspended 
in complete Stempro medium with addition of SDF-1α (Peprotech Rocky Hill, USA) and 
heparin (100 U/ml) then plated on coverslips for 3 or 5 hours, at 37oC, for spreading or 
proplatelet formation respectively. Adhered megakaryocytes were then fixed with 4% PFA (15 
minutes, RT) before immunofluorescence staining and imaging. 
 
2.6. Immunofluorescence staining, imaging and quantification 
2.6.1. Immunofluorescence staining 
PFA fixed platelets or megakaryocyte coverslips were quenched with NH4Cl (50 mM, 10 
minutes, RT), permeablised with Triton-X100 (0.2%, 5 minutes, RT). Coverslips were then 
blocked with 1% fatty acid free BSA with 2% goat serum and stained with conjugated antibody, 
or primary antibody followed by conjugated secondary. Antibodies can be found in Table 2.1. 
Following staining coverslips were mounted on microscope slides using Hydromount or 
Prolong Diamond Antifade Mountant with DAPI (Invitrogen, Carlsbad, USA). 
 
2.6.2. Resting platelets and megakaryocytes 
Washed platelets (4 × 108/ml) were fixed in suspension with 1% PFA (1:1 [v:v], 10 minutes, 
RT), plated onto poly-L-lysine coated coverslips and centrifuged (1,000 rpm, 10 minutes, RT). 
Megakaryocytes were plated on fibrinogen coated coverslips (100 µg/ml, 15 minutes, 37oC), 
before fixing with 4% PFA. Coverslips were then immunofluorescently stained with anti-P-
selectin, TLT-1 and phalloidin-rhodamine for 1 hour, RT (Table 2.1) then imaged. 
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2.6.3. Image acquisition 
Images were captured using a Zeiss Axiovert 200M microscope (Cambridge, UK), Zeiss 
Observer 7 epifluorescent microscope, or Zeiss LSM880 confocal microscope with Airyscan 
processing (Cambridge, UK). Platelets were imaged using a 40× or 63× objectives, 
megakaryocytes using 20×, 40× or 63× objectives. 5 fields of view (FOV) per coverslip were 
captured for platelet spreading, and three 5×5 tiles captured per coverslip for megakaryocyte 
proplatelet formation. Images were acquired using Zen Pro V2.3 (Zeiss, Cambridge, UK). 
 
2.6.4. Quantification spreading and proplatelet formation 
Images were blinded before quantification. For platelets, quantification was either manually 
using Fiji (chapter 3) or using a semi-automated machine learning based KNIME workflow 
(details below) to measure number of adhered platelets, surface area and stages of spreading 
(unspread, forming filopodia, forming lamellipodia and fully spread, Figure 2.1). For 
megakaryocytes, quantification was carried out manually in Fiji (chapter 3) or using a semi-
automated machine learning based KNIME workflow to measure number of proplatelet 
forming megakaryocytes and area of megakaryocyte spreading. 
 
2.6.4.1 KNIME workflow 
An Ilastik pixel classifier (Sommer et al., 2011) was used to produce a binary segmentation. To 
separate touching platelets and megakaryocytes the centre of individual cells were manually 
selected using KNIME (Berthold et al., 2009). These centre coordinates were then used as seeds 
for a watershed transform to produce the final segmentation result. Objects smaller than 5 µm2 
for platelet spreading and 100 µm2 for megakaryocyte proplatelet formation were discarded and 
per cell measurements such as cell area were then calculated. A subset of cells were manually 
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assigned to one of the following classes: adhered, forming filopodia, forming lamellipodia and 
fully spread for platelets; or non-megakaryocyte, non-proplatelet forming or proplatelet 
forming for megakaryocytes. A decision tree based classifier was trained from this subset and 
used to assign classes to the full dataset. This method of analysis has previously been 
characterised and validated against manual spreading analysis by other members of the 
Birmingham Platelet Group. 
 
  




Figure 2. 1. Platelet spreading categories. Representative images of the four categories, 








Analysis of receptor colocalization in platelets and megakaryocytes was performed on 
maximum intensity projections using Icy software (Quantitative Image Analysis Unit, Institut 
Pasteur, (de Chaumont et al.). Colocalization of 488 and 647 channels in platelets was 
determined by Manders overlap coefficient (Pike et al., 2017). Megakaryocyte images were 
processed using Icy’s spot detector plugin 
(http:/icy.bioimageanalysis.org/plugin/Spot_Detector) to effectively threshold 488 and 647 
channels and determine an object based measure of colocalization.  
 
2.7. Biochemistry 
2.7.1. Platelet sample preparation in solution 
Washed platelets (2 × 108/ml) were prewarmed Chrono-Log aggregometer at 37oC (1 minute 
non stirring followed by 1 minute stirring, 1,200 rpm). CRP stimulations were performed for 
30, 90 and 180 seconds. Stimulations were stopped by adding 2× lysis buffer ((LB), 300mM 
NaCl, 20mM Tris, 2mM EGTA, 2mM EDTA and 2% NP-40 detergent) containing 5 mM 
Na3VO4, 1 mM AEBSF, 10 µg/ml aprotinin and 1 µg/ml pepstatin. Whole cell lysates (WCL) 
were precleared with protein-G sepharose (30 minutes, 4oC, constant mixing). Cell debris and 
sepharose beads were pelleted by centrifugation (15,000 × g, 10 minutes, 4 oC). Reducing 
sample buffer (SB, 4% SDS, 20% glycerol, 1% stacking gel buffer, 10% β-mercaptoethanol) 
was then added to WCL and boiled for 5 minutes. 
 
2.7.2. Sample preparation spread platelets 
Six well plates or 10 cm diameter dishes were coated with 100 µg/ml fibrinogen (overnight, 
4oC), and blocked with 5 mg/ml denatured fatty acid free BSA (1 hour, RT). Washed platelets 
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(5 × 108) in Tyrodes-HEPES buffer with indomethacin (10 µM) and apyrase (2 U/ml) were 
plated on coated wells (45 minutes, 37oC). Non-adherent platelets were lysed with 1 × LB plus 
inhibitors on ice for 15 minutes. WCL protein concentrations were determined (Bio-Rad RC 
DC protein assay) and boiled in SB. 
 
2.7.3. Megakaryocyte sample preparation 
Following enrichment megakaryocytes were starved in serum free media (4 hours, 37oC). 
Megakaryocytes were then stimulated with indicated agonists (10 minutes, 37oC) and lysed 
with 2×LB with inhibitors. WCL samples were then precleared and protein levels normalised 
with reducing SB for immunoblotting, or following ProteinSimple Wes protocol. 
 
2.7.4. SDS-PAGE and western blotting 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 4-12% Bis-Tris 
gels (Life Technologies, Paisley, UK) was used to resolve proteins. Proteins were transferred 
to poly vinylidene difluoride membranes (Bio-Rad, Hemel Hempstead, UK) using a Bio-Rad 
semi-dry Turbo transfer system. Broad range unstained protein marker (2-212 kDa) and 
prestained protein standard (New England Biolabs, Hitchin, UK) were used to estimate 
molecular weight (MW). 
Membranes were blocked following transfer with BSA blocking buffer (3% BSA [w:v], in 0.1% 
Tween-20 [v:v], Tris-buffered saline [TBS-T, 200 µM Tizma base, 1.37 M NaCl, 0.1% Tween-
20]). Membranes were then incubated with indicated primary antibodies in blocking buffer 
(overnight, 4oC, constant mixing). Membranes were washed in TBS-T (1 × 10 minutes, 3 × 5 
minutes) before incubation with horseradish peroxidase-conjugated secondary antibodies 
(1/10,000, 1 hour, RT) in TBS-T. Membranes were washed again in TBS-T and subsequently 
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proteins detected using Enhanced Chemiluminescence detection system (Life Technologies, 
Paisley, UK). Autoradiograph exposure was used to visualise chemiluminescence. 
Bound antibodies were removed by membrane incubation (20 minutes, 80oC) in stripping buffer 
(TBS-T containing 2% SDS) with 1% β-mercaptoethanol, followed by a second incubation (20 
minutes, 80oC) in stripping buffer without β-mercaptoethanol. Membranes were then washed 
in TBS-T and blocked with BSA before primary antibody incubation overnight. 
 
2.7.5.  Automated capillary-based immunoassay  
Automated capillary-based immunoassay platform Wes (ProteinSimple, San Jose, USA) was 
used for quantitative protein analysis. WCLs were prepared according to manufacturer’s 
instructions. Pre-filled microplates with Split Running Buffer (PS-MK14) were loaded with 
optimal concentrations of samples and primary antibodies (Table 2.6). Separation time (31 
minutes), stacking loading time (21 s) and sample loading time (9 s) was used for each 24 
sample microplate, with primary antibody incubation time either 30 or 60 minutes and exposure 
detection profile set to high dynamic range. Results were analysed using Compass software 
(ProteinSimple, San Jose, USA). 
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Table 2. 6. ProteinSimple Wes Antibody conditions 











GAPDH Cell Signaling 
Technology 
(14C10) 
1:10 60 0.05 - 
Src p-Y418 Invitrogen 
(44660G) 
1:10 60 0.05 - 
Syk p-Y525/6 Cell Signaling 
Technologies 
(2711) 
1:50 30 0.2 - 
Csk (C20) Santa Cruz (sc286) 1:10 30 0.025 0.05 
Chk Santa Cruz (sc470) 1:80 60 0.2 0.4 
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2.8.  Immunohistochemistry 
Spleens and femurs were isolated from CO2 asphyxiated mice and fixed in 4% PFA. Before 
fixing, spleens were weighed and ends of femurs cut to expose bone marrow. Femurs were then 
decalcified and both tissues embedded in paraffin. Cut sections were mounted on glass 
microscope slides and stained with either haematoxylin an eosin, or reticulin (Pathology 
department, Queen Elizabeth Hospital, Birmingham, UK). Light microscopy images of slides 
were then taken with a Zeiss AxioScan Z1 (Carl Zeiss Ltd, Cambridge, UK). Number of 
megakaryocytes and reticulin staining in images were then assessed. 
 
2.9.  Ex vivo mouse assays 
2.9.1.  Haematology 
Blood cell counts of whole mouse blood were measured using an ABX Pentra 60 
Haematological counter (Horiba Medical, Northampton, UK). 
 
2.9.2.  Surface receptor levels 
Surface receptor levels on platelets in whole blood and cultured megakaryocytes were assessed 
using flow cytometry. Samples were incubated with indicated FITC- or AF488-conjugated 
antibodies or IgG controls in combination with PE. Platelets and mature megakaryocyte 
fractions were gated by FSC-A and SSC-A and MFI of 10,000 and 50,000 events analysed for 
platelets and megakaryocytes respectively. Stained whole blood was analysed using an Accuri 
C6 flow cytometer. Megakaryocytes were analysed using a FACSCalibur.  
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2.10.  In vivo mouse assays 
2.10.1.  Tail bleeding 
Tail tips (3 mm) were excised using a scalpel from isoflurane anaesthetised mice and 
immediately placed in warmed saline (37oC). Mice body temperature was maintained at 37oC 
by heating mat. Time for bleeding to stop and any rebleeds was recorded. Mice were culled if 
bleeding was ceased for 1 minute or after total time reached 20 minutes. 
 
2.10.2.  Laser-injury thrombosis model 
Experiments were conducted on male mice (20-30 g). Mice were anaesthetised by 
intraperitoneal injection with 125-240 mg/kg Avertin (Tribromoethanol dissolved in 2-Methyl-
2-butanol, and diluted in sterile saline). Trachea tube inserted and either carotid artery or jugular 
vein cannulated for indicated antibody infusion prior to injuries. Cremaster muscle was then 
exteriorised over a glass coverslip and continually perfused with warmed bicarbonate buffered 
saline. Laser-induced thrombi were generated in arterioles. Thrombus formation was capture 
by simultaneous real-time brightfield and fluorescence confocal microscopy (Olympus 
BX61WI, upright spinning disk confocal microscope [40× 0.8NA water immersion lens] with 
a Photometrics Evolve camera). 
 
2.10.3.  Ferric chloride-injury thrombosis model 
Experiments were conducted on mice (20-30 g). Mice were anaesthetised by intraperitoneal 
injection with Avertin. Trachea tube inserted and jugular vein cannulated for indicated antibody 
infusion prior to injury. Carotid artery (right side) was then exposed and ferric chloride-soaked 
filter paper applied (2 mm × 1 mm, 10% ferric chloride, 3 minutes). Injury site was then imaged 
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for 15 minutes by time lapse fluorescence confocal microscopy (Olympus BX61WI, upright 
spinning disk confocal microscope [4× 0.13NA air lens] with a Photometrics Evolve camera). 
All intravital data was collected and analysed using Slidebook 6 software (3i, Denver, USA). 
 
2.11.  Statistical analysis 
All data presented as mean ± standard error of the mean (SEM) unless otherwise stated. 
Statistical significance was analysed by Students t-test, Analysis of Variance (ANOVA) or 
Mann-Whitney test. The appropriated parametric or non-parametric test was selected based on 
sample size, sample distribution, number of groups and if the measured variable is continuous. 
All statistical analysis was carried out using GraphPad Prism software (GraphPad Software 
Inc., La Jolla, CA, USA) unless otherwise stated. 
 
















The aim of this chapter was to investigate the physiological role of LAIR-1 in megakaryocyte 
development and platelet production and function. In order to do this, a constitutive LAIR-1 
deficient murine model was generated and utilized. Mice lacking LAIR-1 were hypothesized to 
have hyper responsive megakaryocytes and platelets to collagen. 
 
3.2. Introduction 
ITIM-containing receptors have increasingly been shown to play an essential role in regulation 
of megakaryocyte and platelet reactivity. Several ITIM-containing receptors have been 
identified in megakaryocyte and platelets, with the majority of these receptors reported to 
inhibit ITAM-receptor mediated activation by the collagen receptor GPVI (Coxon et al., 2017).  
Widely expressed in haematopoietic cells, including megakaryocytes, but not in platelets 
(Steevels et al., 2010), the ITIM-containing receptor LAIR-1 has been shown to have an 
inhibitory function in immune cells, mediated via recruitment of Shp1 and Shp2 phosphatases, 
and Csk to the phosphorylated ITIMs of its cytoplasmic tail (Verbrugge et al., 2006). LAIR-1 
has also been implicated as a negative regulator of haematopoiesis (Meyaard, 2010, Tang et al., 
2012, Xue et al., 2011). Crosslinking LAIR-1 on primary human CD34+ cells has been shown 
to decrease generation of megakaryocytes in presence TPO (Xue et al., 2011). Furthermore, 
studies report LAIR-1 to be crucial for the development of acute myeloid leukaemia (Kang et 
al., 2015).  
LAIR-1 is a collagen receptor, binding via the same repeated GPO motifs as GPVI but with a 
much higher affinity (Brondijk et al., 2010, Lebbink et al., 2006, Lebbink et al., 2009). When 
co-expressed in transiently transfected DT40 cells, LAIR-1 has been shown to strongly inhibit 
collagen mediated GPVI activation by an NFAT reporter assay (Tomlinson et al., 2007). 
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Due to the inhibitory nature of the receptor and the important role of collagens in their 
activation, the function of LAIR-1 in megakaryocytes and platelets has been investigated. 
Previous work has shown mice deficient in LAIR-1 present a mild phenotype, including 
thrombocythemia, prolonged platelet half-life in vivo and increased proplatelet formation in 
vitro (Smith et al., 2017). Interestingly despite platelets not ordinarily expressing LAIR-1, 
platelets from deficient mice show enhanced reactivity to GPVI receptor agonists and greater 
spreading on fibrinogen, suggesting transfer of activation signals from megakaryocytes to 
platelets. This enhanced reactivity of megakaryocytes and platelets from LAIR-1 deficient mice 
was attributed to the observed increase in SFK activity, amplifying GPVI-FcRγ-chain and 
integrin αIIbβ3 downstream signalling (Smith et al., 2017). 
In this chapter, megakaryocytes and platelets from LAIR-1 deficient mice were further 
characterised in order to determine the underlying cause of the enhanced SFK activity 
previously observed. It also examines if enhanced responsiveness of LAIR-1 deficient platelets, 
as previously observed to ITAM-mediated activation, also occurs to hemi-ITAM and GPCR 
receptor activation. In addition, it determines if the enhanced reactivity of LAIR-1 deficient 
platelets observed in vitro translates to enhanced thrombosis in vivo.  




3.3.1. Generation of LAIR-1 KO mice 
To investigate the physiological function of LAIR-1, a constitutive KO mouse model was 
generated (Taconic Biosciences, Cologne, Germany). The strategy to generate this mouse 
model is displayed in Figure 3.1. A targeting vector containing a puromycin resistance cassette 
(PuroR) flanked with flippase (Flp) recognition sites was produced. Homology arms of 4 kb 
and 6 kb were cloned into the targeting vector to allow Lair1 exons 1 and 2 to be effectively 
targeted and replaced with the PuroR cassette through homologous recombination in 
C57Bl/6NTac embryonic stem cells. Homologous recombinant clones, isolated using PuroR 
positive and thymidine kinase negative selection, were then injected into mouse blastocysts and 
transplanted into psudopregnant female mice. Replacement of the proximal promoter and exons 
1 and 2 results in loss of Lair1 gene function through deletion of translation initiation codon 
and signal peptide sequence. In addition, deletion of proximal promoter and 5’UTR prevent 
transcription of LAIR-1 mRNA. Removal of PuroR positive selection cassette, mediated by 
crossing with Flp recombinase expressing mice, which excise the Flp target sites, results in 
constitutive KO. Further crossing with C57Bl5/NTac mice removed Flp recombinase. Mice 
were viable and fertile with no developmental or behavioural abnormalities. Mice were bred 
heterozygous and generated at Mendelian frequency, with litter matched WT mice were used 
as controls. 
  





Figure 3. 1. Generation of LAIR-1 deficient mouse model. Targeting strategy used to 
generate LAIR-1 deficient mouse model showing mouse LAIR-1 genomic locus, targeting 
vector and mouse genome following vector insertion by homologous recombination and after 
subsequent removal of selection cassette. Targeting vector consists of puromycin resistance 
cassette (PuroR) and thymidine kinase (TK) for positive and negative selection respectively. 
PuroR is flanked with flippase recognition sites to allow subsequent removal by Flp 
recombinase. Homology arms allow for targeted homologous recombination. Replacement of 
proximal promoter and exons 1 and 2 results in loss of LAIR-1 gene function by deletion of 
translation initiation codon and signal peptide sequence. In addition, deletion of proximal 
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3.3.2. LAIR-1 deficient megakaryocyte spreading unaltered on collagen 
Having previously been demonstrated that megakaryocytes from mice deficient in LAIR-1 
exhibit a marked increase in spreading, and an increased number form proplatelets on 
fibrinogen (Smith et al., 2017), megakaryocyte spreading and proplatelet formation on collagen, 
the ligand of LAIR-1, was investigated. Megakaryocytes from LAIR-1 deficient mice and litter 
matched WT controls spread equally well on collagen, with neither forming proplatelets 
(Figure 3.2). No significant changes in collagen surface receptor expression were found on 
megakaryocytes from LAIR-1 deficient mice, compared to WT mice, by flow cytometry (Table 
3.1). 
 
3.3.3. Src activation proximal to GPVI in LAIR-1 deficient megakaryocytes  
Signalling proximal to GPVI has previously been found to be elevated in LAIR-1 deficient 
megakaryocytes, with phosphorylation of Src, Syk and PLCγ2 activation sites increased at 
resting and following convulxin stimulation (Smith et al., 2017). A possible explanation for this 
finding is decreased inhibition of SFKs. Inhibitory site phosphorylation of Src Tyr529, Lyn 
Tyr507 and Fyn Tyr530 were therefore investigated in LAIR-1 deficient megakaryocytes. 
Phosphorylation levels of inhibitory tyrosines at both resting, and following convulxin 
stimulation, which strongly activates GPVI but not LAIR-1 (Tomlinson et al., 2007), were 
normal in LAIR-1 deficient megakaryocytes (Figure 3.3). 
  




Figure 3. 2. LAIR-1 KO megakaryocyte spreading unaltered on collagen. Bone marrow-
derived megakaryocytes from LAIR-1 KO and litter matched WT mice were plated on collagen 
(100 µg/ml) coated surface for 5 hours at 37oC. (A) Representative images of spread phalloidin 
stained megakaryocytes and (B) surface area (mean ± SEM). N = 20-50 megakaryocytes from 
3 mice/genotype. Scale bar 20 µm; Student’s t-test, non-significant. 
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Table 3. 1. Megakaryocyte surface receptor expression in LAIR-1 KO mice. Surface 
receptor expression of cultured bone marrow derived megakaryocytes from LAIR-1 deficient 
mice and WT controls were measured by flow cytometry. 
Surface receptor WT LAIR-1 KO P value 
GPVI 29 ± 2.7 27 ± 3.1 ns 
Integrin α2 38 ± 1.7 40 ± 3.6 ns 
GPIbα 34 ± 4.7  28 ± 5.6  ns 
Integrin αIIbβ3 214 ± 10  215 ± 29 ns 
CLEC-2 76 ± 5  68 ± 5.6 ns 
G6b-B 25 ± 6  21 ± 5   ns 
PECAM-1 330 ± 28  263 ± 14  ns 
LAIR-1 6 ± 1.5 0.4 ± 1.1 *** <0.001 
Data represents mean values of the mean fluorescent intensity ± SEM; n= 6-10; Student’s t-
test; ns, non-significant; *** P < 0.001 
  




Figure 3. 3. GPVI-proximal signalling in LAIR-1 deficient megakaryocytes. Bone marrow-
derived megakaryocytes from LAIR-1 KO and litter matched WT mice were stimulated with 
30 µg/ml convulxin for 15 minutes at 37oC. Whole cell lysates were Western blotted with anti-
Src Tyr529, Fyn Tyr530 and Lyn Tyr507 antibodies. Membranes were stripped and reblotted 
with anti-Src, Fyn and Lyn antibodies. (A) Representative blots and (B) densitometry 
quantification (mean ± SEM) from 3 independent experiments/genotype. Two-way ANOVA 
with multiple comparisons. 
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3.3.4. LAIR-1 deficient mouse platelets response to non-GPVI agonists unaffected   
Aggregation responses in platelets from LAIR-1 KO mice have previously been shown to be 
enhanced to collagen and CRP, which act through the ITAM-containing GPVI receptor (Smith 
et al., 2017). To determine if the absence of LAIR-1 affects signalling via other receptor 
pathways, aggregation and secretion responses to activation of the hemi-ITAM-containing 
receptor CLEC-2 and GPCR-coupled PAR receptors were investigated. Aggregation and 
secretion responses to CLEC-2 crosslinking were unaffected in platelets from LAIR-1 deficient 
mice, with aggregation to low dose thrombin stimulation also unaltered (Figure 3.4). 
 
3.3.5. Src activation proximal to GPVI in LAIR-1 deficient mouse platelets 
It has previously been shown platelets from LAIR-1 deficient mice exhibit elevated SFK 
activation, as measured by active site phosphorylation, at basal and following CRP stimulation, 
which strongly activates GPVI (Smith et al., 2017). This finding could potentially be explained 
by decreased inhibitory phosphorylation of SFKs. Src Tyr529, Lyn Tyr507 and Fyn Tyr530 
inhibitory site phosphorylation was therefore investigated in resting and CRP stimulated 
platelets from LAIR-1 deficient mice. Phosphorylation levels of inhibitory tyrosines at both 
basal and following CRP stimulation were normal in platelets from LAIR-1 deficient mice 
(Figure 3.5). 
  




Figure 3. 4. Aggregation response to thrombin unaltered in platelets from LAIR-1 
deficient mice. Aggregation and ATP secretion of washed platelets in response to 10 µg/ml 
anti-CLEC-2 antibody and 0.03, 0.04 and 0.06 U/ml thrombin. Representative traces and 
quantification of area under the curve (AUC) for aggregation (A) and secretion (B). Mean ± 
SEM; n=10-11 aggregations/condition; Student’s t-test, non-significant. 
 
  




Figure 3. 5. GPVI-proximal signalling in platelets from LAIR-1 deficient mice.  Whole cell 
lysates of resting and CRP stimulated washed platelets from LAIR-1 KO and litter matched 
WT mice were Western blotted with anti-Src Tyr529, Fyn Tyr530 and Lyn Tyr507 antibodies. 
Membranes were stripped and reblotted with anti-Src, Fyn and Lyn antibodies. (A) 
Representative blots and (B) densitometry quantification (mean ± SEM) from 3 independent 
experiments/genotype; Two-way ANOVA with multiple comparisons. 
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3.3.6. Increased integrin αIIbβ3 signalling in LAIR-1 deficient mouse platelets 
Spreading on fibrinogen was previously shown to be enhanced in LAIR-1 deficient mouse 
platelets (Smith et al., 2017), despite levels of integrin αIIbβ3, as measured by flow cytometry, 
being the same as WT (Table 3.2). Activation state of integrin αIIbβ3 downstream signalling 
proteins Src, Syk and PLCγ2 were therefore investigated upon fibrinogen adhesion as potential 
explanations for the observed enhancement. Phosphorylation of activation sites Src Tyr418 and 
Syk Tyr525/6 were increased in fibrinogen adherent cells, however PLCγ2 activation was not 
significantly increased, although this is potentially explained by the unreliable nature of the 
PLCγ2-pTyr1217 antibody (Figure 3.6). To explain the increased activity, SFK inhibitory site 
phosphorylation was assessed. LAIR-1 deficient mouse platelets show normal SFK inhibitory 
site phosphorylation in non- and fibrinogen adherent platelet lysates (Figure 3.7). 
 
3.3.7. Collagen spreading unaltered in LAIR-1 deficient mouse platelets 
LAIR-1 deficient mouse platelets have previously shown enhanced spreading on fibrinogen 
(Smith et al., 2017). As LAIR-1 is an inhibitory collagen receptor, and deficient mouse platelets 
exhibit enhanced aggregation responses to collagen (Smith et al., 2017), spreading of LAIR-1 
deficient mouse platelets on collagen was therefore evaluated. Interestingly, WT and LAIR-1 
deficient mouse platelets spread equally well on collagen (Figure 3.8). 
 
3.3.8. Enhanced ferric chloride-induced thrombosis in LAIR-1 deficient mice 
Platelets from LAIR-1 deficient mice have enhanced aggregation responses in vitro. Therefore 
the physiological role of LAIR-1 in arterial thrombosis in vivo was investigated. Utilizing the 
laser-injury model of thrombosis in mouse cremaster muscle arterioles, revealed thrombus 
formation was unaltered in LAIR-1 deficient mice (Figure 3.9). Ferric chloride-induced 
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thrombosis in the carotid artery of mice did however show a significant increase in both the rate 
and extent of thrombosis (Figure 3.10), correlating with the increased platelet reactivity to 
collagen in vitro. 
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Table 3. 2. Platelet surface receptor expression in LAIR-1 KO mice. Surface receptor 
expression of platelets from LAIR-1 deficient mice and WT controls were measured by flow 
cytometry. 
Surface receptor WT LAIR-1 KO P value 
GPVI 1401 ± 118 1210 ± 82 ns 
Integrin α2 821 ± 42 747 ± 52 ns 
GPIbα 4305 ± 264 4260 ± 256  ns 
Integrin αIIbβ3 3209 ± 111 3182 ± 167 ns 
CLEC-2 6814 ± 205 6491 ± 466 ns 
G6b-B 701 ± 77 902 ± 181 ns 
PECAM-1 494 ± 35 535 ± 11 ns 
LAIR-1 76 ± 10 72 ± 15 ns 
Data represents mean values of the median fluorescent intensity ± SEM; n=8-12; Student’s t-
test; ns, non-significant. 
 
  




Figure 3. 6. Platelet integrin αIIbβ3 signalling from LAIR-1 deficient mice. Washed 
platelets from LAIR-1 KO and litter matched WT mice were plated on a fibrinogen coated 
surface (45 minutes, 37oC). Whole cell lysates were prepared from non-adherent (NA) and 
adherent (fib) platelets and Western blotted with anti-Src Tyr418, Syk Tyr519/520 and PLCγ2 
Tyr1217 antibodies. Membranes were stripped and reblotted with anti-Src, Syk and PLCγ2 
antibodies. (A) Representative blots and (B) densitometry quantification (mean ± SEM) from 








Figure 3. 7. Platelet integrin αIIbβ3 signalling from LAIR-1 deficient mice. Washed 
platelets from LAIR-1 KO and litter matched WT mice were plated on a fibrinogen coated 
surface (45 minutes, 37oC). Whole cell lysates were prepared from non-adherent (NA) and 
adherent (fib) platelets and Western blotted with anti-Src Tyr529, Fyn Tyr530 and Lyn Tyr507 
antibodies. Membranes were stripped and reblotted with anti-Src, Fyn and Lyn antibodies. (A) 
Representative blots and (B) densitometry quantification (mean ± SEM) from 3 independent 
experiments/genotype; Two-way ANOVA with multiple comparisons. 
 
  




Figure 3. 8. Collagen spreading unaltered in platelets from LAIR-1 deficient mice. 
Platelets from LAIR-1 KO and litter matched WT mice were platelet on collagen-coated surface 
(45 minutes, 37oC). (A) Representative phalloidin stained fluorescence and reflection images. 
Scale bar 10 µm. (B) Individual platelet surface area (mean ± SEM) from140-220 platelets, 5 
mice/genotype; Students t-test, non-significant. 
 
  




Figure 3. 9. Laser-injury induced thrombus formation in vivo. Mice were injected with anti-
GPIbβ antibody (0.1µg/g body weight) and cremaster muscle arterioles subsequently injured 
by laser. Platelet accumulation in thrombi was assessed. (A) Representative composite 
brightfield and fluorescence images of thrombi are shown. Scale bar 10 µm. (B) Median 
integrated thrombi fluorescence intensity trace (arbitrary units, a.u.) and (C) area under the 
curve (mean ± SEM) are shown for 4-12 mice/genotype. Mann-Whitney U test, non-significant. 
See videos 3.I and 3.II. 
 
  




Figure 3. 10. Ferric chloride-induced thrombus formation in vivo. Mice were injected with 
anti-GPIbβ antibody (0.1µg/g body weight) and carotid arteries subsequently injured with ferric 
chloride-soaked filter paper (10%, 3 minutes). Platelet accumulation in thrombi was assessed. 
(A)  Representative fluorescence images of thrombi are shown. Scale bar 200 µm. (B) Median 
fluorescence intensity traces (a.u.) and (C) area under the curve (mean ± SEM) are shown for 
10 mice/genotype. *p<0.05 using Mann-Whitney U test. See also videos 3.III and 3.IV. 
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3.3.9. Unaltered levels of signalling proteins in LAIR-1 deficient mouse platelets 
The enhanced signalling observed in LAIR-1 deficient mice may possible be the result of 
altered levels of LAIR-1 interacting proteins. Protein levels of tyrosine phosphatases CD148 
and PTP1B, which together with Csk regulate activity of SFKs were assessed in platelets, along 
with the levels of Src itself, and of the important downstream activation protein PLCγ2. All 
protein levels were normal in LAIR-1 deficient mouse platelets (Figure 3.11). 
 
  




Figure 3. 11. Unaltered levels of Src, PLCγ2, CD148, Shp1, Shp2, Csk and PTP1B in 
platelets from LAIR-1 deficient mice. Washed platelet whole cell lysates from LAIR-1 KO 
and litter matched WT mice were Western blotted with anti-Src, PLCγ2, CD148, Shp1, Shp2, 
Csk and PTP1B antibodies. (A) Representative blots and (B) densitometry quantification (mean 
± SEM) from 4 independent experiments. Student’s t-test, non-significant. 
 
  




Findings presented in this chapter demonstrate a role for LAIR-1 in regulation of platelet 
reactivity. It also demonstrates platelet and megakaryocyte hyperactivity due to increased SFK 
activation is not a result of decreased levels or activity of Csk, but hypothesised to be due rather 
to uncoupling of SFK inhibition and altered compartmentalisation of signalling proteins. 
Proplatelet formation is a cell autonomous process (Lecine et al., 1998) with the default setting 
appearing to be on, as megakaryocytes have been shown to immediately form proplatelets 
following migration out of bone marrow explants (Eckly et al., 2012). This suggests proplatelet 
formation may therefore be actively suppressed, potentially by several inhibitory signals acting 
in parallel. Collagen type-I mediated proplatelet inhibition surprisingly, has been demonstrated 
to be mainly arbitrated by GPVI (Semeniak et al., 2016).  Through use of inhibitors and 
deficient mice, Semaniak et al revealed megakaryocytes form the same levels of proplatelets 
on collagen type-I in the absence of GPVI signalling as WT megakaryocytes form on surfaces 
(collagen type-IV and laminin) which are conducive to proplatelet formation (Semeniak et al., 
2016). They also demonstrated a bimodal role for α2 integrin, enhancing proplatelet formation 
upon collagen type-IV binding, yet supporting GPVI-mediated inhibition at low collagen type-
I levels (Semeniak et al., 2016). These studies were performed using foetal liver derived 
megakaryocytes, known to form proplatelets at a much higher rate than the bone-marrow 
derived megakaryocyte utilised in this chapter, which may explain the absence of any 
proplatelet formation on collagen (Balduini et al., 2008). Expression of GPVI during 
megakaryopoiesis has been shown to be inversely related, with LAIR-1 downregulated as GPVI 
is upregulated (Smith et al., 2017).  This expression pattern therefore may potentially suggest 
LAIR-1 could be important in providing inhibitory signals to prevent proplatelet formation in 
immature megakaryocytes until they are expressing enough GPVI to mediate the inhibition. 
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Increased phosphorylation of Src Tyr418 and Syk Tyr525/6 in fibrinogen adherent platelet 
lysates from LAIR-1 deficient mice is consistent with the observed increase in spreading (Smith 
et al., 2017). Together with the unaltered phosphorylation of inhibitory sites is additional 
evidence of a proximal signalling defect.   
Interestingly, despite LAIR-1 deficient mouse platelets displaying enhanced aggregation 
responses to collagen and CRP, and forming larger aggregates under shear, platelets from 
deficient mice underwent normal spreading on collagen. This is suspected to be due to the mild 
phenotype being masked by the synergistic effects of multiple receptors (GPVI and α2β1), and 
positive feedback pathways such as secondary mediators ADP and TxA2, allowing WT platelets 
to achieve the same final degree of spreading.  
The normal aggregation responses observed to thrombin were expected as SFKs are not 
involved in GPCR signalling. CLEC-2 however, is a hemi-ITAM containing receptor, which 
signals downstream via a similar pathway to GPVI. The normal aggregation responses upon 
CLEC-2 activation could be explained by the difference in phosphorylation of the (hemi)ITAM. 
Phosphorylation of CLEC-2 upon activation has been shown to be mediated by and dependent 
on Syk, with SFKs playing no role (Severin et al., 2012). GPVI phosphorylation upon activation 
in contrast is mediated by SFKs, which then allow subsequent binding and activation of Syk 
(Poole et al., 1997, Spalton et al., 2009). The enhanced SFK activity observed in LAIR-1 
deficient mouse platelets would therefore enhance GPVI receptor phosphorylation, but not of 
CLEC-2.  
LAIR-1 deficient mice demonstrate increased thrombosis in vivo to ferric chloride, but not 
laser-injury. This agrees with the observed platelet hyper responsiveness in vitro to GPVI, but 
not GPCR agonists. Both thrombosis models are well characterised; laser-injury induced 
thrombosis is highly dependent on tissue factor and thrombin generation, whereas ferric 
 Chapter 3 – LAIR-1 KO mouse  
90 
 
chloride-induced thrombosis is more dependent on collagen exposure following endothelial 
denudation (Dubois et al., 2006). In addition to these mechanisms, the injuries were to vessels 
of differing size, composition and rheological characteristics. Laser-injury was performed on 
arterioles of the cremaster muscle, while ferric chloride-injury was to the much larger carotid 
artery, with these differences likely influencing the phenotype observed. 
Change in SFK activity in megakaryocytes underlies increased platelet production and 
reactivity to GPVI and integrin activation in platelets. Enhanced SFK activity also underlies the 
hyper responsiveness of LARI-1 KO mouse platelets to collagen and fibrinogen (Figure 3.12). 
It is therefore hypothesized that the enhanced SFK activity in megakaryocytes is transferred to 
platelets rendering them hyper responsive. This potentially represents a new paradigm of how 
platelet reactivity can be modulated.  
C-terminal inhibitory site phosphorylation of SFKs was unaltered in both megakaryocytes and 
platelets from LAIR-1 deficient mice. Although, it should be noted that in contrast to activation 
loop tyrosine phosphorylation which correlates with SFK activity, inhibitory site 
phosphorylation does not. Phosphorylation of SFK inhibitory tyrosine residues induces a 
conformation change, blocking the active site and inhibiting SFKs. This however can be 
unclamped by interactions with proline rich or phosphor-tyrosine containing proteins (Figure 
3.13), which disrupt the intramolecular interactions of the SH2 C-terminal phosphor-tyrosine 
or SH3-proline rich linker, resulting in activation of the SFK despite phosphorylation of its C-
terminal inhibitory tyrosine (Senis et al., 2014).  
Levels of SFK proteins themselves or proteins involved in their regulation, such as the receptor 
phosphatase CD148 or kinase Csk, also do not explain the increase in SFK activity as were not 
altered in LAIR-1 deficient mouse platelets and megakaryocytes.   




Figure 3. 12. Effect absence of LAIR-1 inhibition in megakaryocytes. Absence of LAIR-1 
increases SFK activity in megakaryocytes, resulting increased platelet production. Enhanced 
SFK activity is transferred to circulating platelets rendering them hyper-responsive to 
collagen. Visual abstract from Smith et al., 2017. 
 
  




Figure 3. 13. SFK regulation and uncoupling. (A) Regulation of SFK activity. 
Phosphorylation of the C-terminal tyrosine residue mediates intramolecular interaction with the 
SH2 domain blocking the active site. The SFK is maintained in the inactive conformation by a 
second intramolecular interaction between the proline-rich (PxxP) SH2-kinase linker region 
and SH3 domain. C-terminal tyrosine dephosphorylation by protein tyrosine phosphatases 
CD148, PTP1B and Shp1 results in activation of the SFK. Trans-autophosphorylation of the 
activation loop tyrosine residue results in maximal SFK activation. Dephosphorylation of the 
activation by CD148 returns the SFK to basal activation state. Csk or Chk mediated 
phosphorylation of the inhibitory tyrosine residue returns SFK to inactive conformation. (B) 
Activation of SFKs by unclamping. Disruption of SH3-proline-rich linker or SH2-C-terminal 
phosphor-tyrosine intramolecular interactions by proteins containing proline-rich region or a 
phosphor-tyrosine facilitates SFK activation irrespective of C-terminal inhibitory tyrosine 
phosphorylation.  
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The inhibitory effects of LAIR-1 have been shown to be mediated through recruitment of the 
tyrosine phosphatases Shp1 and Shp2 and also the Src inhibitor Csk, to its ITIMs following 
phosphorylation upon activation (Verbrugge et al., 2006, Verbrugge et al., 2003). This brings 
them in close proximity to activation receptors whose signal transduction they can subsequently 
inhibit. It is therefore hypothesized that the increased activity of SFKs in megakaryocytes and 
platelets is due to decreased compartmentalization of the PTPs Shp1 and Shp2, and of Csk at 
the plasma membrane. Further work is needed to elucidate the exact mechanism underlying the 
increase in SFK activity and why it remains elevated in resting platelets. 
Findings in this chapter add to the growing evidence that ITIM-containing receptors are crucial 
in the regulation of platelet production and function. Moreover this chapter demonstrates that 
alterations in the activation state in megakaryocytes can be transferred to their platelet progeny, 
and influence their functional response in the circulation. Opening up a new paradigm of how 
platelet reactivity can be modulated. 
 







LAIR-1/PECAM-1 double deficient mouse model 




The aim of this chapter was to investigate the role of LAIR-1 alongside PECAM-1 in platelet 
production and function to determine if there is functional redundancy between these two ITIM-
containing receptors or if they act through distinct pathways. A murine model deficient in both 
LAIR-1 and PECAM-1 was generated and characterized to achieve this. 
 
4.2. Introduction 
As demonstrated in chapter 3 and additional work in Smith et al (2017), LAIR-1 regulates 
megakaryocyte and platelet reactivity. The absence of LAIR-1 inhibition alters the activity of 
signalling proteins in megakaryocytes, this increased SFK activity within megakaryocytes 
results in increased proplatelet formation and release of platelets into the circulation. The 
enhanced signalling protein activation is then transferred to these platelet progeny, rendering 
them hyper responsive to GPVI and integrin αIIbβ3 mediated activation. Platelets from LAIR-
1 deficient mice demonstrate enhanced responsiveness to GPVI activation, with aggregation 
responses to collagen and CRP and adhesion to collagen under shear all increased. Integrin 
αIIbβ3 mediated activation is also enhanced, with spreading increased on fibrinogen. This 
increased platelet reactivity is also observed in arterial thrombosis in vivo. 
Similar regulation of platelet function has also been reported for another ITIM-containing 
receptor PECAM-1. PECAM-1 was the first identified and most extensively studied ITIM-
containing receptor in platelets and megakaryocytes. Platelet aggregation and secretion 
responses following collagen and CRP activation of GPVI have been shown to be enhanced in 
PECAM-1 deficient platelets (Dhanjal et al., 2007b, Patil et al., 2001, Wee and Jackson, 2005). 
This modest enhancement is however only observed at low agonist doses, with the enhancement 
effect lost at higher concentrations. In agreement, antibody or recombinant ectodomain 
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mediated crosslinking of PECAM-1 on platelets inhibited calcium mobilisation, platelet 
aggregation and dense granule secretion to low doses of collagen, CRP and convulxin, which 
likewise could be overcome at higher concentrations  (Cicmil et al., 2002, Dhanjal et al., 2007b, 
Jones et al., 2009). Interestingly, despite no effect on thrombin aggregation observed in the 
PECAM-1 KO mouse platelets, crosslinking PECAM-1 was shown to inhibit human platelet 
aggregation. This apparent discrepancy was attributed to differences in the PAR composition 
and expression in human (PAR-1, -3 and -4) and mouse (PAR-3 and -4 only) platelets, as 
thrombin primarily acts through PAR-1 in human, but through PAR-4 in mouse platelets (Wee 
and Jackson, 2005). Impaired outside-in integrin αIIbβ3 signalling with delayed clot retraction 
and reduced FAK phosphorylation have been reported in PECAM-1 deficient platelets, 
although fibrinogen spreading was unaffected (Wee and Jackson, 2005). However, a 
subsequent study demonstrated no difference in clot retraction and minor increase in fibrinogen 
spreading in PECAM-1 deficient platelets (Dhanjal et al., 2007b). 
PECAM-1 mice also show enhanced thrombus formation in vivo, with larger thrombi observed 
in cremaster arterioles following laser-injury, and albeit modest an increase in ferric chloride-
induced thrombosis of carotid arteries (Falati et al., 2006). Another model of photochemical 
induced thrombosis in cremaster arterioles was however found to be normal (Vollmar et al., 
2001). Further experiments using bone marrow chimeric mice established the enhancement of 
thrombus formation detected in the laser-injury model was due to loss of platelet and leukocyte 
PECAM-1, rather than loss from the endothelium where PECAM-1 is also highly expressed 
(Falati et al., 2006). 
Although deficient mice have normal platelet counts (Mahooti et al., 2000) and their 
megakaryocytes develop and form proplatelets normally in vitro, PECAM-1 has been shown to 
have a role in thrombopoiesis, through regulation of megakaryocyte migration (Dhanjal et al., 
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2007a). Recovery of platelet counts following antibody mediated depletion of platelets in 
deficient mice was delayed, and attributed to increased megakaryocyte adhesion to the ECM 
and defective migration. The migration defect was due to the absence of SDF-1α receptor 
CXCR4 polarization to the leading edge of megakaryocytes (Dhanjal et al., 2007a), which is 
also thought to underlie the altered spatial localization of megakaryocytes within the bone 
marrow (Wu et al., 2007). 
PECAM-1 inhibition is mediated principally via binding of Shp2 (and Shp1 to a lesser extent) 
to the phosphorylated ITIMs of its cytoplasmic tail. Shp2 then interacts with the p85 regulatory 
subunit of PI3K, disrupting its association with LAT and GAB1 in the signalling complex that 
forms following GPVI activation, thus preventing downstream recruitment of PLCγ2 (Moraes 
et al., 2010). Absence of PECAM-1 therefore enables uninhibited signalling downstream of 
GPVI resulting in enhanced responses. Phosphorylation of PECAM-1 ITIMs is dependent on 
SFKs, in platelets it has been shown to be dependent on Lyn phosphorylation of the C-terminal 
ITIM, with subsequent N-terminal phosphorylation by Csk (or Btk) (Tourdot et al., 2013). 
Despite differences in the ligands of these two ITIM-containing receptors, the phenotypes of 
LAIR-1 KO and PECAM-1 KO mice share several similarities. Platelets from both KO strains 
display enhanced responsiveness to GPVI activation by low agonist concentrations that are lost 
at higher concentrations, and enhanced arterial thrombosis to ferric chloride in vivo. In addition, 
interaction of LAIR-1 and PECAM-1 with the same effector proteins (Shp1, Shp2 and Csk) 
that mediate the inhibition raises the possibility of redundancy between these receptors.  
In this chapter, the role of LAIR-1 is investigated alongside PECAM-1, through 
characterisation a double deficient mouse model, in order to determine the distinct or redundant 
nature of these two ITIM-containing receptors in megakaryocyte development and platelet 
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production, as well as the effect absence of these receptors has on platelet function in vitro and 
in vivo.  
  




In order to investigate whether there is functional redundancy between the ITIM-containing 
receptors LAIR-1 and PECAM-1, a novel mouse model deficient in both receptors was 
generated through crossing of single KO strains (Smith et al., 2017, Duncan et al., 1999). LAIR-
1/PECAM-1 DKO mice were bred as homozygous, with age matched WT mice used as 
controls. Megakaryocyte and platelet function from these LAIR-1/PECAM-1 double KO 
(DKO) mice were then assessed and characterized.  
 
4.3.1. LAIR-1/PECAM-1 DKO mice are mildly thrombocythemic 
LAIR-1 deficient mice have increased platelet counts, whereas counts are normal in PECAM-
1 deficient mice (Smith et al., 2017, Mahooti et al., 2000). It was therefore of interest to 
investigate the effect on platelet count of absence of both these ITIM-containing receptors. 
DKO mice were found to have an increased platelet count (17%), although this was not as 
pronounced as the increase observed in LAIR-1 KO mice (27%; Figure 4.1A). No effect on 
platelet volume was observed (Figure 4.1B). 
 
4.3.2. Megakaryocyte development unaffected in LAIR-1/PECAM-1 DKO mice 
To determine if the absence of LAIR-1 and PECAM-1 effects megakaryocyte development, 
DNA content of primary bone marrow derived megakaryocytes differentiated in vitro was 
assessed. DKO megakaryocytes displayed normal ploidy profiles, suggesting megakaryocyte 
development and differentiation is not affected by ablation of the ITIM-containing receptors 
(Figure 4.2). LAIR-1 and PECAM-1 single KO mice also display normal profiles as previously 
reported (Smith et al., 2017, Dhanjal et al., 2007a).  




Figure 4. 1. LAIR-1 KO and LAIR-1/PECAM-1 DKO mice exhibit increased platelet 
count.  (A) Platelet counts and (B) volumes from PECAM-1 KO, LAIR-1 KO, LAIR-
1/PECAM-1 DKO and litter-matched wild-type mice (WT) were measured in whole blood 
using an ABX Pentra P60 blood counter.  Mean  SEM; n = 20-23 mice/genotype. One-way 
ANOVA with multiple comparisons, *P<0.05, ***P<0.001. 
  
  




Figure 4. 2. Megakaryocyte differentiation unaltered in LAIR-1/PECAM-1 DKO 
megakaryocytes.  Bone marrow-derived megakaryocytes from litter-matched WT, PECAM-1 
KO, LAIR-1 KO and LAIR-1/PECAM-1 DKO mice were stained with propidium iodide and 
DNA content (ploidy) assessed by flow cytometry. (A) Representative profiles and (B) 
percentage of 2-128N ploidy cells was quantified.  Mean  SEM; n = 6 mice/genotype; Two-
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4.3.3. Proplatelet formation unaltered in LAIR-1/PECAM-1 DKO mouse 
megakaryocytes 
The thrombocythemia observed in LAIR-1 deficient mice was due to a combination of 
enhanced proplatelet formation and increased platelet half-life. To determine whether the 
increased platelet count in DKO mice was due to enhanced platelet production, proplatelet 
formation on fibrinogen was investigated in bone marrow derived megakaryocytes. 
Megakaryocytes displayed normal proplatelet formation, with percentage of megakaryocytes 
forming proplatelets, number of proplatelet extensions and area of proplatelet extensions all 
unaltered in DKO mouse megakaryocytes (Figure 4.3). Megakaryocyte surface receptor levels, 
as measured by flow cytometry, were also unaltered in DKO mice (Table 4.1). 
 
4.3.4. LAIR-1/PECAM-1 DKO mouse platelets are hyper responsive to GPVI activation 
Both LAIR-1 and PECAM-1 single KO mice have been shown to have enhanced aggregation 
responses to GPVI receptor agonists, but not to PAR receptor activation (Smith et al., 2017, 
Dhanjal et al., 2007b, Wee and Jackson, 2005). Reactivity to (hemi)ITAM and GPCR 
mediated activation was therefore assessed in platelets from DKO mice by lumi-
aggregometry. DKO mouse platelet aggregation was enhanced in response to low 
concentration collagen and CRP stimulation; however enhancement was not greater than 
observed in platelets from single KO mice (Figure 4.4). Enhanced aggregation responses of 
DKO mouse platelets to collagen and CRP were not observed at other concentrations tested 
(data not shown). Aggregation responses to CLEC-2 antibody and thrombin stimulation were 
normal in all genotypes at all concentrations tested (Figure 4.4 and data not shown). 
Assessment of surface receptor levels on DKO mouse platelets by flow cytometry revealed 
decreased α2 expression compared to WT, with all other receptors unaltered (Table 4.2).  
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These findings are in agreement with previous reports, and indicate ITAM-containing 
receptor signalling, but not GPCR receptor signalling, is increased in the absence of LAIR-1 
and PECAM-1. The lack of further enhancement in aggregation responses of DKO mouse 
platelets suggests functional redundancy in inhibition mediated by these receptors.  




Figure 4. 3. Unaltered proplatelet formation in LAIR-1/PECAM-1 DKO megakaryocytes. 
Bone marrow-derived megakaryocytes from litter-matched WT and LAIR-1/PECAM-1 DKO 
mice were plated on fibrinogen-coated surfaces (5 hours, 37oC, 5% CO2) in the presence of 
SDF1α (300 ng/ml) and heparin (100 U/ml).  (A) Representative images of tubulin stained 
proplatelet forming megakaryocytes. Scale bar: 50 µm. (B) Percent of megakaryocytes forming 
proplatelets, (C) number of extensions per proplatelet forming megakaryocyte and (D) 
proplatelet area. Mean  SEM; n = 600-750 megakaryocytes from 3 mice/genotype; Students 
t-test, non-significant. 
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Table 4. 1. Megakaryocyte surface receptor expression in LAIR-1/PECAM-1 DKO mice. 
Surface receptor expression of cultured bone marrow derived megakaryocytes from PECAM-
1 KO, LAIR-1 KO, LAIR-1/PECAM-1 DKO and WT control mice were measured by flow 
cytometry. 
Surface receptor WT PECAM-1 KO LAIR-1 KO DKO 
GPVI 21.8±3.7 12.5±6.0 22.2±3.6 20.6±3.8 
Integrin α2 38.8±5.6 29.3±7.5 36.9±5.5 38.6±5.0 
GPIbα 79.9±22.4 67.7±28.4 87.2±22.0 97.8±31.8 
Integrin αIIbβ3 185.5±37.8 169.9±39.6 175.6±28.3 209.1±37.0 
CLEC-2 131.8±16.8 117.1±18.2 141.0±15.5 141.1±16.3 
G6b-B 44.5±11.6 28.7±6.1 44.3±9.4 28.2±7.6 
Data represents mean values of the geometric mean fluorescence intensity ± SEM; n = 4-10; 
One-way ANOVA with multiple comparisons. 
  








Figure 4. 4. Increased GPVI-mediated aggregation of LAIR-1/PECAM-1 DKO mouse 
platelets. Washed platelets (2×108/ml)from PECAM-1 KO, LAIR-1 KO, LAIR-1/PECAM-1 
DKO and litter-matched WT mice were stimulated with 1 µg/ml collagen, 1 µg/ml collagen-
related peptide (CRP), 10 µg/ml CLEC-2 antibody and 0.06 U/mL thrombin and platelet 
aggregation and secretion were measured using lumi-aggregometry. (A) Representative traces 
and (B) area under the curve (AUC) quantification of platelet aggregation and secretion. Mean 
 SEM; n= 5-16; One-way ANOVA with multiple comparisons, *P<0.05; **P<0.01.   
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Table 4. 2. Platelet surface receptor expression in LAIR-1/PECAM-1 DKO mice. Surface 
receptor expression of platelets PECAM-1 KO, LAIR-1 KO, LAIR-1/PECAM-1 DKO and 
WT control mice were measured by flow cytometry. 
Surface receptor WT PECAM-1 KO LAIR-1 KO DKO 
GPVI 1622±149 1460±158 1417±1252 1407±55 
Integrin α2 938±26 870±22 909±16 847±6 * 
GPIba 4715±384 4898±406 4702±349 4890±245 
Integrin αIIbβ3 4886±1997 5312±2171 5180±2130 5185±2102 
CLEC-2 6903±541 6533±217 7294±266 7143±155 
G6b-B 582±128 559±128 505±121 525±102 
PECAM-1 450±57 77±23 *** 544±34 71±19 *** 
Data represents mean values of the median fluorescence intensity ± SEM; n = 4-5; One-way 
ANOVA with multiple comparisons, *P<0.05, ***P<0.001 
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4.3.5. Enhanced secretion and fibrinogen binding LAIR1/PECAM-1 DKO mouse 
platelets 
Enhanced reactivity to ITAM-containing receptor agonists has previously been shown in 
platelets from LAIR-1 and PECAM-1 single KO mice (Smith et al., 2017, Jones et al., 2001, 
Dhanjal et al., 2007b, Patil et al., 2001). Platelet activation was assessed using flow cytometry 
to measure upregulation of the α-granule membrane receptor P-selectin following activation of 
platelets with CRP and thrombin. P-selectin surface expression was increased in DKO mouse 
platelets following activation by CRP, which gives robust activation of GPVI, and was mirrored 
by LAIR-1 KO mouse platelets. Thrombin activation also resulted in increased granule release 
in DKO mouse platelets; however this was not paralleled by platelets from either LAIR-1 or 
PECAM-1 single KO mice (Figure 4.5). Increased α-granule secretion is suggestive of 
enhanced reactivity of DKO mouse platelet. 
Activation of integrin αIIbβ3 was also measured using fluorescently labelled fibrinogen. 
Fibrinogen binding following activation with CRP was likewise increased in DKO mouse 
platelets (Figure 4.5), which was copied in platelets from LAIR-1 deficient, but not PECAM-
1 deficient mice in agreement with previous reports (Wee and Jackson, 2005, Smith et al., 
2017). DKO mouse platelets fibrinogen binding was also increased following thrombin 
activation; this was mirrored by PECAM-1 KO platelets, but not those from LAIR-1 deficient 
mice (Figure 4.5). This suggests as previously reported LAIR-1 and PECAM-1 regulate 
integrin αIIbβ3 function, but via different mechanisms. 
 
  




Figure 4. 5. Increased α-granule secretion and fibrinogen binding of LAIR-1/PECAM-1 
DKO mouse platelets. (A) Platelet P-selectin surface expression and (B) AF488-fibrinogen 
binding were measured by flow cytometry in whole blood stimulated with 1, 3 and 10 g/ml 
CRP and 0.06 U/ml thrombin. Thrombin stimulation was in presence GPRP to prevent 
aggregate formation.  Median fluorescence intensity (MFI)  SEM is represented; n = 6; Two-
way ANOVA with multiple comparisons, *P<0.05, **P < 0.01, ***P<0.001. 
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4.3.6. LAIR-1/PECAM-1 DKO mouse platelet spreading on fibrinogen 
ITIM-containing receptors are increasingly being implicated in regulation of integrin signalling 
(Coxon et al., 2017). Previous findings have shown LAIR-1 KO mouse platelets display 
increased spreading on fibrinogen, whereas spreading in PECAM-1 KO platelets was unaltered 
(Smith et al., 2017, Wee and Jackson, 2005). The ability of DKO mouse platelets to spread on 
fibrinogen coated coverslips was assessed at basal and following activation with 0.1 U/ml 
thrombin. Blinded fluorescence images were quantified using a semi-automated machine 
learning method to quantify platelet surface area, this analysis method has previously been 
characterised and its accuracy validated against manual analysis of spreading by members of 
the Birmingham Platelet Group. DKO mouse platelets adhered and spread normally on 
fibrinogen under basal conditions, but show increased spreading area following thrombin 
activation, although platelet adhesion was normal (Figure 4.6). This is in agreement with 
fibrinogen binding results, and suggests enhanced integrin αIIbβ3 function in DKO mouse 
platelets. 
 
4.3.7. Adhesion to collagen under shear unaltered in platelets from LAIR-1/PECAM-1 
DKO mice 
Following minor alterations in platelet function identified to GPVI activation in vitro, a more 
physiologically relevant ex vivo flow adhesion assay was used to investigate recruitment of 
DKO mouse platelets to collagen. Experiments were performed in collaboration with Johan 
Heemskerk, Johanna van Geffen and Marijke Kuijpers (Maastricht University, Netherlands), 
and both experiments and analysis were completed blind.  Whole blood was flowed over 
collagen coated glass coverslips for 3.5 minutes at a shear rate of 1000s-1. Bright field and 
fluorescence images were then captured of thrombi. Platelet adhesion to collagen was normal 
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from DKO mice, as was integrin αIIbβ3 activation and phosphatidylserine exposure (Figure 
4.7). P-selectin surface expression showed a tendency to be increased in DKO mouse platelets 
(Figure 4.7), though it did not reach significance it is suggestive of increased α-granule 
secretion and activation of DKO mouse platelets, as was observed by flow cytometry.  




 Chapter 4 – LAIR-1/PECAM-1 DKO mouse   
114 
 
Figure 4. 6. Fibrinogen spreading unaltered in LAIR-1/PECAM-1 DKO mouse platelets. 
Washed platelets from PECAM-1 KO, LAIR-1 KO, LAIR-1/PECAM-1 DKO and litter-
matched WT mice were plated on fibrinogen (100 µg/ml) coated coverslips under basal and 0.1 
U/ml thrombin pre-activated conditions for 15, 30 or 45 minutes at 37oC. (A) Representative 
phalloidin stained fluorescence images and quantification of platelet surface area, platelet 
perimeter and number of adhered platelets for basal (B) and thrombin preactivated platelets (C). 








Figure 4. 7. Adhesion and activation under flow unaffected in LAIR-1/PECAM-1 DKO 
mouse platelets. Whole blood was flowed over collagen coated microspots at shear rate 1000 
s-1 for 3.5 minutes. (A) Representative bright field and fluorescence images. (B) Quantification 
of surface area coverage (SAC) of adhered platelets, JON/A, P-selectin and annexin V staining. 
Mean  SEM; n = 7-15 mice/genotype; One-way ANOVA with multiple comparisons, 
*P<0.05. Experiments performed in collaboration with Johan Heemskerk, Johanna van Geffen 
and Marijke Kuijpers (Maastricht University, Netherlands). 
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4.3.8. In vivo thrombosis unaltered in LAIR-1/PECAM-1 DKO mice 
Both LAIR-1 and PECAM-1 KO mice form larger thrombi in response to ferric chloride-injury 
(Smith et al., 2017, Falati et al., 2006), consequently this model was chosen to assess the 
physiological effect absence of both these receptors has on in vivo thrombosis. Interestingly, 
ferric chloride-injury induced thrombosis was normal in DKO mice (Figure 4.8) suggesting 
absence of both LAIR-1 and PECAM-1 has no physiological effect on platelet reactivity and 
thrombus formation. 
 
4.3.9. Src activation unaltered in LAIR-1/PECAM-1 DKO mouse platelets 
Increased Src activation was at the heart of the observed hyper reactivity of LAIR-1 KO mouse 
platelets. Activation of Src in platelets following collagen and CRP stimulation was therefore 
assessed in DKO mouse platelets. Platelets from DKO mice display normal levels of active 
loop phosphorylation on Src Tyr418 and Syk Tyr525/6 compared to litter-matched WT controls 
(Figure 4.9). Lack of enhanced SFK activity in DKO mouse platelets to collagen potentially 
explains why no physiological effect of LAIR-1 and PECAM-1 absence was observed on 
thrombosis in vivo. 
Csk plays an important role in regulation of SFK activity, expression of Csk and its homologous 
kinase Chk, which can also inactivate SFKs via phosphorylation of their C-terminal tyrosine 
residue, was therefore evaluated (Mori et al., 2018). Normal protein levels of Csk and Chk were 
detected in both megakaryocytes and platelets of DKO mice (Figure 4.10); indicating Csk/Chk 
mediated inactivation of SFKs is unlikely to be responsible for the reduction in activity 
compared to LAIR-1 KO mouse platelets. 
  




Figure 4. 8. Ferric chloride-induced thrombus formation in vivo unaltered in LAIR-
1/PECAM-1 DKO mice.  Mice were injected with DyLight488-conjugated anti-GPIbβ 
antibody (0.1 µg/g body weight).  Exposed carotid arteries were injured with 10% ferric 
chloride for 3 minutes and the accumulation of platelets (green) into the thrombi was assessed.  
(A) Representative fluorescence images from GPIbβ -labeled platelets after ferric chloride-
injury of carotid are shown.  Scale bar: 200 µm. (B) Each curve represents the integrated 
fluorescence intensity in arbitrary units (a.u.) (C) Area under the curve of the integrated 
fluorescence density is represented. Mean ± SEM; n = 11-12 mice/genotype; Mann-Whitney U 
test, non-significant.  See also videos 4.I and 4.II. 
 
  




Figure 4. 9. Unaltered GPVI-mediated activation of Src and Syk in LAIR-1/PECAM-1 
DKO mouse platelets. Washed platelets (5×108/ml) from DKO mice were stimulated with 
collagen and CRP. Phosphorylation of activation sites of Src and Syk were then assessed in 
whole cell lysates using a capillary based immunoassay (ProteinSimple). (A) Representative 
images and (B) Quantification of normalised peak area. Mean  SEM; n = 3 independent 
experiments/genotype. Two-way ANOVA with multiple comparisons. 
  





Figure 4. 10. Csk and Chk levels in LAIR-1/PECAM-1 DKO mouse megakaryocytes and 
platelets. Expression of Csk and Chk were assessed in whole cell lysates of WT and DKO 
mouse washed platelets (5×108) using a capillary based immunoassay (ProteinSimple). (A) 
Representative images and (B) Quantification of normalised peak area. Mean  SEM; n = 3 
independent experiments. Student’s t-test, non-significant. 
 
  




Findings in this chapter reveal absence of PECAM-1 alongside LAIR-1 does not result in 
further enhancement of platelet reactivity. LAIR-1/PECAM-1 DKO mice have mild 
thrombocythemia, and platelets hyper responsive to GPVI-mediated activation in vitro, but 
interestingly lack the enhanced in vivo thrombosis phenotype observed in LAIR-1 and PECAM-
1 single KO mice. The absence of further enhancement suggests the ITIM-containing receptors 
LAIR-1 and PECAM-1 regulate platelet reactivity via the same signalling pathways. 
Platelet counts in DKO mice were increased, although not as much as those in LAIR-1 KO 
mice. In LAIR-1 KO mice the increase in circulating platelets was attributed to a combination 
of increased megakaryocyte platelet release and longer platelet half-life. Cultured DKO mouse 
megakaryocytes do not exhibit increased proplatelet formation suggesting platelet production 
in vivo is normal. Although not assessed in DKO mice increased half-life of platelets could 
account for the mild thrombocythemia, and together with the normal proplatelet formation in 
DKO mice would explain why the thrombocythemia observed is not as great as that in LAIR-
1deficient mice. Clearance of circulating platelets is determined by multiple triggers which 
signal their removal, including modification of platelet surface glycoprotein glycans. Sialic acid 
loss occurs as platelets age, marking them for removal by hepatic Ashwell-Morrel receptors 
(Grozovsky et al., 2015). In platelets from LAIR-1 deficient mice no alteration in sialic acid 
staining was however observed, instead the increased lifespan was attributed to a change in 
prosurvival and proapoptotic signal interplay, which also regulates platelet survival, and is a 
possible explanation for the increased platelet counts in DKO mice (Smith et al., 2017). 
Aggregation responses to GPVI-agonists collagen and CRP were enhanced in platelets from 
LAIR-1/PECAM-1 DKO mice with responses comparable to those of single KO mice. Lack of 
further enhancement in the DKO mouse platelets is suggestive of redundancy between the 
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inhibition of GPVI signalling mediated by LAIR-1 and PECAM-1. Normal responses to 
thrombin in LAIR-1/PECAM-1 DKO mouse platelets were expected, as although PECAM-1 
has been shown to inhibit GPCR signalling this has only been observed in human platelets upon 
PECAM-1 crosslinking (Cicmil et al., 2002).  
Despite previous reports of increased spreading on fibrinogen of LAIR-1 and controversially in 
PECAM-1 single KO mouse platelets (Smith et al., 2017, Dhanjal et al., 2007b, Wee and 
Jackson, 2005), normal spreading was observed in all genotypes, although adhesion was 
increased in single KO mice platelets. Differences in findings are likely due to differing 
methods of analysis. Normal platelet spreading on fibrinogen was observed in single KO mice 
following pre-activation with thrombin, in agreement with previous studies (Smith et al., 2017, 
Dhanjal et al., 2007b). Interestingly, DKO mouse platelets showed increased spreading, but not 
adhesion, on fibrinogen following thrombin pre-activation. This is a peculiar finding as 
thrombin mediated aggregation responses were normal, although flow cytometry did find 
activation and fibrinogen binding of DKO mouse platelets was increased to thrombin.  
The normal platelet adhesion to collagen under flow conditions was not expected for DKO 
mice, as was the absence of larger platelet aggregates from LAIR-1 deficient mice which has 
previously been shown (Smith et al., 2017). There are conflicting reports regarding adhesion of 
PECAM-1 KO platelets to collagen under shear, with larger platelet aggregates and 
normal/slight reduction in aggregate size reported by different studies even though similar 
experimental conditions were used (Jones et al., 2001, Dhanjal et al., 2007b). Differences in 
experimental setup are likely the cause of results in this chapter being dissimilar to those 
previously published. Blood was flowed over a collagen micro spot coated flow chamber in this 
study, with a capillary based flow system previously utilised for assessment of LAIR-1 KO 
mice (Smith et al., 2017). The tendency for increased activation of platelet aggregates following 
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perfusion over collagen, as observed by P-selectin surface area coverage, agrees with flow 
cytometry data showing enhanced α-granule secretion in DKO mouse platelets. 
Normal in vivo thrombosis in DKO mice was surprising given that both LAIR-1 and PECAM-
1 single KO mice display enhanced thrombosis in the ferric chloride model (Smith et al., 2017, 
Falati et al., 2006). The 3 minute, 10% ferric chloride-soaked filter paper application was the 
same as utilized in both single KO mice studies, however thrombosis was assessed using a 
Doppler flow probe to measure time to 75% occlusion in PECAM-1 KO mice. The LAIR-1 
KO, as was the case for the DKO, measured thrombus formation by assessment of fluorescence 
intensity following labelling of platelets with fluorescently conjugated antibody. Both of these 
methods of measuring in vivo thrombosis are well established but may contribute to the lack of 
enhancement.  
LAIR-1 has been shown in immune cells to interact with Shp1, Shp2 and Csk to inhibit ITAM 
signalling. Expression of LAIR-1 however decreases throughout megakaryocyte development, 
and LAIR-1 is not present on platelets. The enhanced responsiveness of platelets from LAIR-1 
deficient mice, unlike PECAM-1, is therefore not due to absence of inhibitory signalling. 
Instead enhancement is due to increased SFK activity which is present in the megakaryocytes 
and platelets of LAIR-1 deficient mice (Smith et al., 2017). The absence of enhanced SFK 
activity in DKO mice is consistent with the difference in phenotype to LAIR-1 deficient mice, 
as enhanced megakaryocyte proplatelet formation, platelet spreading and thrombus formation 
in vivo all returned to normal in DKO mice. SFKs are central to platelet activation responses 
propagating signals from a variety of platelet receptors including GPVI-FcR γ-chain complex 
and integrin αIIbβ3. SFKs are constitutively associated with the intracellular tail of GPVI and 
β3 subunit of integrin αIIbβ3. Upon GPVI activation, SFKs rapidly phosphorylate ITAMs of 
the FcR γ-chain, providing high affinity docking sites for Syk, which becomes activated by 
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autophosphorylation the further action of SFKs and together propagate downstream signalling 
(Senis et al., 2014, Poole et al., 1997). Integrin αIIbβ3 binding of fibrinogen activates associated 
SFK phosphorylation of β3 subunit. This provides docking sites for adaptor Shc and 
cytoskeletal proteins (vinculin and actinin), which themselves act as docking sites for assembly 
signalling complexes, tyrosine kinases FAK and Syk and lipid kinase PI3K that propagate the 
signal (Senis et al., 2014). Increased SFK activity, such as observed in LAIR-1 deficient mouse 
megakaryocytes and platelets, therefore results in enhanced reactivity to GPVI and integrin 
αIIbβ3 activation. 
To explain the normal SFK activity in DKO mice, expression levels of Csk and its homologue 
Chk were investigated. Levels were however unaltered in DKO mice, further investigation of 
other known regulators of platelet SFK activity such as CD148, and known binding partners of 
LAIR-1 and PECAM-1 such as Shp1 and Shp2, may shed more light on the exact mechanism 
behind this change in signalling. 
In conclusion, findings in this chapter show ablation of both LAIR-1 and PECAM-1 in 
megakaryocytes and platelets does not result in further enhancement of megakaryocyte and 
platelet hyper reactivity. Suggesting LAIR-1 and PECAM-1 mediate their inhibitory functions 
through the same signalling pathways, but are not functionally redundant. 
 







TLT-1: a novel platelet activation biomarker 
 
  




The aim of this chapter was to determine if the ITIM-containing receptor TLT-1 is a more 
sensitive marker of α-granule secretion and irreversible platelet activation during thrombus 
formation in vivo than P-selectin. 
 
5.2. Introduction 
Observations in vivo have demonstrated that platelet activation throughout a developing 
thrombus is not uniform, with some platelets undergoing intracellular calcium mobilization and 
α-granule secretion while others retain a resting morphology (Stalker et al., 2013). Pioneering 
work by Stalker et al characterised the hierarchical structure of growing thrombi in vivo, 
demonstrating thrombi are made up of a tightly packed, irreversibly activated platelet core 
directly adjacent to the vascular injury site, surrounded by a loosely packed and minimally 
activated platelet shell (Stalker et al., 2013). The highly activated platelet core could be defined 
by surface expression of P-selectin, a commonly used marker of α-granule secretion and 
irreversible platelet activation (Maxwell et al., 2007, Nesbitt et al., 2009, Nishimura et al., 2012, 
van Gestel et al., 2002, Dubois et al., 2007, Gross et al., 2005, Vandendries et al., 2007, Hechler 
et al., 2010). 
P-selectin is a type-1 transmembrane protein present in α-granules of platelets and 
megakaryocytes. Following platelet activation, α-granules fuse with the plasma membrane and 
expose P-selectin on the platelet surface. The primary role of P-selectin once on the platelet 
surface is to mediate interactions, via its ligand P-selectin glycoprotein ligand 1, with 
leukocytes (monocytes and neutrophils) to facilitate efficient recruitment to sites of vascular 
injury. 
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The platelet and megakaryocyte specific ITIM-containing receptor TLT-1 is also localized in 
α-granules and undergoes rapid translocation to the surface upon activation (Washington et al., 
2009, Washington et al., 2004). In platelets, TLT-1 is highly abundant. Quantitative 
proteomics-based approaches estimate copy numbers of 14,200 in human and 154,780 in mouse 
platelets, making it more highly expressed than P-selectin (human: 8,900 copies; mouse: 35,970 
copies) (Burkhart et al., 2012, Zeiler et al., 2014). Together with early findings that although 
TLT-1 and P-selectin are both present within α-granules, a proportion localized distinct to P-
selectin, led to TLT-1 being investigated as a marker of platelet activation (Barrow et al., 2004). 
Following activation of both murine and human platelets with thrombin and the GPVI-specific 
agonist CRP, surface expression of TLT-1 and P-selectin was increased, though TLT-1 was 
upregulated to a much greater extent than P-selectin. Time course studies also showed more 
rapid upregulation of TLT-1, which could be detected earlier following platelet stimulation than 
P-selectin (Figure 5.1, Experiments performed by Lola Parfitt, Zaher Raslan and Alexandra 
Mazharian, University of Birmingham, UK) (Smith et al., 2018). Increased surface expression 
could also be detected on mouse bone marrow-derived megakaryocytes in response to collagen 
stimulation, which was not mirrored by P-selectin, suggesting TLT-1 could be used as a marker 
of megakaryocyte activation (Figure 5.1, Experiments performed by Alexandra Mazharian, 
University of Birmingham, UK) (Smith et al., 2018). These initial in vitro findings that TLT-1 
is a more sensitive marker of platelet activation than P-selectin therefore led to assessment of 
TLT-1 during thrombus formation in vivo. 
In this chapter, TLT-1 is investigated as a biomarker of platelet activation during thrombus 
formation in vivo. Upregulation and distribution of TLT-1 is compared to the current gold 
standard platelet activation marker P-selectin, in the laser and ferric chloride-injury models of 
thrombosis.  
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Figure 5. 1. TLT-1 can be detected more easily than P-selectin on the surface of activated 
megakaryocytes and platelets in vitro. Platelet surface expression of TLT-1 and P-selectin 
were measured by flow cytometry in response to the PAR agonist thrombin and the GPVI-
specific agonist collagen related peptide (CRP), in murine (A) and human (B) whole blood.  (i) 
Dose-response (thrombin 0.03 - 3 U/ml and CRP 3 - 30 µg/ml) and (ii) time course (thrombin 
0.1 U/ml, CRP 10 µg/ml).  MFI ± SD; n = 3 - 6 independent experiments/condition. (C) Bone 
marrow-derived megakaryocyte surface expression of TLT-1 and P-selectin following collagen 
stimulation (30 µg/ml) for 20 minutes at 37oC, MFI ± SD; n = 7 - 9. . *P<0.05, **P<0.01 
***P<0.001 vs basal. Experiments performed by Lola Parfitt, Zaher Raslan and Alexandra 
Mazharian, University of Birmingham, UK. 
 
  




5.3.1. TLT-1 is expressed throughout the core and shell of thrombi in vivo 
In vitro findings show TLT-1 is a more sensitive marker of platelet activation than P-selectin 
(Smith et al., 2018). In vivo P-selectin surface expression only occurs on highly activated 
platelets in the thrombus core. TLT-1 surface upregulation was therefore investigated compared 
to P-selectin within thrombi in vivo. TLT-1 was detected more rapidly than P-selectin in 
thrombi following laser-induced injury of cremaster arterioles in WT mice. Interestingly, unlike 
P-selectin, TLT-1 was not restricted to the highly activated platelet core directly adjacent to the 
site of injury, but was present throughout both core and shell of thrombi (Figure 5.2). 
 
5.3.2. TLT-1 distribution throughout thrombi not due to non-specific binding 
In order to confirm the observed rapid upregulation and distribution of TLT-1 throughout 
thrombi in vivo was not due to non-specific antibody binding, anti-TLT-1 antibody was infused 
into TLT-1 deficient mice and cremaster arterioles subsequently injured by laser. No anti-TLT-
1 antibody signal could be detected in thrombi of TLT-1deficient mice (Figure 5.3), 
demonstrating the rapid upregulation and distribution previously observed was due to detection 
of surface TLT-1, and not because of non-specific antibody binding. 
 
5.3.3. TLT-1 is upregulated more rapidly than P-selectin during thrombosis in vivo 
To determine if the rapid upregulation and distribution of TLT-1 is also observed in thrombi 
stimulated by other mechanisms, TLT-1 upregulation was assessed following ferric chloride-
induced injury of the carotid arteries of WT mice. As expected due to the nature of the injury 
model a core and shell was not observed. Both TLT-1 and P-selectin were expressed throughout 
thrombi, however TLT-1 was detected more rapidly than P-selectin (Figure 5.4).  




Figure 5. 2. TLT-1 appears more rapidly and is detected throughout laser-induced 
thrombi in vivo.  Wild type mice were injected with anti-GPIbβ, -TLT-1 or –P-selectin 
antibody.  Arterioles of cremaster muscles were subsequently injured by laser.  (A) 
Representative composite brightfield and fluorescence images of platelets (GPIbβ), TLT-1 and 
P-selectin in thrombi.  (B) Quantification of fluorescence area in pixels (mean ± SEM); n = 25 
- 32 injuries from 4 - 6 mice. Scale bar 10 µm. See also videos 5.I – 5.III.  




Figure 5. 3. Specificity of anti-TLT-1 antibody binding during thrombus formation in 
vivo.  Anti-GPIbβ and TLT-1 antibody were injected into a TLT-1 deficient mouse. Arterioles 
of cremaster muscles were subsequently injured by laser. Representative composite brightfield 
and fluorescence images of platelets (GPIbβ) and TLT-1 in thrombi. n = 10 injuries from 1 
mouse.  Scale bar 10 µm. See also video 5.IV. 
 
  




Figure 5. 4. Upregulation of TLT-1 and P-selectin during ferric chloride-induced 
thrombus formation in the carotid artery.  Wild type mice were injected with anti-GPIbβ, 
TLT-1 or P-selectin antibody.  Exposed carotid arteries were injured with 10% ferric chloride 
for 3 minutes and thrombi fluorescence area assessed.  (A) Representative fluorescence images 
after ferric chloride-injury of carotid are shown.  Scale bar: 200 m.  (B) Each curve represents 
the mean fluorescence area (± SEM) in pixels for 4-7 mice/condition.  See also videos 5.V – 
5.VII. 
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5.3.4. Distinct and overlapping staining of TLT-1 and P-selectin in platelets and 
megakaryocytes 
To explain the difference in TLT-1 and P-selectin upregulation observed in vivo and in vitro 
(Smith et al., 2018), immunofluorescence microscopy was performed on resting human and 
WT mouse platelets and primary bone marrow derived megakaryocytes. TLT-1 colocalized 
with P-selectin within α-granules.  A proportion however localized to distinct granules as 
determine by Manders overlap coefficient in platelets (Figure 5.5) and object based 
colocalization in megakaryocytes (Figure 5.5), which suggests differential distribution or 
localization of a proportion of TLT-1 to other as-yet-unidentified compartments. 
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Figure 5. 5. Distinct and overlapping staining of TLT-1 and P-selectin in platelets and 
megakaryocytes. (A) Resting human and WT mouse platelets on poly-L-lysine and primary 
mouse bone marrow (BM)-derived megakaryocytes (MKs) spread on fibrinogen matrix for 15 
minutes at 37°C were fixed, permeabilised and stained with anti-TLT-1 and -P-selectin 
antibodies.  The right column represented an overlay of both images.  Images are representative 
of 3-4 independent experiments. Scale bar 5 µm. (B) Degree of TLT-1 and P-selectin 
colocalization. Determined by the Manders overlap coefficient in (i) resting human and (ii) 
mouse platelets, and object based colocalization in (iii) BM-derived mouse MKs. N=3-4 
independent experiments/condition, 400-600 platelets or 25-35 MKs/experiment.  
 
  




TLT-1 was found to more rapidly translocate to the surface of activated platelets compared with 
P-selectin during laser-induced thrombus formation in mouse cremaster arterioles. TLT-1 
expression was detected throughout the entire thrombi whereas P-selectin was only observed in 
a highly localized region within the thrombus core, directly adjacent to the site of injury. While 
TLT-1 distribution does not suggest the core, which has additional defining characteristics, is 
larger than previously thought, it does demonstrate for the first time the presence of activated 
platelets in the thrombus shell (Figure 5.6). 
The rapid upregulation of TLT-1 compared with P-selectin during in vivo thrombosis is most 
likely due to the greater abundance of TLT-1 than P-selectin in mouse platelets. However, 
differential compartmentalization of the 2 receptors and differences in binding affinities of the 
antibodies may also contribute. Although all antibodies tested irrespective of staining yielded 
the same results, area rather than fluorescence intensity was assessed to avoid any differences 
in fluorophores. 
Although both receptors are reportedly localized in α-granules, differences in the surface 
translocation rates and distribution within thrombi suggest distinct mechanisms of upregulation. 
Another possibility is TLT-1 is present in an early release granule, either an α-granule 
subpopulation or distinct granule type, that is devoid of P-selectin. 
It has previously been reported that stimulation of platelets with different agonists results in 
differential α-granule cargo release. This led to the proposal of distinct α-granule 
subpopulations which undergo specific release to specific agonists (Chatterjee et al., 2011, 
Italiano et al., 2008, Jonnalagadda et al., 2012, Ma et al., 2005). Alternatively differential 
release has been suggested to result from segregation of randomly distributed cargo into sub 
regions within each α-granule, and partial activation producing release of some but not all cargo 
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sub regions (Sehgal and Storrie, 2007, van Nispen tot Pannerden et al., 2010). Tubular α-
granules have also been identified, which raises the possibility of α-granule secretion being 
polarised. 
These mechanisms could explain the differences in distribution of TLT-1 and P-selectin 
throughout thrombi, as agonists and extent of platelet activation are stratified at sites of vascular 
damage (Stalker et al., 2013, Jonnalagadda et al., 2012, Chatterjee et al., 2011). In the core, full 
platelet activation is driven by thrombin generation from the site of injury, though due to the 
packing density of platelets this only propagates a limited distance from the vessel wall (Stalker 
et al., 2013). ADP and TxA2 released by the activated platelets though are able to extend further, 
driving accumulation of platelets which form the shell region (Stalker et al., 2013). Positive 
feedback pathways reinforce this architecture through additional signalling pathways, such as 
contact dependent signalling (Stalker et al., 2013). 
Consistent with the hypothesis that rapid TLT-1 upregulation is due to its presence in an early 
release granule, immunofluorescence demonstrated distinct pattern of TLT-1 and P-selectin 
staining that suggests a proportion of these 2 receptors are localised differentially within 
platelets and megakaryocytes (Barrow et al., 2004). Additional work is required to characterise 
these distinct P-selectin negative granules and the mechanism of translocation to the surface. 
In conclusion, this chapter demonstrates TLT-1 is a more sensitive platelet activation marker 
than current gold standard P-selectin that can be detected throughout both the core and shell of 
in vivo thrombi. Findings also raise important questions about platelet activation in the shell 
region of thrombi, and how proteins are compartmentalized within secretory granules of 
megakaryocytes and platelets. This opens the possibility of TLT-1 being used clinically as a 
biomarker for early detection of platelet activation in various pathologies, including coronary 
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artery disease and deep vein thrombosis, as well as megakaryocyte activation in bone marrow 
in myeloproliferative disorders and myelofibrosis. 
  




Figure 5. 6. Updated Core-shell thrombus model. (A) Architecture of a growing thrombus. 
Core tightly packed P-selectin and TLT-1 positive platelets directly adjacent to the site of 
injury. Surrounded by a loosely adherent P-selectin negative, TLT-1 positive platelet shell. (B) 
TLT-1 distribution throughout a growing thrombus. TLT-1 appears rapidly before P-selectin 
and is present in both core and shell regions of growing thrombus. 
 
 







TLT-1 deficient mouse model 
  




The aim of this chapter was to determine the physiological function of the non-conventional 
ITIM-containing receptor TLT-1 in megakaryocyte development, platelet production, and 
function in haemostasis and thrombosis. This was achieved through characterisation of a TLT-
1 deficient mouse model. 
 
6.2. Introduction 
TLT-1 is an ITIM-containing receptor exclusively expressed in the megakaryocyte lineage. 
Sequestered in α-granules TLT-1 is upregulated to the surface following activation. 
Intriguingly, TLT-1 is a non-conventional receptor shown to enhance rather than inhibit platelet 
activation like other conventional platelet ITIM-containing receptors. The specificity and 
abundance of TLT-1 suggests that it may play a unique role in vascular haemostasis, yet at the 
same time TLT-1 is also a member of the TREM family of proteins that play important roles in 
both adaptive and innate immunity (Giomarelli et al., 2007). Previous investigations into the 
function of TLT-1 have therefore been in respect to both platelet aggregation and inflammation.  
The function of TLT-1 during platelet aggregation has been interrogated through the generation 
of human single-chain Fv antibody fragments (scFv) and recombinant soluble TLT-1 (rsTLT-
1). Anti-TLT-1 scFvs inhibited thrombin, but not GPVI-mediated platelet aggregation. This 
inhibition was reversible and could be overcome with higher doses of thrombin, suggesting 
anti-TLT-1 scFv affects the threshold of thrombin-mediated responsiveness rather than 
complete blockade (Giomarelli et al., 2007). The inhibition mediated by the scFvs comes after 
shape change, with the likely explanation that scFvs block TLT-1-ligand interactions during 
aggregation (Giomarelli et al., 2007). Recombinant soluble TLT-1 (rsTLT-1) enhanced human 
platelet aggregation to the thromboxane A2-mimetic U46619, and to suboptimal doses of ADP 
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and collagen (Washington et al., 2009). This suggests TLT-1 maybe a platelet specific 
secondary activation factor, promoting aggregation in the presence of low levels of agonists 
(Washington et al., 2009). Recombinant sTLT-1 has also been shown to increase platelet 
adherence and spreading on fibrinogen (Morales et al., 2010) and is consistent with a model of 
sTLT-1 and TLT-1 on the platelet surface cross-linking the fibrinogen secreted upon platelet 
activation and thereby facilitating higher order platelet aggregation (Washington et al., 2009). 
Generation of a TLT-1 deficient mouse model has also been utilized to interrogate the 
functional role of TLT-1 in platelet aggregation. Deficient mice are viable and fertile, with a 
mild decrease in platelet count. Aggregation responses to thrombin, collagen, ADP and U46619 
were reduced in platelet rich plasma at all concentrations tested, with fibrinogen binding of 
deficient platelets showing a tendency to be decreased compared to wild type following 
suboptimal stimulation with ADP (Washington et al., 2009). In vivo tail bleeding time show 
deficient mice bleed more than controls, which is consistent with the decreased aggregation 
response of TLT-1 deficient platelets. Together these results suggest a role for TLT-1 in 
potentiating haemostasis (Washington et al., 2009). 
The role of TLT-1 has also been evaluated in various models of inflammation. In mice, 
lipopolysaccharide (LPS)-induced sepsis led to detectable levels of plasma sTLT-1 within 2 
hours, which continued to increase over 24 hours. This increase in sTLT-1 inversely mirrored 
the pattern of thrombocytopenia in these mice, suggesting sTLT-1 is released or shed as 
platelets leave the circulation during endotoxemia (Washington et al., 2009). TLT-1 deficient 
mice also succumb to LPS challenge faster than controls, and were predisposed to haemorrhage 
associated with inflammatory lesions (Washington et al., 2009). Together findings advocate a 
protective role for TLT-1 during inflammation, dampening the inflammatory response and 
enhancing platelet aggregation at sites of vascular injury (Washington et al., 2009). 
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This chapter investigates the role of TLT-1 in megakaryocytes and platelets. Utilizing a TLT-1 
deficient mouse model, the absence of TLT-1 was assessed on megakaryocyte development, as 
well as platelet reactivity to a range of agonists, including the putatative ligand fibrinogen. In 
addition, the effect of TLT-1 absence on haemostasis and thrombosis in vivo were assessed. 
  




The TLT-1 deficient mouse model used in this chapter was provided by Dr Daniel McVicar 
(National Institute of Health, USA) / Dr Valance Washington (Universidad de Puerto Rico, 
Puerto Rico), the targeting strategy used can be found in Washington et al (2009). TLT-1 
deficient mice were bred homozygous and with age matched WT mice used as controls. 
 
6.3.1. Reduced platelet count TLT-1 deficient mice 
TLT-1 deficient mice have previously been reported to have a mild thrombocytopenia 
(Washington et al., 2009); platelet count was therefore investigated in the TLT-1 deficient mice 
used in this study. TLT-1 deficient mice exhibited a mild reduction (15 %) in platelet count 
(Figure 6.1 A). Platelet volume however remained unaltered (Figure 6.1 B). 
 
6.3.2. Increased spleen size TLT-1 deficient mice 
To prevent inappropriate thrombus formation, activated platelets are cleared rapidly from the 
circulation by the spleen and liver. Reduced platelet production can increase plasma levels of 
TPO, which can result in expansion of the spleen megakaryocyte population. Release of 
cytokines from these megakaryocytes within the spleen can cause myelofibrosis by triggering 
stromal cell expansion and collagen deposition. Spleen size was therefore investigated in these 
thrombocytopenic mice. Spleens from TLT-1 deficient mice were larger than WT by 16 % 
(Figure 6.2). Further investigation into spleen morphology was conducted on fixed and 
sectioned spleens, revealing normal megakaryocyte counts after Haematoxylin and Eosin 
staining (Figure 6.2), and no evidence of myelofibrosis (reticulin staining) in TLT-1 deficient 
mice (Figure 6.2). Similar sectioning and staining of mouse femurs also revealed unaltered 
megakaryocyte counts and absence of myelofibrosis within bone marrow (Figure 6.2). This 
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suggests the enlarged spleens of these mice are not due to increased numbers of megakaryocytes 
and myelofibrosis, but possibly due to increased platelet clearance. 
  




Figure 6. 1. Decreased platelet count TLT-1 deficient mice. (A) Platelet counts and (B) 
volumes from TLT-1 deficient and litter-matched wild-type mice (WT) were measured in whole 
blood using an ABX Pentra P60 blood counter.  Mean  SEM; *P < 0.05; n = 22 mice/genotype. 
Student’s t-test, *P<0.05. 
 
  




Figure 6. 2. Increased spleen size TLT-1 deficient mice. (A) Spleens from TLT-1 deficient 
and litter-matched WT mice were collected and spleen weight to bodyweight ratio calculated. 
Mean  SEM; n = 6 mice/genotype; Student’s t-test, *P < 0.05. (B) Representative images of 
femurs and spleens stained with haematoxylin and eosin (H&E) and reticulin, after fixation, 
paraffin embedding and sectioning. Femurs were decalcified after fixation. (C) Quantification 
of megakaryocytes in blinded H&E sections. Scale bar 20 µm. Mean ± SEM, n = 3. 
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6.3.3. Development unaltered in TLT-1 deficient megakaryocytes  
The effect of TLT-1 absence on megakaryocyte development was investigated by assessing 
DNA content of primary bone marrow derived megakaryocytes differentiated in vitro. TLT-1 
deficient megakaryocytes developed normally in vitro as shown by the normal ploidy profiles 
(Figure 6.3). 
ERK1/2 have been shown to play a critical role in differentiation of megakaryocytes and platelet 
production (Mazharian et al., 2009). Mature bone marrow-derived megakaryocytes were 
stimulated with TPO for 10 minutes at 37oC, cells were lysed and phosphorylation of ERK1/2 
and Src were assessed by Western blot. Phosphorylation of ERK1/2 and the activation loop of 
Src were normal at resting and following stimulation in TLT-1 deficient megakaryocytes 
(Figure 6.4), consistent with the normal growth and ploidy of these cells, indicating TLT-1 is 
not involved in regulation of megakaryocyte development. Future studies are required to 
investigate the cause of the thrombocytopenia of the TLT-1 deficient mice, likely due to 
defective proplatelet formation and/or increased platelet clearance. 
  




Figure 6. 3. Unaltered development of TLT-1 deficient megakaryocytes.  Bone marrow-
derived megakaryocytes from litter-matched WT and TLT-1 deficient mice were stained with 
propidium iodide and ploidy assessed by flow cytometry. (A) Representative profiles and (B) 
percentage of 2-128N ploidy cells was quantified.  Mean  SEM; n = 6 mice/genotype.  Two-
way ANOVA with multiple comparisons. 
 
  




Figure 6. 4. TPO signalling unaltered in TLT-1 deficient megakaryocytes. Bone marrow-
derived megakaryocytes from litter-matched WT and TLT-1 deficient mice were stimulated 
with TPO (10 minutes, 37oC). Whole cell lysates were then Western blotted with anti-ERK1/2-
p and Src-pTyr418 and ERK1/2. (A) Representative blots and (B) densitometry quantification. 
Mean  SEM from 3 independent experiments. Two-way ANOVA with multiple comparisons. 
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6.3.4. Aggregation responses unaltered in TLT-1 deficient platelets 
TLT-1 deficient platelets have previously been shown to aggregate less than WT in platelet rich 
plasma (Washington et al., 2009). Aggregation and dense granule secretion of washed TLT-1 
deficient platelets was assessed by lumi-aggregometry. Aggregation responses to the GPVI 
receptor agonists collagen and CRP and to hemi-ITAM-containing receptor CLEC-2  activation 
were normal, as were responses to the GPCR agonists thrombin and thromboxane A2 mimetic 
U46619 (Figure 6.5). Dense granule secretion measured by ATP release was increased in 
response to high, but not low, concentrations CRP, with all other agonists displaying normal 
ADP release (Figure 6.5). No alteration in surface receptor levels of TLT-1 deficient platelets 
were observed by flow cytometry (Table 6.1). Normal aggregation responses to a wide range 
of agonists suggest TLT-1 has no role in platelet aggregation. 
  












Figure 6. 5. Aggregation responses unaltered in TLT-1 deficient mouse platelets. Washed 
platelets (2×108/ml) from TLT-1 deficient and litter-matched WT mice were stimulated with 
collagen (3 and 10 µg/ml), collagen-related peptide (CRP; 1 and 3 µg/ml), CLEC-2 antibody 
(10 µg/ml), thrombin (0.04 and 0.06 U/ml) and thromboxane A2 mimetic U46619 (3 and 10 
µM) and platelet aggregation and secretion measured by lumi-aggregometry. Representative 
traces of (A) (hemi)ITAM and (B) GPCR agonist induced aggregation and secretion response. 
(C) Area under the curve (AUC) quantification of platelet aggregation and secretion. Mean  
SEM; n = 4-8 / condition; Student’s t-test, **P<0.01.   
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Table 6. 1. Platelet surface receptor expression in TLT-1 KO mice. Surface receptor 
expression of platelets from TLT-1 KO and WT control mice were measured by flow 
cytometry.  
Surface receptor  WT TLT-1 KO P value 
GPVI 1563 ± 263 1470 ± 228 ns 
α2 731 ± 200 645 ± 160 ns 
αIIBβ3 7070 ± 2460 7500 ± 2633 ns 
GPIbα 5774 ± 214 3634 ± 962 ns 
CLEC-2 8616 ± 304 7662 ± 427 ns 
PECAM-1 654 ± 88 635 ± 98 ns 
G6b-B 1451 ±362 1239 ±314 ns 
Data represents mean values of the median fluorescence intensity ± SEM; n = 5-9. Student’s t-
test; ns, non-significant. 
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6.3.5. Reduced α-granule secretion in TLT-1 deficient platelets 
TLT-1 is an α-granule protein requiring platelet activation and granule secretion before being 
expressed on the surface of platelets. α-granule secretion (P-selectin surface expression) was 
assessed in TLT-1 deficient platelets in response to various platelet agonists. Interestingly, α-
granule secretion was reduced in response to stimulation by both (hemi)ITAM and GPCR 
agonists (Figure 6.6). Decreased secretion response to all agonists advocates a role for TLT-1 
in regulating α-granules secretion. 
Fibrinogen has been proposed as a ligand for TLT-1. Binding of fluorescently labelled 
fibrinogen by TLT-1 deficient platelets was therefore assessed following stimulation with 
(hemi)ITAM and GPCR agonists. However, fibrinogen binding was normal in TLT-1 deficient 
mice following stimulation with all agonists tested (Figure 6.6), suggesting TLT-1 does not 
significantly contribute to fibrinogen binding of platelets. 
 
  




Figure 6. 6. Decreased α-granule secretion TLT-1 deficient platelets. (A) Platelet P-selectin 
surface expression and (B) AF488-fibrinogen binding were measured in whole blood stimulated 
with thrombin (0.06 and 0.6 U/ml), PAR4 peptide (100 and 500 µM), collagen related peptide 
(CRP; 3, 10 and 30 g/ml) and CLEC-2 antibody (3 and 30 g/ml).  Median fluorescence 
intensity (MFI)  SEM is represented; n = 6 mice/genotype; Two-way ANOVA with multiple 
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6.3.6. Spreading unaltered in TLT-1 deficient platelets 
The cytoplasmic tail of TLT-1 has been shown to interact with the ERM family of actin 
cytoskeleton binding proteins (Morales et al., 2010, Washington et al., 2009); consequently 
TLT-1 deficient platelets were assessed for defects in platelet spreading. Washed platelets from 
WT and TLT-1 deficient mice were allowed to spread on coverslips coated with fibrinogen or 
collagen under basal conditions and on fibrinogen following pre-activation with thrombin. 
Following spreading, coverslips were washed, fixed and stained with phalloidin (actin 
cytoskeleton). Blinded fluorescence images were then quantified by a semi-automated machine 
learning method to quantify platelet surface area and assessment of four different classes of 
spreading (unspread, filopodia, lamellipodia and fully spread), this analysis method has 
previously been characterised and its accuracy validated against manual analysis of spreading 
by members of the Birmingham Platelet Group. No differences in platelet adhesion, surface 
area, perimeter or morphology were identified compared to WT platelets on collagen or 
fibrinogen under basal conditions (Figure 6.7). Pre-activation with thrombin resulted in a minor 
decrease in perimeter of TLT-1 deficient platelets spread on fibrinogen, but surface area was 
not altered. Platelet adhesion and morphology were also normal (Figure 6.7). 
 
  








Figure 6. 7. Spreading unaltered in TLT-1 deficient platelets. Washed platelets from TLT-
1 deficient and litter-matched WT mice were plated on fibrinogen (100 µg/ml) and collagen 
(10 µg/ml) coated coverslips under basal conditions, and on fibrinogen following pre-
activation with 0.1 U/ml thrombin, for 45 minutes at 37oC. (A) Representative phalloidin 
(actin cytoskeleton) stained fluorescence images. (B) Quantification of number of adhered 
platelets (i), platelet surface area and platelet perimeter (ii), and platelet morphology (iii).  
Mean  SEM; n = 196-393 platelets from 3 mice/genotype; Student’s t-test,*P<0.05. 
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6.3.7. Aggregate formation on von Willebrand factor under shear unaltered in TLT-1 
deficient platelets 
Studies by the McKinnon group have shown recombinant sTLT-1 binds vWF with high affinity, 
and propose it as a physiological ligand for TLT-1 (Doerr A., 2017). They have also shown that 
antibody mediated blocking of TLT-1 ligand interactions reduces aggregate formation on 
collagen type-1 under shear (Doerr A., 2017). In order to assess this, TLT-1 deficient mouse 
blood was flowed over collagen type-1 and vWF coated surfaces for 4 minutes at 1500s-1 and 
surface area coverage of platelets assessed. Experiments were performed blinded in 
collaboration with Tom McKinnon and Angela Doerr (Imperial College London, London, UK). 
TLT-1 deficient platelets demonstrate a tendency for reduced aggregate formation on collagen 
(Figure 6.8 A); although this did not reach significance, it is suggestive of a role for TLT-1 in 
platelet aggregate formation on collagen. On vWF however TLT-1 deficient platelets aggregate 
normally compared to WT under flow (Figure 6.8 B). 
  




Figure 6. 8. Platelet adhesion under flow unaltered in TLT-1 deficient mouse platelets. 
Whole blood was flowed over (A) collagen and (B) von Willebrand factor (vWF) coated 
coverslips at shear rate 1500 s-1 for 4 minutes. (i) Representative bright field images. (ii) 
Quantification of surface area coverage (SAC) of adhered platelets. Mean  SEM; n = 6-7 
mice/genotype; Two-way ANOVA with multiple comparisons, *P<0.05. Experiments 
performed in collaboration with Tom McKinnon and Angela Doerr (Imperial College London, 
UK).  
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6.3.8. Haemostatic response unaltered in TLT-1 deficient mice 
To determine if TLT-1 has a role in haemostasis, time for bleeding to stop following tail tip 
excision and immersion in saline was assessed.  Haemostatic response of TLT-1 deficient mice 
was normal (Figure 6.9) suggesting TLT-1 plays no role in haemostasis. This is in contrast to 
the extended bleeding times previously reported in TLT-1 deficient mice (Washington et al., 
2009). 
 
6.3.9. Decreased stability of laser-injury induced thrombi in vivo 
The effect of TLT-1 absence on thrombus formation in vivo was assessed using the ferric 
chloride-induced injury and laser-induced injury models. Thrombus formation in TLT-1 
deficient mice was normal following application of ferric chloride-soaked filter paper to the 
carotid artery (Figure 6.10). However, thrombi formed following laser-injury displayed 
altered kinetics (Figure 6.11). Although peak thrombus size was normal, thrombi formed 
faster than WT and had reduced stability (Figure 6.11 C). 
  





Figure 6. 9. Haemostatic response unaltered in TLT-1 deficient mice. TLT-1 KO and litter 
matched WT mice were anaesthetised and 3 mm of tail tip excised and immersed in warmed 
saline. Time for bleeding to stop was then recorded for up to a maximum 20 minutes. Bleeding 
was considered stopped when no blood was observed from tail tip for 1 minute. Total bleeding 
time was then calculated. Mean  SEM; n = 18-19; Mann-Whitney U test, non-significant. 
 
  




Figure 6. 10. Ferric chloride induced thrombosis unaltered in TLT-1 deficient mice. Mice 
were injected with DyLight488-conjugated anti-GPIbβ antibody (0.1 µg/g body weight).  
Exposed carotid arteries were injured with 10% ferric chloride for 3 minutes and the 
accumulation of platelets (green) into the thrombi was assessed.  (A) Representative 
fluorescence images from GPIbβ-labeled platelets after ferric chloride-injury of carotid are 
shown.  Scale bar: 200 µm. (B) Each curve represents the median integrated fluorescence 
intensity in arbitrary units (a.u.) for 10-12 mice/genotype.  (C) Area under the curve of the 
integrated fluorescence density is represented (mean ± SEM); Mann-Whitney test, non-
significant.  See also videos 6.I and 6.II. 
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Figure 6. 11. Decreased thrombus stability TLT-1 deficient mice. Mice were injected with 
DyLight488-conjugated anti-GPIbβ antibody (0.1 µg/g body weight).  Arterioles of cremaster 
muscles were subsequently injured by laser. (A) Representative composite brightfield and 
fluorescence images of platelets (GPIbβ). Scale bar: 10 µm. (B) Each curve represents the 
median integrated fluorescence intensity in arbitrary units (a.u.).  (C) Distribution of (i) max 
thrombus size (a.u.), (ii) time to max thrombus size in seconds and (iii) thrombus stability. 
Thrombus stability was assessed as time (s) for thrombi after maximal fluorescence intensity to 
reduce by 50%. Mean ± SEM, 25-26 injuries in 4-5 mice mice/genotype; Mann-Whitney test, 
*P = 0.05.  See also videos 6.III and S6.IV. 
 
  




Findings presented in this chapter demonstrate ablation of the megakaryocyte and platelet 
specific ITIM-containing receptor TLT-1 has only a minor effect on platelet function in 
thrombosis and haemostasis. Deficient mice were mildly thrombocytopenic, likely due to 
increased platelet clearance as megakaryocyte development was normal. Interestingly, 
responses to putative ligands of TLT-1 were unaltered in deficient platelets. Haemostatic 
response in vivo was likewise normal; however stability of laser, but not ferric chloride-induced 
thrombi was reduced in deficient mice. Findings suggest the role of this highly abundant and 
specific protein is more likely mediating interactions with immune cells during thrombo-
inflammation rather than in primary haemostasis. 
As previously reported, TLT-1 deficient mice in this study exhibited a mild reduction in platelet 
count (Washington et al., 2009). Decreased platelet count can be a product of reduced platelet 
production or increased clearance of platelets. Normal megakaryocyte development and 
distribution within spleens and bones and no myelofibrosis in TLT-1 deficient mice, suggests 
platelet production is unaffected. Spleen weight was however increased in deficient mice, 
suggesting increased platelet clearance is the likely cause of the mild thrombocytopenia. Further 
studies to examine platelet half-life and recovery of platelet count following depletion, as well 
as megakaryocyte proplatelet formation are required in order to elucidate the exact underlying 
mechanisms of the mild thrombocytopenia. 
Despite previous reports from the Washington Group of reduced aggregation responses in 
platelet rich plasma of TLT-1 deficient mice, aggregation responses in washed platelets were 
normal to all agonists tested (Washington et al., 2009). The absence of reduced aggregation 
responses in washed platelets suggests a component of the blood plasma is able to interact with 
TLT-1 and enhance aggregation. sTLT-1 which has been detected in blood plasma, has been 
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shown to enhance aggregation responses in washed human platelets (Washington et al., 2009). 
Although sTLT-1 does not interact directly with the platelet surface, it is instead proposed to 
bind fibrinogen and in partnership with surface TLT-1 mediates higher order platelet 
aggregation (Washington et al., 2009). 
Surprisingly, in platelet rich plasma the strongest reduction in aggregation response of TLT-1 
deficient mice was to ADP stimulation (Washington et al., 2009). The method of washed 
platelet isolation used in this chapter, however, renders platelets insensitive to ADP. The 
requirement of TLT-1 to be upregulated to the surface before mediating any effect negates the 
possibility of any effect on primary aggregation response, but would fit with enhancement of 
secondary feedback pathways such as ADP. 
Interestingly, experiments performed in washed human platelets showed reduced aggregation 
responses when TLT-1-ligand interactions were blocked by anti-TLT-1 sv antibodies 
(Giomarelli et al., 2007). The inhibition mediated occurred after shape change, and was 
attributed to blocking of TLT-1-ligand interactions during aggregation (Giomarelli et al., 2007). 
The most interesting result in this chapter is the reduction in α-granule secretion observed in 
TLT-1 deficient platelets following activation with both (hemi)ITAM and GPCR receptor 
agonists. This suggests TLT-1 is not just simply an α-granule cargo protein but rather has some 
regulatory role. This is not the first result leading to this speculation, a role for TLT-1 in granule 
formation has previously been put forward following observed differences in distribution 
patterns of TLT-1 and P-selectin on spread platelets (Washington et al., 2004). Both TLT-1 and 
P-selectin are synthesised in megakaryocyte ER and subsequently exported and sorted in the 
trans-Golgi network (Blair and Flaumenhaft, 2009). However, the receptors differ greatly in 
their cytoplasmic domains. TLT-1 has a much larger cytoplasmic tail (118 residues to P-
selectins’ 35) and contains multiple domains for protein interactions. TLT-1 may therefore 
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function in production, movement or regulation of α-granules rather than simply cargo 
(Washington et al., 2004). Alternatively, TLT-1 could play a role in secretion of α-granules 
rather than their packaging. TLT-1 mediated regulation of granule release could help explain 
the differences in speed of TLT-1 and P-selectin surface upregulation observed in chapter 5 and 
Smith et al (2018). Either way further investigation is required before any conclusions can be 
drawn on this interesting observation. 
No alteration in platelet spreading was observed in TLT-1 deficient platelets on fibrinogen with 
or without pre-activation or on collagen coated surfaces. This result is surprising given 
fibrinogen has been identified as a physiological ligand for TLT-1, and the cytoplasmic tail of 
TLT-1 shown to interact with the ERM family of actin binding proteins. In agreement with 
spreading results, binding of fluorescently labelled fibrinogen was also normal in deficient 
mice. Previous studies with TLT-1 deficient platelets demonstrated a reduction in fibrinogen 
binding following activation with sub optimal doses of ADP, although it did not reach 
significance (Washington et al., 2009). The absence of alteration in fibrinogen spreading and 
binding of TLT-1 deficient platelets is likely explained by the presence of other surface 
receptors that bind fibrinogen, such as integrin αIIbβ3, masking any phenotype. 
Recent work by the McKinnon group has shown recombinant sTLT-1 binds vWF with high 
affinity, and blocking the TLT-1-vWF interaction reduces platelet aggregate formation under 
shear on collagen type-1 (Doerr A., 2017). In collaboration, flow adhesion experiments on both 
collagen type-1 and murine vWF were performed with TLT-1 deficient mouse blood. TLT-1 
deficient mouse blood had a tendency for reduced platelet adhesion to collagen type-1 but did 
not reach significance, nevertheless is suggestive of a minor role for TLT-1 in aggregate 
formation on collagen under shear. Platelet adhesion to vWF was normal under flow in TLT-1 
deficient mouse blood. This is probably due to the fact TLT-1 is stored in α-granules and 
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requires upregulation to the platelet surface. vWF is only a weak platelet agonist (Tomaiuolo et 
al., 2017), and likely normal platelet adhesion is observed as vWF fails to stimulate α-granule 
release and exposure of TLT-1 on the platelet surface. Further experiments with pre-activation 
of platelets before flow over vWF may yield different results. 
Although previously shown to have a decreased haemostatic response following excision of tail 
tip (Washington et al., 2009), normal tail bleeding times were observed in this study. 
Differences in observed findings may be due to the inherent variability of this crude assay, as 
the increase in bleeding time previously observed was only minor (Washington et al., 2009). 
Alternatively slight differences in experimental procedure may account for the lack of 
agreement between studies. 
Altered thrombus kinetics were observed in TLT-1 deficient mice following laser, but not ferric 
chloride-injury, with differences likely reflecting the models different mechanisms. The 
reduced stability of laser-induced thrombi is potentially explained by the marked reduction in 
α-granule secretion observed in TLT-1 deficient platelets. α-granules contain many proteins 
that contribute to thrombus stability, including fibrinogen, thrombospondin-1 and integrin 
αIIbβ3, which mediates firm adhesion and ½ - ⅔ of integrin αIIbβ3 resides in α-granules (Blair 
and Flaumenhaft, 2009, Kuijpers et al., 2014). In addition, leukocytes contribute to fibrin 
deposition within thrombi (Palabrica et al., 1992). Reduced surface exposure of P-selectin 
which mediates platelet-leukocyte interactions will thus reduce fibrin deposition within the 
thrombus. P-selectin has also been shown to stabilize integrin αIIbβ3-fibrinogen interactions 
and aggregate formation in vitro (Merten and Thiagarajan, 2000, Prakash et al., 2017). 
Furthermore, TLT-1 has been shown to mediate interactions with leukocytes including 
neutrophils (Derive et al., 2012). Absence of TLT-1 interactions with these cells types within 
thrombi may similarly contribute to reduced stability. Recently, platelet secretion has been 
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shown to differentially contribute to thrombosis and haemostasis, with normal thrombosis 
having a greater requirement for platelet secretion (Joshi et al., 2018), which might explain why 
no effect on haemostasis was observed.  
Alternatively, TLT-1 has been put forward to bind fibrinogen and mediate higher order platelet 
interactions (Morales et al., 2010, Washington et al., 2009). Absence of these interactions could 
possibly explain the decreased stability in TLT-1 deficient thrombi. However, no reduction in 
spreading or binding of fibrinogen was observed in TLT-1 deficient platelets in this study. 
In conclusion, despite its specificity to platelets and megakaryocytes and abundant expression 
suggesting an important role in thrombosis and haemostasis, findings demonstrate TLT-1 plays 
only a minor role in classical platelet function. Previous work from other groups has shown a 
role for TLT-1 in thrombo-inflammation, suggesting the function of TLT-1, similar to another 
α-granule protein P-selectin, is mediating interaction with immune cells such as leukocytes at 
sites of vascular inflammation. Further work is needed to elucidate the exact role of this highly 
abundant platelet protein. 
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7.1. Summary of results 
The work presented in this thesis further establishes ITIM-containing receptors in the regulation 
of platelet production and function. Absence of LAIR-1 from megakaryocytes was found to 
alter platelet reactivity to GPVI activation in vitro and in vivo. Absence of PECAM-1 alongside 
LAIR-1 did not result in further enhancement of GPVI-mediated platelet activation, suggesting 
redundancy between these receptors. Absence of TLT-1 was found to alter platelet count with 
reduced numbers circulating in deficient mice. TLT-1 absence also altered α-granule secretion, 
and reduced thrombus stability in vivo, however had no effect on in vivo haemostasis. Finally, 
TLT-1 was shown to be a highly sensitive marker of platelet activation, shedding new light on 
the level of platelet activation in growing thrombi in vivo. 
 
7.2. ITIM-containing receptor regulation of megakaryocyte development and platelet 
production 
Investigations carried out in this thesis provide further evidence that ITIM-containing receptors 
have a critical role in megakaryocytes, regulating platelet production. This is clearly 
demonstrated by the altered platelet counts of the LAIR-1, LAIR-1/PECAM-1 and TLT-1 
deficient mice used in this thesis, in addition to those previously published for G6b and PIR-B 
(Smith et al., 2017, Washington et al., 2009, Mazharian et al., 2012, Fan et al., 2014). 
Interestingly absence of ITIM-containing receptor signalling can result in increased (LAIR-1 
and PIR-B) or decreased (TLT-1 and G6b) platelet count, indicating these receptors regulate 
multiple signalling pathways involved in thrombopoiesis. 
LAIR-1 KO mice demonstrate a 25% increase in platelet count, due to an increase in both 
production and platelet half-life (Smith et al., 2017). Underlying the increase in proplatelet 
formation was elevated SFK activity (Smith et al., 2017). Inhibition of SFK activity has 
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previously been shown to cause mild reduction of platelet count in vivo, and abolish 
megakaryocyte proplatelet formation in vitro (Mazharian et al., 2011, Mazharian et al., 2010), 
highlighting the importance of SFKs in this process. In addition to inhibiting proplatelet 
formation, SFK inhibition also altered megakaryocyte development, increasing megakaryocyte 
ploidy (Mazharian et al., 2011). Csk and receptor phosphatase CD148 are major regulators of 
SFK activity in platelets (Mori et al., 2018). Interestingly deletion of Csk, a major SFK 
inhibitor, in the megakaryocyte lineage was reported to result in reduced platelet count (65%). 
Although proplatelet formation was not directly assessed in this study, extramedullary 
haematopoiesis was observed and circulating platelets in these mice were 35% larger and a 
greater proportion were immature, suggesting defective thrombopoiesis (Mori et al., 2018).  
Platelet counts in mice lacking the intracellular tail and thus signalling of PIR-B are also 
thrombocythemic with counts increased by nearly 50% (Fan et al., 2014). In these mutant mice, 
increased numbers of megakaryocytes are observed in the bone marrow and credited for the 
increase in platelet count (Fan et al., 2014). This is not surprising given PIR-B is known to 
support self-renewal of HSCs and inhibit differentiation of acute myeloid leukaemia cells 
(Zheng et al., 2012). 
The mechanism underlying the decreased platelet counts in TLT-1 deficient mice were not 
determined. Reduction in platelet count could be due to a decrease in platelet production or 
increase in platelet clearance. But it is interesting to think how a protein present in α-granules 
would be able to influence platelet production. Activation of megakaryocytes and surface 
exposure of TLT-1 during proplatelet formation is unlikely, as the inactivated circulating 
platelets released would be expected to have high levels of TLT-1 on their surface which is not 
the case (Smith et al., 2018, Washington et al., 2004). Alternatively releasate from activated 
platelets has been shown to increase megakaryocyte proplatelet production (Machlus et al., 
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2016). It is therefore possible that sTLT-1 which is known to be released upon platelet 
activation may have a role facilitating platelet production. Further studies are required to define 
if absence of TLT-1 does indeed effect megakaryocyte platelet production. 
The strongest megakaryocyte phenotype and effect on platelet count is by deletion of ITIM-
containing receptor G6b, with KO mouse platelet count decreased by 80% (Mazharian et al., 
2012). Megakaryocytes in these mice develop normally but fail to produce proplatelets to the 
same extent as WT. Increased clearance of the presumably pre-activated platelets was also 
thought to contribute, however more recent investigation in a loss of function model, which 
recapitulates the platelet count of the KO, was found to have normal rates of platelet clearance 
suggesting this may not be the case (Mazharian et al., 2012, Geer et al., 2018). In these mice 
circulating Tpo levels result in increased megakaryopoiesis causing myelofibrosis and 
destruction of the bone marrow (Geer et al., 2018, Mazharian et al., 2012). G6b-B is 
constitutively associated with the phosphatases Shp1 and Shp2, both of which have significant 
roles in megakaryocyte development (Mazharian et al., 2013). Megakaryocytes deficient in 
Shp1 or Shp2 have defective development, with partial block at 2/4N ploidy. Platelet counts 
are however normal in Shp1 deficient mice and only mild thrombocytopenia observed in Shp2 
deficient, due to Shp2, but not Shp1, deficient megakaryocytes exhibiting reduced proplatelet 
formation (Mazharian et al., 2013). Deletion of both these phosphatases is required to 
phenocopy the absence of G6b-B. These studies established Shp1 and Shp2 as major regulators 
of megakaryocyte development and platelet production, and G6b-B as a major regulator of 
Shp1/2 (Mazharian et al., 2013, Mazharian et al., 2012). 
Recently, four distinct G6b mutations in five consanguineous families, which result in loss or 
severe reduction in expression have been identified (Hofmann et al., 2018, Melhem et al., 2017). 
These patients are all macrothrombocytopenic with focal myelofibrosis, similar to mouse 
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models of G6b, confirming the pathophysiological function of G6b and role of ITIM-containing 
receptors in human platelet production. 
The other ITIM-containing receptors identified in megakaryocytes do not appear to effect 
platelet production, as normal platelet counts are observed. However, reduced recovery of 
platelet count following immune induced depletion was observed in PECAM-1 deficient mice 
(Dhanjal et al., 2007a). This is due to defective polarization of the SDF1α receptor CXCR4 
preventing migration and results in abnormal megakaryocyte distribution (Dhanjal et al., 2007a, 
Wu et al., 2007). 
ITIM-containing receptors may therefore have potentially significant implications for the 
megakaryocyte biology field. Although great advances in the mechanism of megakaryocyte 
maturation, proplatelet elongation and platelet release have been made (Machlus and Italiano, 
2013), the mechanism initiating proplatelet formation remains elusive. ITIM-containing 
receptors are known to interact with the Shp phosphatases and SFKs, so are likely contributing 
to regulation of proplatelet formation. 
 
7.3. ITIM-containing receptor regulation of platelet function 
Platelet reactivity must be tightly regulated, maintaining a balance between positive and 
negative signals as too much results in either thrombosis or bleeding (Gibbins, 2002). The 
classical role of ITIM-containing receptors in platelets is inhibition of ITAM signalling 
downstream of GPVI-FcRγ chain. Mice deficient in LAIR-1 exhibit the enhanced platelet 
reactivity to collagen and CRP stimulation associated with this classical inhibitory function. 
Platelets from LAIR-1 deficient mice also show a role for LAIR-1 inhibiting αIIβ3 function, 
another receptor whose function is increasingly shown to be under ITIM-containing receptor 
regulation (Coxon et al., 2017). The detection of any platelet function defects from LAIR-1 
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deficient mice is surprising, given LAIR-1 is not normally expressed in platelets; but further 
demonstrates alterations in megakaryocyte phenotype can affect the platelet progeny they 
produce. It has previously been reported that transfer of altered megakaryocyte mRNA to 
platelets can affect their function (Rondina and Weyrich, 2015). Similar to this in LAIR-1 
deficient mice transmission of active SFKs and altered compartmentalization of binding 
partners from megakaryocytes underlies the observed platelet phenotype, and adds to the 
growing number of ways megakaryocytes influence platelet reactivity. 
Characterisation of the LAIR-1/PECAM-1 DKO mice, the first mouse model where two ITIM-
containing receptors have been simultaneously ablated, demonstrated no further enhancement 
of platelet hyper responsiveness, suggesting redundancy between these receptors. Given the 
strength of platelet activation elicited by GPVI-FcRγ chain stimulation, it would be expected to 
be highly regulated. Redundancy between ITIM-containing receptor mediated inhibition of this 
pathway is likely a mechanism to prevent GPVI activation going unchecked and the serious 
consequence of excessive thrombosis if this occurs. The inhibition mediated by LAIR-1 and 
PECAM-1 is however only mild, with more profound inhibition of GPVI mediated by G6b-B. 
In the absence of G6b-B signalling, surface levels of GPVI are significantly reduced by 
cleavage in order to prevent constant activation of the receptor (Geer et al., 2018, Mazharian et 
al., 2012). 
Interest in the role of LAIR-1 in megakaryocytes and platelets was based around the importance 
of collagens in proplatelet formation and platelet activation. Assessment of LAIR-1 deficiency 
revealed only a minor role of the receptor in megakaryocyte and platelet function. The 
expression profile of LAIR-1 is broad; indeed LAIR-1 was first discovered in immune cells 
(leukocytes and NK cells) where it potently inhibits cell lysis (Meyaard et al., 1997, Poggi et 
al., 2008). The LAIR-1 deficient transgenic mouse model utilised in chapter 3 was a global 
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knockout, lacking the receptor from all cells. It is possible that observed differences in vivo may 
in part be due to absence of LAIR-1 from immune cells which are known to contribute to 
thrombosis. More recently, LAIR-1 has been shown to negatively control osteoclastogenesis, 
inhibiting osteoclast formation in the presence of collagen degradation fragments (Boraschi-
Diaz et al., 2018). Like LAIR-1, PECAM-1 is also widely expressed. PECAM-1 has been 
shown to maintain endothelial cell junction integrity and a role in circulating leukocytes, as 
well as its minor inhibitory role in platelets (Lertkiatmongkol et al., 2016). The broad specificity 
of these receptors clearly indicates they possess a general inhibitory function. In 
megakaryocytes and platelets, inhibitory signalling from LAIR-1 and PECAM-1 does 
contribute to regulation of platelet production and function, but is not critical in the same way 
as inhibitory signalling from the megakaryocyte lineage specific ITIM-containing receptor 
G6b. 
More powerful and global inhibition of platelet activation is mediated by PGI2 and NO to limit 
platelet activation (Nagy and Smolenski, 2018). Inhibition mediated by ITIM-containing 
receptors should be thought of more as fine tuning of platelet reactivity, setting a threshold for 
platelet response to specific agonists. 
The specificity and abundance of TLT-1 in megakaryocytes and platelets suggested an 
important role in haemostasis and thrombosis. Interestingly, no defects in aggregation and 
spreading in vitro, or haemostasis in vivo were observed. Decreased thrombus stability was 
observed following laser-injury, and attributed to the decreased α-granule secretion observed 
in TLT-1deficient platelets. However, ferric chloride-induced thrombosis was normal, likely 
reflecting the differing mechanisms of the models.  In addition to being an ITIM-containing 
receptor, TLT-1 is also a member of the TREM family of proteins that have important roles in 
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both adaptive and innate immunity (Giomarelli et al., 2007). The function of TLT-1 has 
therefore also been investigated in respect to thrombo-inflammation. 
Sepsis is a systemic inflammatory response to severe infection. Sepsis is caused by the 
mechanisms meant to fight infection and can be accompanied by thrombocytopenia and often 
associated with disseminated intravascular coagulation (DIC), where platelets become 
systemically active resulting in increased fibrin deposition. Inflammation and coagulation are 
intrinsically linked in this setting as consumption of coagulation factors leads to simultaneous 
clotting and haemorrhage (Ferrer-Acosta et al., 2014). Mice deficient in TLT-1 were found to 
succumb in an LPS induced sepsis model faster and in greater numbers than WT mice. In 
another model which recapitulates the mechanisms of DIC in localized form, TLT-1 deficient 
mice were predisposed to haemorrhage at inflammatory lesions (Washington et al., 2009, 
Ferrer-Acosta et al., 2014). A protective role for TLT-1 was also shown in LPS induced acute 
lung injury. Increased alveolar bleeding and pulmonary tissue damage and decreased fibrinogen 
deposition were observed in TLT-1 deficient mice (Morales-Ortiz et al., 2018a). Fibrinogen 
deposition could be restored, and haemorrhage and tissue damage reduced by infusion of sTLT-
1 (Morales-Ortiz et al., 2018a). These findings suggest a protective role for TLT-1 during 
thrombo-inflammation. 
Further studies have also shown mice deficient in TLT-1 have increased susceptibility to 
bacterial infection (Derive et al., 2012). Outcomes were improved in TLT-1 deficient mice 
through administration of 17 amino acid peptide (LR17) derived from the extracellular domain 
of TLT-1 (Derive et al., 2012). The anti-inflammatory activity of this sequence, and TLT-1, is 
mediated through dampening of TREM-1 signalling. This is achieved through binding of 
TREM-1 ligand, thereby inhibiting TREM-1 activation (Derive et al., 2012). Similar 
improvements in outcomes have also been observed in a faecal peritonitis model in mini pigs 
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and LPS challenged non-human primates following TLT-1 derived peptide LR12 (LR17 minus 
5 amino acids) administration (Derive et al., 2013, Derive et al., 2014). Preclinical trials 
administering LR12 during acute myocardial infarction have shown it was able to control 
leukocyte recruitment, limit inflammation, excessive cardiac remodelling and infarct size 
(Boufenzer et al., 2015). The ability of TLT-1 to inhibit inflammatory TREM-1 signalling in 
these studies therefore implicates TLT-1 in regulation of leukocyte recruitment and activation 
(Derive et al., 2012). 
Primarily expressed on neutrophils and monocytes, and recently shown to be expressed in 
platelet α-granules, TREM-1 acts synergistically with pathogen-associated molecular patterns 
(PAMPs) amplifying inflammatory signals (Ford and McVicar, 2009, Jolly et al., 2017). The 
natural ligand of TREM-1 remains unknown (Thomas and Storey, 2015, Ford and McVicar, 
2009). During systemic inflammation endothelial dysfunction leads to platelet activation. P-
selectin exposure and interaction with PSGL-1 then initiate platelet-neutrophil binding, with 
the interaction stabilized by Mac-1-GPIb-α (Derive et al., 2012, Thomas and Storey, 2015). 
Neutrophils are then activated through membrane bound and soluble receptor interaction, 
including that of TREM-1 (Haselmayer et al., 2007, Derive et al., 2012). The above study 
findings suggest TLT-1 (both membrane bound and soluble forms) are able to inhibit this 
interaction through competing with TREM-1 to bind TREM-1 ligand and thus prevent 
neutrophil activation (Derive et al., 2012). 
Platelets have also been shown to recognize LPS directly, interestingly this does not induce 
aggregation or P-selectin exposure instead leading to intense platelet-neutrophil binding and 
release of neutrophil extracellular traps (NETs) (Thomas and Storey, 2015, Clark et al., 2007, 
McDonald et al., 2012). It would be interesting to see if TLT-1 is present on the surface under 
these conditions, as although TLT-1 is an α-granule protein, differential upregulation of TLT-
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1 and P-selectin has been observed (Smith et al., 2018). Although fibrinogen and vWF have 
been identified as ligands for TLT-1, the lack of functional response observed suggests other 
binding partners of TLT-1 are yet to be identified which may point towards the physiological 
role of this receptor. 
  
7.4. TLT-1 as a more sensitive marker of platelet activation 
Another aim of this thesis was to investigate TLT-1 as a marker of platelet activation. Findings 
from chapter 5 demonstrate TLT-1 is a more sensitive marker of platelet activation than P-
selectin. This finding has important implications for future studies of platelet activation and 
thrombosis models, as well as potential clinical use.  
Although extensive work was carried out by the Brass group characterising the architecture of 
growing thrombi, it was thought that platelets in the shell region were minimally active, only 
enough to tether them to the growing thrombi. This was based around the lack of the platelet 
activation marker P-selectin and observation that these platelets undergo embolization. P-
selectin-positive platelets within the core do not embolize and remained attached; leading to the 
suggestion that firm attachment requires a level of platelet activation sufficient to cause α-
granule secretion (Stalker et al., 2013). 
The identification of TLT-1 expression in the shell region of thrombi, however suggests these 
platelets are more than minimally activated, as TLT-1 is an α-granule protein requiring platelet 
activation and granule secretion before being exposed upon the platelet surface. The presence 
of TLT-1 in the shell therefore suggests these platelets have undergone α-granule secretion, 
which is thought to be an irreversible platelet activation event. TLT-1-positive platelets in the 
shell, in contrast to the P-selectin-positive platelets in the core, can embolize and therefore are 
not firmly attached despite α-granule secretion. Further investigation is needed to understand 
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the differences in TLT-1 and P-selectin positive platelet activation. Whether TLT-1 surface 
exposure indicates reversible activation, or if differences are due to differential granule 
secretion as observed in resting platelets and megakaryocytes. Experiments utilising P2Y12 
antagonists such as Cangrelor and thrombin inhibitor hirudin may help explain differences in 
the upregulation of TLT-1 and P-selectin in vivo. 
The work in chapter 5 was carried out in the small arterioles of cremaster microcirculation, yet 
should be applicable to much larger arteries which have recently been shown to have the same 
thrombus architecture (Welsh et al., 2017). It is not readily possible to study human platelets in 
vivo, however microfluidic devices that incorporate collagen and tissue factor can form a core-
shell architecture like that observed in mice in vivo (Muthard and Diamond, 2013, Zhu et al., 
2015, Sakurai et al., 2018). Using such a system to assess TLT-1 distribution across human 
platelets, where abundance is more comparable to that of P-selectin, would give some indication 
how applicable in vivo mouse findings are to human thrombi. Based on flow cytometry 
observations of more rapid and greater surface upregulation of TLT-1 on human platelets 
(Smith et al., 2018), TLT-1 distribution throughout thrombi would be expected to be similar to 
that in mice thrombi in vivo. 
The increased sensitivity of TLT-1 over P-selectin opens the possibility of use to detect 
activation level of circulating platelets. To this end, it is currently being used within the 
Birmingham Platelet Group to assess the level of pre-activated platelets in transgenic mouse 
models known to have increased platelet clearance, with very promising initial results. 
In addition to research uses, TLT-1 as a platelet activation marker may have clinical application, 
where activation of circulating platelets has increasingly been associated to various disease 
states. TLT-1 could possibly be used as a clinical biomarker to detect early platelet activation 
in various disease pathologies such as coronary artery disease and deep vein thrombosis. Patient 
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response to antiplatelet therapy varies widely; with high on-treatment platelet reactivity 
associated with adverse cardiovascular events (Thomas and Storey, 2015). TLT-1 could 
possibly therefore be used to not only identify those patients at higher risk of cardiovascular 
events before P-selectin, but also assist with monitoring and dosing of antiplatelet therapies 
(Thomas and Storey, 2015).  
Detection of sTLT-1 has already been shown to correlate with sepsis and high levels associated 
with acute respiratory distress syndrome which is common among sepsis patients (Morales-
Ortiz et al., 2018a, Washington et al., 2009, Morales-Ortiz et al., 2018b). Elevated sTLT-1 
levels have likewise been detected in acute coronary syndrome (ACS) patients, which covers a 
range of heart conditions. A study by Esponda et al (2015) showed elevated levels of sTLT-1 
compared to healthy controls could be detected in the plasma of ACS patients admitted to 
hospital with chest pain. A later study conducted by Fu et al (2018) showing serum levels of 
sTLT-1 increased with severity of ACS, and could be decreased with effective treatment. 
Although detection of sTLT-1 in plasma and serum has been associated with these disease 
states, a direct marker on platelet activation is likely to provee a better indicator of degree of 
platelet activation. Only time will tell the usefulness of this new tool for assessing platelet 
activation. 
 
7.5. Summary and future directions 
Findings presented in this thesis add further evidence of the role ITIM-containing receptors 
play in regulation of platelet production and function, as well as demonstrate a new more 
sensitive biomarker of platelet activation, TLT-1. Although TLT-1 showed minor role in 
thrombosis and haemostasis, further studies into inflammation and infection are likely to return 
a significant role for this highly abundant and specific receptor mediating platelet-leukocytes 
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interactions. Use of TLT-1 as a biomarker has various research applications in the study of 
platelet biology, and has the potential for translation into clinical use in patients. 
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